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L’isotrétinoïne est un médicament efficace dans le traitement de l’acné
sévère. Cependant, nombreux sont les cas rapportés signalant possiblement
une association entre l’utilisation de cette pharmacothérapie et la
dépression, qui mène les médias à lui porter une attention toute particulière.
Plusieurs études observationnelles ont été menées sur le sujet, mais aucune
association significative n’a été trouvée. Cependant, la plupart de ces études
n’avaient pas de groupe témoin adéquat, ou encore avaient une taille
d’échantillon insuffisante, et souffraient donc de problèmes méthodologiques
i m po riants.
L’objectif de cette étude se voulait ainsi de déterminer s’il existe une
association entre l’utilisation de l’isotrétinoïne et la dépression chez les
sujets diagnostiqués d’acné et ayant reçu au moins une prescription
d’isotrétinoïne entre le jer janvier 1984 et le 31 décembre 2003. Afin d’y
parvenir, une étude cas-chassé-croisé a été réalisée au sein de cette
population. Les données utilisées ont ainsi été obtenues à partir des
banques de données administratives de la Régie de l’Assurance Maladie du
Québec (RAMQ) et de Med-Écho (hospitalisations) de la province du
Québec. Nous avons été en mesure de définir les cas comme des sujets
ayant reçu un premier diagnostic de dépression ou une hospitalisation en
lien avec la dépression (CIM-9: 296.2, 298.0, 300.4, 309.0, 309.1, et 311.0)
durant la période d’étude. Ces derniers devaient également avoir reçu au
liv
moins une prescription d’antidépresseur dans les 30 jours suivant leur
diagnostic ou à l’hospitalisation. La date index correspondait au diagnostic
ou l’hospitalisation considéré. Par ailleurs, les cas devaient aussi être
couverts par le régime médicaments de la RAMQ et avoir reçu au moins un
diagnostic d’acné (CIM-9: 706.1) dans les 12 mois précédant la date index.
Un cas se voyait donc exclus s’il avait reçu une prescription d’antidépresseur
dans les 12 mois précédant la date index. On a pu comparé l’exposition à
l’isotrétinoine durant la période à risque (cinq mois immédiatement avant la
date index) à la période témoin (cinq mois précédant la période à risque).
Les risques relatifs et intervalles de confiance (10) à 95% ont pu ainsi être
estimés en utilisant la régression logistique conditionnelle, tout en ajustant
pour les variables confondantes qui variaient dans le temps.
La cohorte initiale était ainsi composée de 30,496 sujets parmi lesquels 126
(0.4%) cas répondaient aux critères de sélection. Le risque relatif non ajusté
correspondant à l’exposition à l’isotrétinoïne était de 2.00 (95% 10: 1.03,
3.89). Après avoir ajusté pour les variables contondantes qui variaient dans
le temps, le risque relatif était de 2.68 (95% 10:1.10, 6.48).
Il s’agit de la première étude à avoir démontré une association significative
entre l’isotrétinoïne et la dépression. Sachant que la dépression est une
maladie pouvant avoir des conséquences non négligeables, une attention
particulière devrait être portée aux patients recevant l’isotrétinoïne.
Mots-clés : Acné ; isotrétinoïne ; dépression cas-chassé-croisé
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Isotretinoin is an effective medication for the treatment 0f severe nodular
acne. Over the years however, case reports and adverse reaction databases
have signaled a possible association with depression, which led to
considerable media attention. Several observational studies have been
conducted on the subject, but failed to show an association. However, these
studies were either uncontrolled, had small sample sizes, or suffered from
other methodological problems.
Thus, the objective of the present study was to determine whether
isotretinoin increases the risk of depression in patients with acne vulgaris. A
case-crossover study was performed among subjects who received at least
one isotretinoin prescription between January 1, 1984 and December 31,
2003. Data were obtained from the Régie de l’Assurance Maladie du Québec
(RAMQ) and Quebec’s hospital discharge (Med-Écho) administrative
databases. Cases were defined as those with a first diagnosis or
hospitalization for depression (lCD-9 codes: 296.2, 298.0, 300.4, 309.0,
309.1, and 311.0) during the study period (1984-2003), and who filled a
prescription for an antidepressant in the 30 days tollowing their diagnosis or
hospitalization. The index date was the calendar date of the diagnosis or
hospitalization for depression, whichever came first. Cases were covered by
the RAMQ drug plan and had at least one acne diagnosis in the 12 months
prior to the index date. Those who received an antidepressant in the 12
months prior to the index date were excluded. Exposure to isotretinoin in a
jvi
five-month risk period immediately prior to the index date was compared to a
five-month control period that preceded the risk period. Relative risks along
with 95% confidence intervals (Cl) were estimated using conditional Iogistic
reg ression.
0f the 30,496 subjects in the initial cohort, 126 (0.4%) cases met inclusion
criteria. The crude relative risk was 2.00 (95% Cl: 1.03, 3.89). After adjusting
for potential time-dependent confounders, the relative risk was 2.68 (95%Cl:
1.10, 6.48).
This is the first controlled study to find a statistically significant association
between isotretinoin and depression. Because depression could have
serious consequences, close monitoring of isotretinoin users is indicated.
Keywords: Acne; isotretinoin; depression; case-crossover
P e vii
-
IDENTIFICATION DU JURY.ii
RÉSUMÉ iii
ABSTRACT y
TABLE 0F CONTENTS vii
LIST 0F TABLES xv
LIST 0F FIGURES xvii
List 0f abbrevïatïons xviii
DEDICATION xix
REMERCIEMENTS xx
CHAPTER 1: INTRODUCTION 1
CHAPTER 2: LITERATURE REVIEW 3
2.1 Epidemiology 0f acne 3
2.2 Pathogenesis of acne 4
2.2.1 Pilosebaceous unit 4
2.2.2 Increased sebum production 5
2.2.3 Abnormal follicular differentiation 7
2.2.4 Propionibacterium acnes and inflammation 7
2.3 Types 0f lesions 8
2.3.1 Papules 8
2.3.2 Pustules 9
2.3.3 Macules 9
2.3.4 Nodules 9
2.3.5Cysts 10
2.4 Acne severities 10
p p viii
2.4.1 Comedonal acne.10
2.4.2 lnflammatoryacne 10
2.4.3 Nodulocystic acne 11
2.5 Psychosocial impact of acne 12
2.6 Anti-acne treatments 16
2.6.1 Topical treatments 16
2.6.1.1 Topical antibiotics 17
2.6.1.1.1 Erythromycin and clindamycin 17
2.6.1.2 Topical retinoids 18
2.6.1.2.1 Tretinoin 18
2.6.1.2.2 Adapalene 19
2.6.1.2.3 Tazarotene 19
2.6.1.3 Other topical treatments 20
2.6.1.3.1 Benzoyl peroxide 20
2.6.1.3.2 Salicylic acid 20
2.6.1.3.3 Azelaic acid 21
2.6.2 Systemic treatments 23
2.6.2.1 Systemic antibiotics 23
2.6.2.1.1 Tetracycline, minocycline and doxycycline 24
2.6.2.1.2 Erythromycin 25
2.6.2.1.3 Clindamycin 25
2.6.2.2 Hormonal therapy 25
2.6.2.3 lsotretinoin 29
2.6.3 Adjunctive therapies 29
2.6.3.1 Comedone extraction 29
2.6.3.2 Chemical peels 30
2.6.3.3 Photodynamic therapy 30
2.6.3.4 Corticosteroids 30
g e ix
2.6.3.5 Other therapies.31
2.7 Canadian acne treatment guidelines 31
2.8 Isotretinoin 34
2.8.1 Mechanism of action 34
2.8.2 Isotretinoin utilization 35
2.8.3 Rates of acne relapse 38
2.8.5 Side effects 44
2.8.5.1 Teratogenecity of isotretinoin 44
2.8.5.1.1 Warning symbols on capsules 44
2.8.2.1 .2 Congenital malformations associated to isotretinoin 45
2.8.5.1 .3 The Pregnancy Prevention Program 48
2.8.5.1.4 The SMART program 51
2.8.5.1.5 The iPLEDGE program 53
2.8.5.2 Mucocutaneous side effects 54
2.8.5.3 Ophthalmologic side effects 55
2.8.5.4 Neuromuscular side effects 57
2.8.5.5 Elevation in plasma lipids and liver side effects 57
2.8.5.6 Psychiatric effects of isotretinoin 59
2.8.5.6.1 Case reports 60
2.8.5.6.2 Case series 62
2.8.5.6.3 Adverse drug event reporting systems 67
2.8.5.6.4 Package label changes and other warnings 71
2.8.5.6.5 Observational studies 72
2.8.5.6.6 Biological plausibilïty 86
2.8.6 Costs 87
CHAPTER 3: OBJECTIVES AND HYPOTHESES 90
3.1 Objectives Study 1 90
3.2 Hypotheses Study 1 90
Page Ix
3.3 Objectives Study2.91
3.4 Hypothesls Study 2 91
3.5 Objective Study 3 92
3.6 Hypothesis Study 3 92
3.7 Objective Study 4 93
3.8 Hypothesis Study 4 93
CHAPTER 4: METHODS 94
4.1 Data sources 94
4.1.1 RAMQ databases 94
4.1.2 Med-Écho databases 95
4.2 Study population 96
4.3 Methods for Study 1 97
4.3.1 Study cohort 97
4.3.2 Treatment duration and mean daily dosage 98
4.3.3 Previous anti-acne medications 98
4.3.4 Characteristics of isotretinoin users and predictors of utilization 99
4.3.5. lnterrupted time-series modeling 100
4.4 Methods for Study 2 103
4.4.1 Study cohort 103
4.4.2 Study design 103
4.4.3 Cohort entry and exit 104
4.4.4 Case and control defintion 105
4.4.4.1 Definition for first nested case-control study 105
4.4.4.2 Defintion for second nested case-control study 106
4.4.5 Potential predictors 106
jxi
4.4.6 Statistical analysis.108
4.5 Methods for Study 3 109
4.5.1 Study base 109
4.5.2 Study design 109
4.5.3 Case definition 111
4.5.4 Time windows 112
4.5.5 Potential confounders 114
4.5.6 Statistical analysis 114
4.6 Methods for Study 4 116
4.6.1 Case-crossover and case-time-control designs 116
4.6.3 Statistical analysis 118
CHAPTER 5: MANUSCRIPTS 119
5.1 Patterns and utilization of isotretinoin for acne f rom 1984 to 2003: Is there
need for concern9 120
5.1 .1 Abstract 121
5.1.2 Introduction 123
5.1.3 Methods 125
5.1.3.1 Data sources 125
5.1.3.2 Study cohort 126
5.1.3.3 Indication for isotretinoin 127
5.1.3.4 Treatment duration and mean daily dosage 127
5.1.3.5 Previous anti-acne medications 128
5.1.3.6 Statistical analysis 129
5.1.3.6.1 Characteristics of isotretinoin users and predictors of utilization
129
5.1.3.6.2 Isotretinoin utilization and impact of guidelines 130
5.1.4 Results 131
lxii
5.1.4.1 Indication for isotretinoin.132
5.1 .4.2 Patient and prescriber characteristics 132
5.1.4.3 Previous anti-acne treatments 133
5.1.4.4 Treatment characteristics 133
5.1.4.5 Predictors of inappropriate isotretinoin use 134
5.1.4.6 Impact of guidelines 134
5.1.5 Discussion 135
5.1.5.1 Impact of guidelines 138
5.1.6 References 140
5.2 Isotretinoin therapy and the incidence of acne relapse: a nested case
control study 149
5.2.1 Summary 150
5.2.2 Introduction 152
5.2.3 Methods 153
5.2.3.1 Data sources 153
5.2.3.2 Study cohort 155
5.2.3.3 Study design 155
5.2.3.4 FoIIow-up 156
5.2.3.5 Cases and controls 156
5.2.3.6 Potential predictors 158
5.2.3.7 Statistical analysis 159
5.2.4 Results 160
5.2.4.1 Predictors of receiving an anti-acne medication 160
5.2.4.2 Predictors of receiving a second isotretinoin treatment 161
5.2.5 Discussion 162
5.2.6 References 168
5.3 Isotretinoin and the risk of depression in patients with acne vulgaris: a case
crossover study 181
P a g xiii
5.3.1 Abstract 182
5.3.2 Introduction 184
5.3.3Methods 185
5.3.3.1 Data sources 185
5.3.3.2 Study design 187
5.3.3.3 Case definition 187
5.3.3.4 Time windows 189
5.3.3.5 Potential confounders 189
5.3.3.6 Statistical analyses 190
5.3.4 Results 190
5.3.4.1 Isotretinoin and depression 191
5.3.4.2 Cumulative dose 192
5.3.5 Discussion 192
5.3.5.1 Dose-response relationship 194
5.3.6 References 198
5.4 Isotretinoin and the risk of depression: a comparison cf self-matched
designs 209
5.4.1 Abstract 210
5.4.2 Introduction 211
5.4.3 Materials and methods 213
5.4.3.1 Data sources 213
5.4.3.2 Study population 214
5.4.3.3 Case-crossover design 214
5.4.3.4 Case-time-control design 216
5.4.3.5 Statistical analysis 218
5.4.4 Results 219
5.4.4.1 Case-crossover design 219
5.4.4.2 Case-time-control design 219
lxiv
5.4.5 Discussion 220
5.4.6 References 225
CHAPTER 6: DISCUSSION 232
CHAPTER 7: CLINICAL IMPLICATIONS 237
CHAPTER 8: REFERENCES 238
APPENDIX I: Ethics committee approval certificate xxi
APPENDIX Il: Commission de l’accès à l’information approval xxii
APPENDIX III: List of anti-acne medications xxv
APPENDIX IV: Dermatologic procedure codes xxvi
)j; XV
Table 1. Observational studies on the psychosocial impact 0f acne .15
Table 2. Topical treatments for acne vulgaris 22
Table 3. Systemic treatments for acne vulgaris 33
Table 4. Acne relapse foilowing an isotretinoin treatment 43
Table 5. Congenitai malformations associated with isotretinoin exposure 47
Table 6. Case reports and case se ries associating isotretinoin to depression. . .66
Table 7. Cases of suicide, suicide attempt, and suicidai ideation reported in UK
MCAADERS 69
Tabie 8. Summary of observational studies on the association between
isotretinoin and depression 84
Manuscript 5.1
Table 1. Characteristics of patients and prescribers 145
Table 2. Anti-acne medications dispensed in the 12 months immediateiy
preceeding the index date 146
Table 3. Characteristics related to the isotretinoin treatment 147
Table 4. Predictors of an isotretinoin treatment 20 weeks 148
Manuscrïpt 5.2
Table 1. Characteristics of cases and controis for the anti-acne medication
analysis 172
Table 2. Type of anti-acne medications dispensed (n=7100) 173
Table 3. Predictors of receiving an anti-acne treatment after being initially
treated with isotretinoin 174
Table 4. Characteristics of cases and controls for the isotretinoin analysis 176
Table 5. Predictors of receiving a second isotretinoin treatment 177
Manuscrïpt 5.3
Table 1. Characteristics of cases (n=1 26) 204
o
lxvi
Table 2. Two-by-two table cf cases exposed in the risk and control periods . . .205
Table 3. Risk cf depression associated with exposure te isotretinoin using 5-
month risk and control periods 206
Table 4. Risk cf depression associated with isotretinoin cumulative dose using
5-month risk and control periods 207
Manuscript 5.4
Table 1. Characteristics of cases and controls 230
Table 2. Relative risks of depression associated with the use cf isotretinoin in
the case-crossover and case-time-control designs 231
e e I xvii
Manuscript 5.2
Figure 1. Kaplan-Meier curve of first-time isotretînoin users requiring further
treatment with an anti-acne medication (isotretinoin or other) 179
Figure 2. Kaplan-Meier curie of first-time isotretinoin users requiring a second
isotretinoin treatment 180
Manuscript 5.3
Figure 1. Case-crossover analysis using 5-month risk and control periods
separated by a 2-month washout period 208
Manuscript 5.4
Figure 1. The interrelationship between the case-crossover, case-time-control
and case-control designs usîng 5-month time windows 229
P e g e xviii
ADERS
AERS
AQOL
ARIMA
BDI
BHS
CES
CI
DHPL
DHT
DLQI
DSM-IV
EQ-5D
FDA
GPRD
HAD
lCD-9
MCA
Med-Écho
NAMCS
OR
P. acnes
PPP
RAMQ
RR
SD
SE-36
SMART
SSRI
UK
US
VAS
WHO
WHOQOL-BREF
Adverse drug event reporting system
Adverse Event Reporting System
Acne Quality of Life Scale
Autoregressive integrated moving average
Beck Depression lnventory
Beck Hopelessness Scale
Center for Epidemiologic Studies Depression Scale
Confidence interval
Dear Healthcare Professional Letter
Dihyd rotestosterone
Dermatology Life Quality Index
Diagnostic and Statistical Manual of Mental Disorders,
fourth edition
EuroQol
Food and Drug Administration
General Practice Research Database
Hospital Anxiety and Depression Scale
International Classification of Diseases, ninth revision
Medicines Control Agency
Maintenance et Exploitation des Données pour l’Etude de la
Clientèle Hospitalière
National Ambulatory Medical Care Survey
Odds ratio
Propionibacterium acnes
Pregnancy Prevention Program
Régie de l’Assurance Maladie du Québec
Relative risk
Standard deviation
Short Eorm-36
System to Manage Accutane Related Teratogenicity
Selective serotonin reuptake inhibitor
United Kingdom
United States
Visual analog scale
World Health Organization
World Health Organization Quality of Life-100- questionnaire
I xix
To my wife, Jessica, for her unconditional love and support
xx
o
______
Mes plus vifs et mes plus sincères remerciements à ma directrice de
recherche, Dre Anick Bérard, pour sa disponibilité et son professionnalisme
tout au long de mes études de doctorat. Je suis fière d’avoir profité de son
expertise, de son soutien, et de ses talents. Dr Bérard m’a offert toutes les
opportunités facilitant ainsi mon cheminement et mes succès durant mon
doctorat. Je garderai de ce parcours, un vibrant souvenir et toute ma
reconnaissance.
A tous mes collègues; Dr Driss Oraichi, Élodie Ramos, Anaïs
Lacasse, Dr Benjamin Ofori, Krystel Moussaly, Marie-Pierre Gendron, et
Fabiano Santos. Avec vous j’ai découvert tous les volets positifs du travail en
équipe. Vous avez participé chacun de vous avec vos connaissances à
réaliser une équipe dynamique et créative. Merci pour votre amitié et vos
encouragements. Je vous souhaite à tous beaucoup de succès dans vos
entreprises futures.
Mes remerciements les plus sincères aux membres de mon jury de
thèse, Dre Sylvie Perreault, Dre Jocelyne Moisan, et Dre Carol Louik, pour
m’accorder leur précieux temps.
Je profite également pour exprimer toute ma reconnaissance aux
différents organismes qui m’ont offert le support financier essentiel à la
réalisation de ce projet. La Faculté des études supérieures de l’Université de
Montréal pour une bourse de recrutement au doctorat, le Comité
organisateur du congrès pharmaceutique international de Montréal, 1985
pour un prix d’excellence, le Fonds de la recherche en santé du Québec
(FRSQ) pour une bourse de formation doctorale, et le Réseau québécois de
recherche sur l’usage des médicaments (RQRUM) pour des bourses d’appui
à la diffusion des résultats de recherche.
Un merci tout spécial à ma très chère famille qui m’a encadré et
encouragé avec toute leur affection.
Acne is a highly prevalent disorder costing over one billion dollars in the
United States (US) every year (1). There are a number of medications
available for the treatment of acne, several of which are available over-the
counter. However, isotretinoin is the only medication that has been shown to
be effective in the treatment ot severe recalcitrant nodulocystic acne. It was
dubbed a miracle drug by physicians and patients when it was first approved
in the US in 1982 and in Canada in 1983.
lsotretinoin’s popularity has since been marred by its side effect profile. It is a
potent human teratogen if taken during the first trimester of pregnancy (2).
This was known at the time of its marketing, but there were no risk
management programs in place to prevent isotretinoin-exposed pregnancies.
In addition to being a teratogen, isotretinoin has also been associated with
mucocutaneous, ophthalmologic, neuromuscular, and gastrointestinal side
effects (3). Because of these serious side effects, isotretinoin is considered a
second line treatment to patients with severe nodular acne who have flot
responded to conventional therapy (4).
Over the years, there has been growing concern regarding isotretinoin’s
possible psychiatric effects. Such side effects have been reported as early
as 1983, a year after it was introduced in the US market (5). Case reports
2and signais from adverse reaction databases have indicated a possible
association between isotretinoin and depression, suicidai ideation, and
suicide. However, controiled observationai studies failed to find an
association between isotretinoin and depression. Because of methodological
limitations in these studies and continued concerns that an association may
truly exist, several governments have modified the isotretinoin package
labeling to better inform physicians and patients cf this possible side effect.
In 2000, isotretinoin’s possible psych iatric effects received considerable
media attention after US Congressman Ban Stupak blamed isotretinoin for
triggering the suicide cf his 17-year old son (6). Thus in view of the growing
concerns regarding the use cf isotretinoin, its possible association with
depression warrants funther investigation.
2.1 EPIDEMIOLOGY 0F ACNE
Acne vulgaris, or acne, is the most common dermatologic disorder treated by
physicians, costing over one billion dollars a year in the US (1). It is a highly
prevalent disorder, affecting 85% to 100% of young adults 12 to 24 years of age
(7,8). Acne affects males and females equally, and usually develops sooner in
females than males because of their earlier onset 0f puberty (9). This concords
with a longitudinal study that followed students for 8 years where females
developed acne sooner than males (10). Females reach their peak between ages
16 and 17 and males between ages 17 and 19 (9).
For most affected individuals, acne will usually clear spontaneously by 24 years
of age (11). However, acne may persist well beyond puberty. This was
demonstrated in a study conducted among 749 adults between 25 and 58 years
o
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In order to fully appreciate the literature pertaining to isotretinoin, it is essential to
provide an overview of the epidemiology and pathogenesis of acne, as well as
the available treatments for this condition. Subsequent sections will describe in
detail isotretinoin’s mechanism of action, its utilization, and its various side
effects with a special emphasis on its potential psychiatric effects.
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0f age, where 40% of males and 54% of females had some form of acne (12). In
another study, Cunhiife and GoulU (13) surveyed 2155 volunteers between 18
and 75 years 0f age. At 18 years of age, 35% of males and 23% of females had
clinical acne (13). By 40 years of age, the prevalence cf clinical acne was 1% in
males and 10% in females (13). A low prevalence of adolescents and young
adults may suifer from acne well into the sixties and seventies (14).
2.2 PATHOGENESIS 0F ACNE
2.2.1 PILOSEBACEOUS UNIT
Acne occurs at the pilosebaceous unit (15). The pilosebaceous unit is composed
of the hair fohhicle, sebaceous gland, and the infundibulum which is a duct
connected to the surface of the skin. The epithelial cells that une the infundibulum
are an extension of the epidermis (15). Four factors have been found to be
implicated in the pathogenesis of acne. They are 1) increased sebum secretion,
2) abnormal follicular differentiation, 3) propionibacterium acnes (P. acnes), and
4) inflammation. The following sections will detail the role of each of these factors
in the pathogenesis cf acne.
5C 2.2lNCREASEDSEBUM PRODUCTION
Sebacecus glands secrete sebum, which consists cf lipid, celiular debris, keratin
and bacteria in a complex mixture cf triglycerides, fatty acids, wax esters,
squaiene and cholesterol (11). Sebum has lubricating and antimicrobiai action to
the skin, and heips prevent water ioss to maintain 10% hydration cf skin and hait
(16). However, acne is present in areas with large concentrations cf sebaceous
glands. in fact, it has been shown that sebum production is greatest in persons
with acne, where the rate cf its production is directly proportionai to the severity
cf the condition (9,17,18). Excessive amounts cf sebum contribute te the
obstruction cf the piiosebacecus unit (19), and provides an ideai grcwth
envi ronment for P. acnes (9).
The iargest and most abundant sebaceous glands are found on the face, namely,
the cheekbones, forehead, and ncse (15). A dense concentration is aise located
over the neck and shoulders, chest, upper back and upper arms (15). They are
net present on the paims cf the hands or soles cf the feet (20).
The sebacecus’ gland activity is mcdulated by andrcgenic hormones, especially
dihydrctestcstercne (DHT). Sebacecus glands possess the enzymes 5a-
reductase, and 3Œ- and 17Œ-hydroxystercid dehydrogenase that convert weaker
16
Ç androgens to DHT. DHT binds to androgen receptors in sebaceous glands to
stimulate sebum secretion. Before puberty, sebum secretion is reiatively dormant
but surges after androgens leveis increase after the onset of puberty (11).
Sebum production reaches its peak in the late teens, and its level remains stable
until about 70 years of age in men, and the onset of menopause in women (11).
Some women may notice a flare-up in acne prior to menstruation, while others
may experience a flare-up with ovulation and pregnancy (12). Furthermore, oral
contraceptives that contain androgenic progestins are sometimes impiicated in
causing flare-ups. Paradoxically, as wiil be discussed in section 2.6.2.2, certain
oral contraceptives with specific formulations may be used as anti-acne
treatments in women (21).
Sebum production has been shown to be high after birth (22). It has aiso been
shown that sebaceous glands respond to maternai androgens delivered through
breast milk in infants. Together, this may cause infantile acne. In a case series of
29 infants (24 boys and five girls) with a median age at onset of nine months,
24% had miid, 62% had moderate and 14% severe acne (22). The type of acne
was predominantiy inflammatory (59%). No chiid had any ciinicaily obvious
endocrinopathy. The authors noted the probable contributory role of testicuiar
androgen (22).
7C 2.2.3ABNORMALFOLL1CULARDHZFERENflAflON
In individuals with acne, the keratinocytes that une the lumen of the follicle are
not readily excreted (15). This is due to abnormal follicular epithelial
differentiation (9). Thus these celis are retained instead of being normally shed
off through the follicular opening. This obstruction eventually forms a
hyperkeratotic plug in the follicular canal. This plug is known as the
microcomedo. The exact mechanism by which this abnormal process occurs is
not fully elucidated. However, some evidence suggest a possible follicular
deficiency in linoleic acid in subjects with acne (23).
2.4PROPiONlBACTERlUM AGNES AND INFLAMMATION
Cutaneous propionibacteria, such as P. acnes, are pathogens that are implicated
in the development of inflamed acne lesions. P. acnes are anaerobic, gram-
positive diphtheroids that colonize within pilosebaceous follicles. However, t is
unknown whether they are permanent or temporary follicular residents (24). P.
acnes produce an extracellular lipase that hydrolyzes sebum triglycerides to
glycerol and fatty acids. The glycerol portion is the growth substrate for P. acnes.
The free fatty acids that are produced by the hydrolysis are proinflammatory (25).
P. acnes also release other proinflammatory substances, such as esterases,
proteases, hyaluronidsea and chemotactic factors that ailtact neutrophils. These
in turn release hydrolytic enzymes that damage and weaken the follicular waIl
8and eventually cause its rupture into the dermis (19). Such an inflammation may
resuit in the formation of a pustule or cyst (25).
2.3 TYPES 0F LESIONS
Acne is typically characterized by comedones, a plug of sebum and keratin
lodged in the follicular duct (26). Comedones may appear as either black- or
whiteheads. A closed comedo or micromedo can cause the follicular walI to
rupture, which resuits in an inflammatory reaction (19). Clinically, the
inflammation is associated with papules, pustules, macules, nodules and cysts.
Each of these lesions will be described in detail below.
2.3.1 PAPULES
Papules are generally five millimeter or less in size, and elevated slightly above
the skin surface. They often appear as small red lumps. A group of papules may
nearly be invisible to the naked eye, and may feel like ‘sandpaper’ on the skin.
They are caused by localized cellular reactions (27).
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Pustules are dome-shape, fragile lesions, which contain pus. The pus consists of
a mixture of white blood celis, dead skin and bacteria. Pustules form around a
hair (i.e. the pilosebaceous unit). There is usually no scarring if the pustule can
heal without progressing to a cystic form (27).
2.3.3 MACULES
Macules are temporary red or red-pink spots with weII-detined borders left by a
healing acne lesion. The presence of numerous macules resuits in an inflamed
‘red-taced’ look, as though the face has acne (27).
2.3.4 NODULES
Nodules are similar to papules, but are larger in size. They may appear as
domes or have an irregular shape. Inflammation is often present and extends
deeper into the skin layers. This can cause tissue damage and scarring (27).
Nodules can be extremely painful and do not respond to therapies, other than
isotretinoin.
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O 2.3.5CYSTS
Cysts refer to pus-filled acne lesions greater than five millimeter in diameter, in
which the walls are composed of inflammatory celis and scar tissue (26). Cysts
are large, sac like lesions containing a Iiquid or semi-liquid material consisting 0f
white blood ceils, dead skin cells and bacteria. They are often severely inflamed,
extremely painful and similar to nodules, extend into deeper layers 0f the skin,
causing tissue damage and scarring (27).
2.4 ACNE SEVERITIES
2.4.1 COMEDONAL ACNE
Comedonal acne is the mildest form of this condition and is non-inflammatory. It
is characterized by comedones on the forehead, chin, nase and paranasal areas
(9). This form of acne is non-inflammatory because P. acnes have not yet
colonized the follicle. Comedonal acne is mostly seen in the pre-teenage years
and early in adolescence (28).
2.4.2 INFLAMMATORY ACNE
lnflammatory acne develops after an initial phase of comedonal acne. This
condition is characterized by the formation of small papules and pustules (19).
P a g e 11
The inflammation is due to the proliferation of the P. acnes in the obstructed
follicle (28).
2.4.3 NODULOCYSTIC ACNE
Nodulocystic acne is a degradation of the condition. It is characterized by
pustular lesions larger than 0.5 cm (29). This represents the worst form of acne
and such Individuals often require aggressive treatment.
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2.5 PSYCHOSOCIAL IMPACT 0F ACNE
Although acne is a non Iife-threatening condition, it may have an important
psychosocial impact on an individual. Because of its effects on a person’s
physical appearance, acne could Iead to feelings of embarrassment and
shame while decreasing one’s self-esteem and self-confidence (30,31).
Severe acne has also been associated with a high unemployment rate (32).
The section below wiII describe several observational studies that have been
conducted to determine the psychosocial impact of acne. In a study
conducted by Yazici et aI. (33), the psychosocial impact of acne was
assessed in 61 subjects with acne and compared with 38 healthy subjects.
Subjects with acne responded to the Acne Quality of Life Scale (AQOL),
Dermatology Life Quality Index (DLQI) and Hospital Anxiety and Depression
Scale (HAD), while healthy subjects only responded to the HAD. The anxiety
(HAD-A) and depression (HAD-D) subscales of the HAD were significantly
greater in patients with acne than healthy subjects. Furihermore, there were
no correlations between acne severity and the AQOL, DLQI, HAD-A or HAD
D, indicating that subjects with acne were at an increased risk of anxiety and
depression irrespective of their acne severity. Finally, there were no
statistically significant differences in AQOL, DLQI, HAD-A, HAD-D scores
between males and females.
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C In another study conducted by Gupta et ai. (34), the prevaience of
depression and suicidai ideation in 480 patients with diverse dermatological
conditions was compared. Close to 6% of patients with acne had ciinicai
depression and suicidai ideation, compared with 0% of patients with aiopecia
areata, 2.1% of patients with atopic dermatitis and miid-to-moderate
dermatitis. Patients with severe psoriasis had a prevaience of 7.1% of ciinicai
depression and suicidai ideation, and were thus the oniy group to have
higher rates than the acne group. However, it must be noted that this study
used patients with miid-to-moderate acne, and as such, it is possible that
patients with severe acne wouid have had similar or greater rates of
depression or suicidai ideation than the severe psoriasis group.
in addition to causing greater depression and suicidai ideation, the quaiity cf
iife of individuais with acne may aiso be affected. Quaiity of iife, a measure of
the degree of enjoyment or satisfaction experienced in everyday iife, was
determined in a study of 130 patients with acne referred for speciaiist care
(35). Three measures were used, which inciuded two generic questionnaires
(EuroQoi (EQ-5D), Short Form-36 (SE-36)) and one disease-specific
questionnaire (Dermatoiogy Life Quaiity index (DLQ1)). The questionnaires
were administered two to three weeks before the outpatient appointment,
and at four and 12 months after the treatment began. Before the outpatient
visit, when compared to population norms, acne patients reported more
pain/discomfort (42.1% versus 17.7%) and anxiety/depression (52.8%
114
Ç versus 15.5%) on the EQ-5D. The mean score for the DLQI varied from 9.2
at baseline to 2.2 at 12 months, compared to 0.82 and 0.93 for the EQ-5D
and SE-36 physical and mental component scaies 49.7 and 44.1 fat
baseline) to 53.4 and 50.9 fat 12 months), respectively. Therefore, DLQI
demonstrated greater responsiveness to change in health status at four and
12 months than did the other two generics. However, this study had
considerable Ioss to follow-up; out the 130 patients recruited, oniy 60 (46%)
completed the questionnaires by 12 months. In an another study, 111
patients with acne referred to a dermatologist were found to have a mean
DLQI score of 7.5 (range 0-29), which is similar in deficits in quality of lite in
patients suffering from other chronic conditions like asthma, epilepsy,
diabetes, back pain, arthritis, coronary artery disease (36).
Table 1 displays a summary of the observational studies conducted on the
psychosocial impact of acne. These studies concluded that acne can have
important psychiatric consequences on those who suifer from it. Fortunately,
therapeutic treatments are effective at improving the mental state ot those
individuals (30,31,35,37). lnterestingly, some studies tound no correlation
between acne severity and level of depressive symptoms (33,36). In fact,
patients with mild-to-moderate acne have aiso been found to have
depression, suicidai ideation (34), and some have even committed suicide
(38). This indicates that acne severity is perceived differently from one
individual to another.
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2.6 ANTI-ACNE TREATMENTS
2.6.1 TOPICAL TREATMENTS
When topical treatments for acne are appropriate, they offer a number of
advantages over systemic treatments. In fact, the current trend is to fayot
topical treatments over the iong-term use of systemic antibiotics (39). Since
the skin is the iargest organ cf the body and is thus readily available, direct
application cf a topical agent would offer better monitoring cf the therapy
(40). Another major advantage is that topical agents do net cause as many
side effects as systemic agents (40). Drug-drug interactions with topical
agents are aise uncommon for this same reason (41,42). Another concern is
that many systemic agents, such as systemic antibiotics, do flot readily
penetrate the environment inhabited by P. acnes. This is due to the fact that
the micromedo is highly iipid and therefore is pooriy penetrated by
hydrophiiic antibiotics (41). Therefore, applying high concentrations cf a drug
directly upon its intended site of action can maximize the chance cf
penetration and a beneficial outcome. However, it shouid be noted that
topicai treatments are indicated for patients with non-infiammatory or mild te
moderate infiammatory acne (9). Systemic treatments, on the other hand,
are preferred when the condition is resistant te topical therapy, covers large
areas cf the body, causes significant psychoiogicai distress, or requires rapid
improvement (41).
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There are a number of topical treatments available for the treatment of acne.
Their indication for use primarily depends on the severity of the acne and
patient tolerability. A description of the main topical treatment is presented
below.
2.6.1.1 TOPICAL ANTIBIOTICS
Topical antibiotics are effective treatments for m ild-to-moderate inflam matory
acne. They work by reducing the population of P. acnes in sebaceous
follicles and by suppressing neutrophil chemotaxis (43). One of the main
advantages of topical antibiotics over other topical treatments is their 10w
irritative profile (44). Despite this advantage, there has been growing
concern regarding P. acnes resistance to these agents (24,44). Erythromycin
and clindamycin are the most commonly used topical antibiotics.
26.t1.1 ERYTHROMYCIN AND CLINDAMYCIN
In a randomized, double-blind clinical trial of 60 patients with moderate acne,
topical erythromycin and clindamycin were found to be therapeutically
equivalent (45). In fact, in several large randomized controlled trials, topical
erythromycin and clindamycin when applied twice daily were superior in
reducing the number of papules and pustules in patients with moderate-to
severe acne compared to placebo (46-48). However, because of growing
Ils
Ç concerns of P. acnes resistance, erythromycin and clindamycin
concentrations have been increased from one to four percent (24).
Current recommendations are that topical antibiotics should be given in
combination with other topical agents like benzoyl peroxide or tretinoin (44).
Such combination therapies result in a superior therapeutic effect than if
each component was used alone. This was demonstrated in two double
blind, randomized clinical trials involving 334 patients (49). The results of
these trials were that a combination gel containing clindamycin one percent
and benzoyl peroxide five percent was superior in reducing inflammatory
lesions as compared to each component alone, and superior to the
clindamycin-only gel in reducing non-intlammatory lesions (49).
26.12 TOPICAL RET1NOIDS
26.12.1 TRETINOIN
Tropical tretinoin, a vitamin A derivative, was the first topical retinoid to be
introduced in the US market in 1971 (26). Tretinoin prevents micromedo
formation by reversing the process of abnormal follicular differentiation (9). A
meta-analysis of randomized controlled trials involving 900 patients showed
that tretinoin 0.05% gel may induce up to a 53% reduction in comedones and
papules (50). Despite its efficacy, tretinoin may be photoirritant (28), and has
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been associated with erythema and peeling which have often limited its use
in clinical practice (26).
2.6.1.2.2 ADAPALENE
Adapalene is a synthetic retinoid used to treat mild to moderate acne. As
with tretinoin, adapalene inhibits comedo formation but also has anti
inflammatory activity (51). In a comparative trial of adapalene and tretinoin,
adapalene was shown to produce a 49% reduction in inflammatory and non
inflammatory lesions compared to 37% for tretinoin by week 12 of the
treatments (52). In other trials, adapalene was also shown to be better
tolerated than tretinoin and caused Iess erythema, scaling and dryness of the
skin (53-55).
2.6.1.2.3 TAZAROTENE
Tazarotene s the f irst of a family of receptor-selective acetylenic retinoids. In
a review of anti-acne treatments, tazarotene induced reductions in total
lesions of up to 71% compared to tretinoin at 37% and adapalene at 49% by
week 12 (56). This increased effectiveness has been attributed to its
increased specificity for certain retinoic acid receptors (28). However, it must
be noted that tazarotene may cause greater skin irritation than other topical
retinoids, and is therefore considered a second-line option to patients who
have not responded to topical tretinoin or adapalene (29).
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O 26.13OTHERTOPtCALTREATMENTS
2.61.3.1 BENZOYL PEROXIDE
Benzoyl peroxide has been Iabeled the gold standard for mild-to-moderate
acne (44). It is a potent bactericidal agent that inhibits the growth 0f P. acnes
more effectively than topical antibiotics (erythromycin and clindamycin) (19).
In addition, no bacterial resistance to benzoyl peroxide has been detected
(44).
Benzoyl peroxide is available in 1%, 2.5%, 5%, and 10% gels and lotions
(19). In two trials of 153 patients with mild to moderate acne, Milis et al. (57)
compared the efficacy of topical benzoyl peroxide at different concentrations
(2.5% vs. 5% and 2.5% vs. 10% used twice daily). Based on lesion counts,
there were no differences in efficacy among the different concentrations.
However, erythema and scaling occurred most often with the 10%
concentration formulation. Their conclusion was that the 2.5% and 5%
concentrations were preferable becaused they caused less side effects than
the 10% formulation.
26.13.2 SALICYLIC ACID
Salicylic acid is used to treat comedonal acne (28). It bas keratolytic effects
by shedding off the epithelial cells in the lining of the follicle (28,44). It is
available over-the-counter in either solutions, cleansers, and soaps (28). It is
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considered an alternative for patients who cannot tolerate the side effects of
topical retinoids (9).
26.1.3.3 AZELAIC ACID
Azelaic acid is a naturally occurring dicarboxylic acid that works by
normalizing keratinization and reducing the proliferation of P. acnes (58). In
an randomized controlled trial of 92 patients with moderate acne, treatment
with azelaic acid 20% resulted in a 72% in total lesion reductions compared
to 47% for placebo (59). In another randomized controlled trial, azelaic acid
20% was shown to have a similar efficacy as tretinoin 0.05%, benzoyl
peroxide 5%, and topical erythromycin 2% (60). In comparison to other
topical treatments, azelaic acid poses no teratogenic risks, exhibits excellent
local tolerability, and does flot induce P. acnes resistance as with topical
antibiotics (60). A summary of the main topical treatments for acne is
presented in Table 2.
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Table 2. Topical treatments for acne vulgaris
Topïcal agent Mechanism of action Side effects
Topical antibiotics
IrritationErythromycin Reduction of P. acnes population p• acnes resistance
IrritationClindamycin Reduction of P. acnes population p• acnes resistance
Topical retinoids
Photoirritant
Tretinoin Prevents microcomedo formation Erythema
Peeling
Prevents microcomedo formationAdapalene Anti-inflammatory activity Same as tretinoin, but Iess severe
High specificity for retinoic Same as tretinoin, but moreTazarotene
receptors severe
Other topical agents
Inhibits growth of P. acnes ErythemaBenzoyl peroxide MiId keratolytic effects Peeling
D rynessSalicylic acid Keratolytic effects Irritation
D ryness
Normalizes keratinization PeelingAzelaic acid Inhibits proliferation of P. acnes Erythema
Irritation
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2.6.2 SYSTEMIO TREATMENTS
Section 2.6.1 described the different topical treatments availabie for the
treatment of mild acne. However, these treatments are not as effective for
moderate to severe acne. The following sections wiN describe ail available
systemic treatments, as well as describe their mechanism of action, their
efficacies, and side effects. A summary of the main systemic treatments is
presented in Table 4.
2.6.2.1 SYSTEMIC ANTIBIOTIOS
Systemic antibiotics have been used in the treatment of moderate to severe
acne for many years. They work in several ways. First, they suppress the
growth of P. acnes, and thus prevent the release of its inflammatory
mediators (61). Second, certain systemic antibiotics, such as tetracycline
and erythromycin, have anti-inflammatory properties which work by
preventing neutrophil chemotaxis (43). Third, systemic antibiotics reduce
comedone formation by suppressïng the infiltration of perifollicular
lymphocytes (62). Because they are systemic agents, oral antibiotics cause
more side effects than topical agents (40). As with topical antibiotics, there is
concern of increased P. acnes resistance to systemic antibiotics (40).
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2.62.t1 TETRACYCUNE, MINOCYCLINE AND DOXYCYCLJNE
Tetracycline and its lipophilic derivatives, minocycline and doxycycline, are
the most commonly prescribed oral agents for acne vulgaris (63). A six-week
treatment with tetracycline reduces the number cf lesions by 50% (64).
Therapy usually starts at 500 mg twice daily for three to six weeks, and then
reduced to 250 mg twice daily (28). Side effects associated with tetracycline
use include nausea, vomiting, diarrhea, vaginal candidiasis, photosensitivity,
and hypersensitivity reactions (28,63). Permanent tooth discoloration may
occur in children under the age of fine (28). In addition, tetracycline should
not be prescribed to pregnant women because cf possible neural tube, cleft
palate, and cardiovascular malformations (65).
If tetracycline therapy fails, doxycycline and minocycline may be indicated.
Both are prescribed at a dosage of 50 mg to 100 mg twice daily, which is
reduced after three to six weeks if improvement is observed (28). Because
minocycline is more lipophilic than tetracycline and doxycycline, it can cross
the blood-brain barrier and cause headaches, vertigo, ataxia, and light
headedness (28). Minocycline has also been associated with serum
sickness-like reactions, drug-induced lupus, and hypersensitivity reactions
(66).
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2.62.12 ERYTHROMYCN
Erythromycin s flot as effective as tetracycline in the treatment 0f moderate
to severe acne. This was shown in a trial of 200 patients randomly assigned
to either erythromycin or tetracycline. Seventy percent of those who got
erythromycin and 89% 0f those who got tetracycline stated that their acne
got better by week 12 (67). However, the erythromycin group reported a
greater number of gastrointestinal side effects (nausea, vomiting, abdominal
cramping, diarrhea) than the tetracycline group (67). Others have found that
P. acnes exhibits greater resistance to erythromycin than to tetracycline (68).
These side effects have Iimited the use 0f erythromycin in clinical practice
(28).
2.62,1.3 OL!NDAMYCIN
Clindamycin has been shown to have a similar efficacy as tetracycline in the
treatment of inflammatory acne (69). However, its use has been associated
with pseudomembranous colitis, affecting between two and 30% of patients
(70). Because of this important side effect, clindamycin is rarely used as an
acne treatment (9).
:2622 HORMONAL THERAPY
As was discussed in section 2.2.2, there is a direct correlation between
androgen levels and acne (71). It has been proposed that androgens
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C increase sebaceous gland activity, and may also cause hyperkeratosis of the
pilosebaceous gland (72). This is especially true in acne patients, where their
sebaceous glands are thought to be hyperresponsive ta normal serum
androgen levels (73).
Over the Iast few years, oral contraceptives (OC) have been proposed as
another therapeutic option for women with acne. This is because OCs have
been shown to reduce the amount of circulating androgens, thereby
decreasing the severity of acne (71). There are currently twa hormonal
preparations indicated for the treatment of acne; those containing
norgestimate and those containing cyproterone acetate (74).
Twa randomized, double-blind placebo-controlled clinical trials were
performed ta assess the efficacy of the ethinyl estradiol/norgestimate
combination in the treatment of moderate acne (21,75). In the first, Lucky et
al. (21) randomized 257 patients ta receive either the OC or placebo. The
OC group experienced a 53% reduction in total lesion counts at 26 weeks,
compared with a 27% reduction in the placebo group. The main adverse
effect was nausea. The OC treatment was protective of pregnancy and
alleviated dysmenorrhoea (21). These resuits concord with those of a
second study that randomized 250 patients ta either OC or placebo (75). The
OC group experienced a 46.4% reduction in total lesion counts at 24 weeks,
compared with a 33.9% reduction in the placebo group. The authors attribute
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the rather large reduction in lesion counts in the placebo group to the study
protocol itself, since the frequent office visits may have increased patient
awareness and led to better skin care in some patients (75).
Cyproterone acetate, a progestin, works by acting as a competitive inhibitor
to testosterone and DHT on androgen binding sites, and also inhibits
gonadotropin secretion (74). Studies conducted on cyproterone acetate have
been of poor quality. Only one study was a randomized trial, but used
subjective dermatological measurements, such as “complete healing” and
“definitive healing” to assess treatment efficacy (76). Other studies were not
randomized trials (77,78) and only one used an objective dermatological
measure such as lesion count to assess treatment efficacy (78). In ail, these
studies reported 60% to 73% in improvement compared to baseline (76-78).
In Canada, the use of cyproterone acetate has been a controversial issue
since it was first Iicensed for sale in 1998. The Food and Drug Administration
f FDA) has neyer approved the licensing of this agent. This s because of
concerns over a possible association with liver cancer. In 1994, German
regulatory authorities commissioned a safety review after a woman died from
liver cancer after she had used the ethinyl estradioi/cyproterone acetate
combination as a birth control method for 14 years (79). Supporting this
association are Iaboratory studies showing abnormal liver ceil growth in
animal and human tissue exposed to cyproterone (80). This evidence ied
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C German regulatory authorities to restrict the US 0f cyproterone acetate
women suffering from severe acne with hormonal imbalances.
The risks associated with the use of cyproterone acetate prompted Health
Canada to issue an advisory in May 2005 (81). The Product Monograph now
states that ethinyl estradiol/cyproterone acetate combination puis shouid not
be used as a means for birth control, and shouid be discontinued three to
four months atter signs of acne have resolved (81).
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2.62,3 SOTRETINOIN
Isotretinoin (13-cis-retinoic acid) is a systemic retinoid that represented a
major breakthrough in the treatment of severe nodular acne. Because
isotretinoin is the focus of this thesis, section 2.8 will be dedicated to
describing ail aspects related to this medication. They include its mechanism
of action, its utilization since its marketing, its effectiveness at preventing
acne relapse, its cost, as well as its documented side effects.
:26.3 ADJUNCT1VE THERAPIES
Sections 2.6.1 and 2.6.2 listed ail currently available pharmacologic
treatments for acne. There are however, non-pharmacological treatments
that have seen some success in the treatment of acne. The following
sections will describe the effectiveness of chemical peels, photodynamic
therapy, corticosteroids as weli as other adjunctive therapies.
2631 COMEDONE EXTRACTION
Comedone extraction is performed using a comedone extractor by an
experienced operator (28). This procedure is believed to provide faster
improvement that topical therapy (28). However, patients are usualiy advised
not to per(orm this procedure themselves since the infiammatory material
130
may be pushed deeper in the skin and resuit in a deterioration of the
condition (15).
2.6.3.2 CHEMICAL PEELS
Chemical peels help correct the surface of scarred and hyperpigmented skin
(82). Peeling agents include alpha-hydroxy acids, salicylic acid (28,44), and
trichioroacetic acid (15). Chemical peeling should only be performed once
the acne s deemed to be under control (15).
2.6.3.3 PHOTODYNAMIC THERAPY
Photodynamic therapy, usually performed in patients with mild or moderate
acne, uses ultraviolet light to target P. acnes in the pilosebaceous unit
(83,84). Significant reductions in acne lesions are possible atter four to 12
weeks of photodynamic therapy (using blue light and mixed blue and red
light) (84). However, photodynamic therapy should not be performed for long
periods of time because it might enhance comedogenesis and damage the
skin (15).
• 26.34 CORTICOSTEROIDS
Corticosteroid injections are indicated for large pustular nodulocystic lesions.
They have the ability of rapidly reducing the size and inflammation of lesions
131
C (9,28). Corticosteroid injections have possible side effects, which include
skin depression (28) and atrophic scars (15). Therapy is usually repeated
every two to three weeks (28).
2.6.3.5 OTHER THERAPIES
A number of other therapies are available for patients with acne, especially
for those with scarring acne. They include dermabrasion, laser resurfacing,
punch grafts, and collagen injections (28).
2.7 CANADIAN ACNE TREATMENT GUIDELINES
Two Canadian acne treatment guidelines were published over the years.
Both sets of guidelines primarily focused on the treatment of severe acne.
The first Canadian acne treatment guidelines were published in 1995 (85). In
these guidelines, severe acne was defined as having numerous comedones,
papules, nodules and scars. In the more recent Canadian acne treatment
guidelines published in 2000, severe acne was defined as having either
persistent inflammatory papules, papulopustular disease, scarring, presence
of sinus tracts, or inadequate therapeutic response (86). The difference in
these definitions has thus implications on how to treat severe acne.
According to the 2000 guidelines, the presence of scars and the severity of
inflammatory lesions are deemed independent indicators of severe acne.
32
C Therefore, these guidelines put a higher emphasis on the presence
scarring than did the 1995 guidelines.
There are three major differences between the 1995 and 2000 guidelines.
The first is that the 1995 guidelines proposed up to three courses of systemic
antibiotics, each lasting four to six months, before considering isotretinoin
therapy. In contrast, the 2000 guidelines propose initiating an isotretinoin
treatment after failure of a four-month therapy of a single course of systemic
antibiotics or hormonal therapy. The second is that the 2000 guidelines
emphasize scarring as a primary decision criterion for prescribing
isotretinoin. Finally, the 2000 guidelines propose initiating an isotretinoin
therapy in the presence of scars, irrespective of the severity of acne.
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2.8 ISOTRETINOIN
Isotretinoin is an effective medication for the treatment of severe nodular
acne. It has been labeled a miracle drug by many physicians and patients.
This is because it is the only anti-acne agent able to target the various
etiological factors associated with acne (3). However, since its release in the
market it has been associated with some serious side effects. As a result,
several guidelines and programs have been implemented to better prescribe
this medication. The present section will describe isotretinoin’s mechanism cf
action, its utilization, its effectiveness at maintaining long-term remissions, its
relative cost compared to other anti-acne treatments, as well as its side
effects.
2.8.1 MECHANISM 0F ACTION
Isotretinoin is a systemic retinoid. Retinoids, which could either be synthetic
or natural, are a family of compounds possessing functional properties cf
vitamin A. Retinoids are known to affect cellular growth (87,88), immune
functions, tumor promotion, and malignant potential of cells (89).
Isotretinoin is actually a natural compound that circulates in the blood after a
meal rich in vitamin A (90). It is administered orally and is usually absorbed
in two to four hours, and is primarily transported by albumin in the plasma
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(91). It has an elimination haif-life of 10.4 to 29.5 hours (91). To date, the
exact mechanisms through which isotretinoin mediates its therapeutic eftects
are unknown. However, it has been shown to induce a dramatic reduction in
the size of the sebaceous glands, while being able to inhibit the production of
sebum (3). It also has the ability to reduce the formation of comedones, and
decrease the inflammation associated with acne (3).
2.8.2 ISOTRETINOIN UTILIZATION
According to the product monograph, isotretinoin is indicated for severe
nodular acne (92). The recommended duration of an isotretinoin treatment is
between 15 to 20 weeks (92,93).
Since its introduction in the market, isotretinoin’s popularity in the treatment
of dermatologic conditions has increased significantly. Fleischer et al. (94)
used the National Ambulatory Medical Care Survey (NAMCS) to determine
the demographics of patients with acne using isotretinoin, minocycline and
tetracycline between 1990 and 1997. Out of the 35 million visits to the
physician, isotretinoin was prescribed 5.8 million times (17% of the visits).
Whites were 2.3 times more likely to being prescribed isotretinoin than
blacks. It was suggested that this difference was due to the socioeconomic
situation ot blacks in the US. lnterestingly, although women consulted 1.4
times more than men, men were 1.7 times more likely than women to receive
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isotretinoin. This difference was not associated with the expense of the
medication, but rather to the teratogenecity of the medication.
The results of the study above are likely to be different in countries with
medication reimbursement programs, such as Canada. In such systems, the
expense of the medication is no longer an issue. Thus, we would flot expect
to observe racial differences solely because of the cost of the medication. If
differences did appear, then they would most Iikely be associated with
cultural perceptions of the risk benefit ratio of treatment as well as
perceptions of trust in physicians and the medical care system (95). Sex
differences in the use of isotretinoin may be related to the teratogenecity of
the medication. Therefore, physicians may be more reluctant to prescribe
isotretinoin to women.
In a second study, Wysowski et aI. (96) used two US pharmaceutical
marketing research databases, the National Prescription Audit Plus and the
National Disease and Therapeutic Index, as weII as two health plan
networks. A total of 19.8 million isotretinoin prescriptions were dispensed
between 1982 and 2000. From 1983 through 1993, the media,, number of
prescriptions was just over 800,000. Interestingly, between 1992 and 2000
there was a 2.5-fold increase in the median number of prescriptions
dispensed. During the same period, the proportion of patients with severe
137
C acne receiving isotretinoin declined from 63% ta 46%. In contrast, the
proportion of patients with mild and moderate acne increased from 31% ta
49%. The authors interpreted this as a red flag, given that it is increasingly
being prescribed outside of its intended severity. Others have become
concerned over the use of isotretinoin for new off-label indications such as
gram-negative folliculitis, recalcitrant rosacea, pyoderma faciale, generalized
lichen planus, psoriasis, cutaneous lupus erythematosus and acne fulminans
(97).
Isotretinoin is intended for patients with severe nodular acne or for those who
have not responded ta conventional therapy. However, Chen et aI. (98)
found that 39% cf patients had flot received any anti-acne medication in the
six months prior ta the f irst isotretinoin prescription as recommended by
product guidelines. This is consistent with another study conducted by Wert
et al. (92), where 47% to 72% of patients did flot receive conventional
therapies prior ta initiating an isotretinoin treatment.
With the expiration of the patent held by the manufacturer cf Accutane®,
three generic forms of isotretinoin have entered the US market: Amnesteem®
(November 2002), Sotret® (December 2002), and Claravis® (April 2003).
These are expected to drive prices down, and further increase the use of
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isotretinoin. As a resuit, it is likely that more individuals with mild-to-moderate
acne or with other off-label indications will receive isotretinoin.
2.8.3 RATES 0F ACNE RELAPSE
The effectiveness of isotretinoin at reducing acne lesions and preventing
relapses has been documented in a number of observational studies. Seven
0f these studies were conducted in Europe (five in France and two in the
United Kingdom [UK]) (99-105) , three in Asia (two in Singapore and one in
the Philippines) (106-108), one in the Middle-East (Kuwait) (109), and only
one in North America (US) (1 10). The relapse rates varied between studies,
ranging from 5.6% to 65.4% (99-110). There are several possible
explanations for this large discrepancy. First, these studies had small sample
sizes, ranging between 52 and 299 patients (99-110). Second, some studies
had short tollow-up periods (105,106,108,109), and may have thus
underestimated the relapse rate. Finally, relapse was flot defined
consistently across the different studies. A summary of these studies is
presented in Table 4.
In 1986, Harms et aI. (99) published a prospective cohort of 89 patients with
severe acne recruited from a French dermatology clinic. Patients were
followed for up to 47 months from the initiation of their isotretinoin treatment.
A total of 13 (14.6%) patients relapsed during follow-up. Isotretinoin
39
Ç cumulative dose was flot found to be a predictor of acne relapse. Moreover,
more males tended to relapse than females (16.6% versus 8.6%), while
younger patients relapsed more frequently than older patients.
In another study, Chivot and Midoun (100) investigated 172 patients who
underwent isotretinoin therapy in a French dermatology clinic. Patients were
followed from a minimum 0f 12 to 41 months after the end of their isotretinoin
treatment. A total of 37 (21%) patients experienced an acne relapse. The
authors determined whether the following variables were predictors of acne
relapse: patients’ age, duration of acne prior to the treatment, total dose
received, daily dosage, the duration of treatment, and acne severity. Only
young age and severity ot acne were predictive of acne relapse.
In 1993, Stainforth et al. (101) published the largest study to date. They
investigated 299 patients who have been treated with isotretinoin in a
dermatology clinic in the UK, and which were followed for up to five years
after their treatment. Out of the 299 patients, 68 (22.7%) patients required at
Ieast a second course of the treatment during the tollow-up period.
lnterestingly, 75% of those patients relapsed in the tirst 12 months and most
only required an additional course of treatment. Patients who had received
Iower dose regimens (0.1 to 0.5 mg/kg), had severe acne, were females over
the age of 25 at the time of the first treatment, and had a long history of acne
140
Ç were more prone to repeat a course of isotretinoin. The authors did flot
perform any analyses to adjust for potential confounding factors.
Lehucher-Ceyrac and Weber-Buisset (102) conducted a prospective cohort
study of 188 treated with isotretinoin at a dermatology clinic in France.
Patients were followed for up ta nine years from the initiation of the
treatment. Patients were evaluated at regular intervals for signs of acne
relapse. Patients underwent a new treatment course if the relapse resulted in
an acne grade greater than two (considered the pre-nodular threshold). The
authors categorized the outcome of the patients according to the following
algorithm: 1) immediate, long-term remissions following one course of
isotretinoin, 2) stable remissions after twa ta three courses of isotretinoin,
and 3) partial remissions. A total of 111 (59%), 54 (29%), and 23 (12%)
patients were categorized according ta the algorithm above. There were
statistical differences between the f irst and second groups with respect ta
age, sex, acne grade and duration of acne prior ta the first isotretinoin
treatment. The third group had a greater proportion of patients with
microcystic acne and women with endocrinological problems than the other
two groups.
In a smaller study, Layton et al. (103). studied 88 patients treated with
isotretinoin ta determine factors which might affect long-term outcomes.
41
Patients were recruited from a dermatology clinic in the UK and foilowed for
up to 10 years after their isotretinoin treatment. To date, this is the study with
the longest follow-up. A total of 21 (31%) patients experienced a relapse in
their acne, and 96% 0f them did so with three years after the isotretinoin
treatment. Twenty-three percent of ail patients required a second isotretinoin
treatment. The authors report that age, sex and duration of acne were flot
predictive of acne relapse. On the other hand, patients with truncal acne
were at a greater risk of relapse than other patients. Cumulative dose was
also a predictor cf relapse, where those who received a cumulative dose 0f <
120 mg/kg were at a greater risk.
In a study conducted in a skin clinic in Singapore, Shahidullah et al. (106)
investigated the case records 0f 250 patients with severe inflammatory and
nodulocystic acne treated with isotretinoin. The authors collected data
pertaining to the patients’ demographics, response to isotretinoin, clinical
follow-up, and relapse. Acne relapse occurred in 14 (5.6%) patients over a
six-month follow-up period. Predictors of relapse were flot reported by the
autho rs.
In Kuwait, Al-Mutairi et al. (109) followed 160 patients with moderate-to
severe acne treated with isotretinoin. Patients were followed regularly for a
period cf 12 months after the end ot the isotretinoin treatment. Relapse was
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defined as having a reccurence of mild acne eight weeks after the end of the
isotretinoin treatment. Patients were followed up regularly for a period of 12
months after stoppage of isotretinoin for any evidence of relapse. In the
event of a recurrence greater than mild acne after eight weeks of stoppage
of isotretinoin therapy, the patients were given another course of the drug.
Patients were considered to be non-relapsing if they had no evidence of
recurrence after 12 months of folIowup. Twenty seven patients were
excluded from the study. 0f the remaining 133 patients (51 male and 82
female) only 117 patients (36 male and 81 female) coutd follow up for at
least 12 months after stopping therapy. 0f the 133 patients, a total of 127
patients (95.5%) achieved complete or partial clearance. Forty two percent
(total 49 patients: 20 maIe and 29 female) experienced relapse after stopping
therapy. 0f these, 21 (42.85%) were given a second course of the drug.
None of the patients developed a rise in lipids levels significant enough to
warrant stoppage of the drug.
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2.8.5 SIDE EFFECTS
Since isotretinoin is a vitamin A analogue, many of the side effects of this
drug are similar to what is observed in hypervitaminosis A syndrome (3).
Side effects ot ail sorts have been documented; mucocutaneous,
ophthalmologic, neuromuscular, and elevations in plasma cholesterol and
liver enzymes.
2.8.5.1 TERATOGENECITY 0F ISOTRETINOIN
Before the launch of isotretinoin in the US market in 1982, its teratogenecity
was well known based on animal studies (111). However, since isotretinoin
was seen by many physicians as a cure for acne, it was a question of time
until infants would be born atter being exposed to isotretinoin in utero (112).
The teratogenic effects of isotretinoin have been reported as early as 1983
by Rosa et al. (113), in which they described congenital abnormalities in four
infants exposed early in gestation. Following that report, the FDA listed
isotretinoin as a severe hazard during pregnancy (114). Despite the new
FDA warnings, exposed pregnancies continued to occur (112,115,116).
2.8.5.1.1 WARNING SYMBOLS ON CAPSULES
In an effort to inform patients about the teratogenic risk of isotretinoin, the
manufacturer of the drug used a warning symbol depicting the silhouette of a
n 45
C pregnant woman covered by the symbol for “No”. In 1989, isotretinoin
packaging was changed from loose puis in a bottie to a blister pack, and the
‘no pregnancy’ symbol was placed behind every capsule (2). The goal of
such a symbol was to inform non-pregnant women who were taking
isotretinoin not to become pregnant while on treatment, or women who were
pregnant flot take the drug. Daniel et al. (117) were interested in determining
patient interpretation of the symbol, and whether it had a place in a patient
education program. They recruited 97 women from 10 different locations,
and administered a questionnaire pertaining to the interpretation of the
symbol. They found that oniy 21% of the women correctly identified the
symbol. Twenty-seven percent responded the package contained birth
control medication, and 24% said the package simply contained drugs.
Moreover, seven percent said they did not know what the symbol meant.
Aiarmingly, 39% of respondents claimed there were circumstances in which
the drug might be shared. This study illustrates that misinterpretation of
warning symbols may potentiaiiy lead to serious consequences. The authors
advocate that careful pretesting and modification of warning symbols should
be done before they appear on drugs that have a teratogenic risk.
2.82.1 .2 CONGENITAL MALFORMATIONS ASSOCIATED TO
ISOTRETINOIN
There are several congenital malformations associated to isotretinoin
C exposure in utero. Since its marketing in 1982 in the US, and 1983 in
I 46
Ç Canada, several reports have been published on its teratogenic effects.
Table 5 below displays the main congenital malformations associated with
isotretinoin-exposed pregnancies.
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Table 5. Congenïtai malformations associated with isotretinoin exposure
Craniofaciai malformations
Frontal bossing (112)
Microphthalamia (2,112,118)
Cleft palate (112,118,119)
Smaii mouth (112)
Triangular microcephalic skuli (1 18)
Depressed midface (118)
Depressed nasal bridge (119)
Micrognathia (118,119)
Confluent eyebrows (2)
Unspecified craniofaciai malformations (120-122)
Ear malformatïons
Undifferentiated ears (112,118)
Absent or imperforate auditory canai (118)
Small ear canais (112)
Anotia (123-1 25)
Microtia (123,124)
Unspecified ear malformations (2)
Cardiovascuiar malformations
Congenitai heart disease (112)
Overriding aorta (118)
Hypoplastic aortic arch (118)
Septation defects of atria or ventricles (118,119)
Abnormal subciavian arteries (118)
Double-outlet right ventricle with dextrocardia (121)
Unspecified cardiovascuiar malformations (118,120,124)
Centrai nervous system malformation
Microcephaly (119,124,126)
Hydrocephaly (112,124)
Unspecified central nervous malformations (118,120,123)
Other malformations
Limb reduction defect (118)
Dandy-Walker malformation (112)
Hypoplastic scrotum (2)
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28.5.l.3THE PREGNANOY PREVENTION PROGRAM
Since neariy 50% cf ail pregnancies in North America are unplanned (127),
an inadvertent exposure to a teratogenic drug may eaU to disastrous
consequences. Therefore, to ensure a zero pregnancy tolerance while on
isotretinoin, the manufacturer cf the drug and the FDA jointly instituted the
Pregnancy Prevention Program fPPP) in October 1988. The PPP instructs
physicians that wcmen cf childbearing age should meet the follcwing three
conditions:
1. Signing cf a consent form
2. Taking a pregnancy test seven days prier te initiation cf the treatment
3. Using twc forms cf contraception simultaneously during and a month
after the treatment, unless the patient daims she is net sexuaiiy active
Despite the impiementation cf the PPP, isotretinoin expcsed pregnancies
continued te occur (2,128). This is because there were ne means cf verifying
that patients and physicians compiied with the prcgram. In 1992, Dai et al.
(120) scught te determine the reasons for and cutcomes cf in utero
isctretincin expcsure. They used spontanecus reports cf isotretincin
expcsed pregnancies that were voluntarily submitted to the manufacturer cf
the drug (Hcffmann-La Roche Inc.) in the US frcm September 1982 te July
1989. The repens cf 433 isotretincin-exposed were obtained, but timing cf
conception in relation te isctretinoin exposure was kncwn for only 396
49
women. 0f these, 133 (33%) were already pregnant before isotretinoin
therapy was initiated, and 65 (16%) patients became pregnant in the first
three weeks of isotretinoin use. The authors also found that the rates of
pregnancy while on treatment declined from 1982 to 1988. However, these
were reporting rates and flot absolute rates. The numerator was based on
spontaneous reports, and thus did flot reflect the true number of pregnancies
that have occurred during the treatment. Furthermore, the denominator was
calculated by projecting isotretinoin use among female patients between 12
and 44 years of age. Dai et al. (120) were able to obtain the pregnancy
outcomes for 409 out 0f the 433 patients. 0f these, 222 (54%) ended in
elective termination, and 29 (7%) in spontaneous or missed abortion. There
were 151 births; 72 (48%) were normal, 71 (47%) had congenital
malformations, and eight (5%) had abnormalities other than malformations.
There were 94 live births; 28% had congenital malformations.
In 1995, Mitchell et al. (2) from the Slone Epidemiology Unit were the first to
assess the compliance of physicians and patients with the PPP. They
enrolled women through their physician, by filling out a form in their
medication package, or by calling a toII-free telephone number. As a means
to increase participation, patients received $10 for taking part in the study.
As such, this study was limited to those who accepted to participate, and
therefore, these patients may have been inherently different from those who
did not accept to participate. Furthermore, the physicians were asked to
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encourage patients to participate in the study. This may have increased
physician awareness of the study objectives, and thus it is possible that it
had an impact on the implementation and compliance with the PPP. The
same could be said about the patients who volunteered to participate in the
study. Accepting to participate in the study may have also increased their
awareness of the teratogenecity of isotretinoin. In addition, patients were
contacted at the start of therapy as weII as during the treatment. The authors
acknowledged that these inquiries might have “transformed the survey,
which was intended to be observationaI into a form 0f intervention” (2).
Despite these limitations, this study remains a hallmark on the effectiveness
of the PPP. Between 1989 and 1993, 177,216 eligible women were enrolled
in the survey. For the 24,503 women interviewed within one month of
enrollment, 99% revealed that they had been told to avoid pregnancy.
Furthermore, 78% were told to wait for pregnancy test results and 63% to
wait until the next menstrual period before starting isotretinoin, and 60% had
a pregnancy test.
Mitcheli et aI. (2) found an overail pregnancy rate during isotretinoin of 3.4
per 1000 for a 20-week course of isotretinoin. 0f the women who became
pregnant during the treatment, they found that 72% had elective
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terminations. Among the live births, the authors found that 38% had a
congenital abnormality compatible with isotretinoin exposure.
In 2007, Bérard et aI. (129) published a study on a cohort of 8609 women
undergoing a first isotretinoin treatment between 1984 and 2003. The
pregnancy rate during the treatment was 12.6 (95% 0110.2, 15.4) per 1000
for a 20-week course of isotretinoin. This rate was nearly four times greater
than the one reporled by Mitcheil et aI. (2). A possible explanation for this
large discrepancy between studies is the observational approach in the study
conducted by Bérard et al., compared to the more interventional approach
employed by Mitcheil et al. (2). Interestingly, there were no reductions in the
pregnancy rate after the implementation of the PPP in October 1988,
indicating potential failures of the program at preventing pregnancies in this
population. Finally, the rate of elective abortions was relatively high (84%),
although the rate of congenital malformations was low (11%).
2.85.1 A THE SMART PROGRAM
Because of the failure of the PPP to prevent isotretinoin-exposed
pregnancies, the System to Manage Accutane Related Teratogenicity
(SMART) program was implemented in April 2002 in the US. This program
was aimed at improving the PPP by additionally requiring that two pregnancy
tests be performed before initiation of treatment, while improving patient
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education of the risks related to the treatment. In addition, the SMART
program required yeilow qualification stickers on ail prescriptions. The
qualification stickers were meant to be filled out by prescribers in order to
ascertain that ail female patients receiving isotretinoin are qualified (two
negative pregnancy tests prior to treatment, and that they are using two
forms of birth control). Pharmacists were instructed to fiN only those
prescriptions with qualification stickers (130).
Despite these new regulations, the performance of the SMART program was
deemed suboptimal. In 2005, Brinker et al. (130) published a study in which
9% of women received a qualification sticker without taking a pregnancy test.
Thirty-four percent of women failed to receive two pregnancy tests, and 54%
did flot use two birth control methods. Despite increasing patient awareness
of the risks associated with an isotretinoin-exposed pregnancy, the SMART
program did flot significantly reduce the number of exposed pregnancies as
compared to the PPP (130). Reasons cited for these tailures include
prescriber under-compliance with the program, lack of motivation from the
patients, or the ability to use to two forms of contraception during the
treatment (131).
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285.1 5 THE PLEDGE PROG RAM
The iPLEDGE program was implemented in March 2006 in the US. It is more
stringent than its predecessor, the SMART program. iPLEDGE is a
computer-based risk management program that was designed to further
prevent isotretinoin-exposed pregnancies. Contrary to past programs, both
male and female isotretinoin users must register anime
(www.ipledqeproqram.com) or by telephone. Furihermore, prescribers as
weII as wholesaiers of isotretinoin must register in the database. Under the
iPLEDGE program, prescribers must enter the resuits of two negative
pregnancy tests, specify the two forms of contraception the patient agreed to
use, perform monthly pregnancy tests, provide pregnancy prevention
counseling, and identify at every month the patient’s contraception choices.
The patient on the other hand, must register in the database, sign a consent
form, and identify their twa forms of contraception on a monthly basis (which
must match the prescriber’s entries). Finally, pharmacists can onIy dispense
isotretinoin when both prescriber and patient have met ail system
requirements. To date, the iPLEDGE program has not been formally
evaluated.
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Ç 2.8.5.2 MU000UTANEOUS SIDE EFFECTS
Many 0f the mucocutaneous side effects 0f isotretinoin are dose-dependent.
It has been proposed that twice daily dosing regimens of the drug can
decrease the appearance 0f side effects (132).
Cheilitis (inflammation and cracking 0f the skin 0f the Iips) is one of the most
common side effects of isotretinoin therapy, affecting close to 100% of
patients (3). Interestingly, the absence of cheilitis during the treatment may
be an indicator 0f non-compliance (132). Other mucocutaneous side effects
have been reports of the thinning cf the hair and increased brittleness of the
nails. This occurs three to eight weeks into the treatment, but stops six to
eight weeks after stopping the drug (133). In one study 0f 720 patients
followed-up for a mean of 4.9 years, alopecia was reported in two (0.3%)
patients only (134).
In a study evaluating 104 reports sent to Adverse Drug Reaction Reporting
System between 1982 and 1985, 29/104 (28%) reports were related to
mucocutaneous side effects (135). Because these were based on
spontaneous reports, it was not possible to estimate the incidence 0f such
complications. Between 1982 and 1987, McElwee et al. (136) prospectively
followed 466 patients who were prescribed isotretinoin throughout a four- to
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Ç five-month course treatment. Neariy ail patients (97%) were found to develop
mucocutaneous side effects.
2.8.5.3 OPHTHALMOLOGIC SIDE EFFECTS
In addition to mucocutaneous side effects, isotretinoin can induce
ophthalmologic conditions such as the drying of the ocular conjunctivae
(134). It appears that isotretinoin decreases secretions from the meibomian
gland just as t does with sebaceous glands (3). This resuits in the loss of the
surface lipid layer over the corneal tear film and thus increases evaporation
of basal tears and leads to dry eye syndrome. For this reason, the wear of
contact lenses during the treatment is not recommended in order to avoid
more serious complications (137). Dry eye syndrome may persist after
isotretinoin discontinuation, although this occurs in only one percent of
patients (134).
Fraunfelder et al. (138) investigated ail types of ocular side effects that may
be associated with isotretinoin exposure. They reviewed 1741 spontaneous
reports that were sent to the manufacturer of the drug or found in literature
and classified them according to the World Health Organization Causality
Assessment Guide of Suspected Adverse Reactions. Symptoms or
abnormalities were classified as either “certain”, “probable/likely”, “possible”,
“unhikely”, or “conditional/unclassifiable”. Side effects that were classified as
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C “certain” included abnormal meibomian gland secretion,
blepharoconjunctivitis, corneal opacities, decreased dark adaptation,
decreased tolerance to contact lens, decreased vision, increased tear
osmolarity, keratitis, meibomian gland atrophy, myopia, ocular discomfort,
ocular sicca, photophobia, and teratogenic ocular abnormalities.
“Probable/Iikely” side effects included decreased color vision (reversible) and
permanent loss of dark adaptation. Those that had a “possible” association
included permanent keratoconjunctivitis sicca. Because these were derived
f rom spontaneous reports, it is not possible to calculate the incidence of
these ophthalmologic complications since there is no denominator. Egger et
al. (139) prospectively followed 55 patients before, during and after an
isotretinoin treatment. Staphylococcus aureus in the corneal sac was found
in 7.3% of patients before initiation of treatment and increased to 61.8%
during treatment. In addition, 40% deveioped blepharitis (inflammation of the
eyeiids), although ail ocular side effects disappeared compieteiy one month
after stopping the treatment (139).
The studies above were Iimited by their designs and sample sizes. Since
ocular side effects are rare events, large prospective studies would be
needed to investigate the incidence of these complications.
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C 2.8.5.4 NEUROMUSCULAR SIDE EFFECTS
Headache, fatigue and Iethargy have been associated with isotretinoin
therapy (3). It is recommended that isotretinoin therapy be discontinued if
headaches become persistent, since they may be associated with
papilledema (swelling around the optic nerve) and pseudotumor cerebri
(intracranial hypertension). If that were the case, the use cf concomitant
drugs such as tetracyclines should be avoided (3). Some patients report
more muscle pain while on isotretinoin. This is especially true for those who
exercise regularly; gymnasts, competitive ice skaters, ballet students, and
long distance runners (137). In a study cf 466 patients who were followed
throughout their isotretinoin treatment, 42% reported musculoskeletal side
effects (136).
2.8.5.5 ELEVATION IN PLASMA LIPIDS AND LI VER SIDE EFFECTS
Elevations in plasma cholesterol and triglyceride levels are known to
accelerate atherosclerotic disease, and induce eruptive xanthomas (irregular
yellow nodules on the skin, usually the eyelids, neck and back) or acute
pancreatitis (140). In the early 1980s, several studies found that isotretinoin
may cause increases in plasma lipids and liver enzymes. In 1983, Zech et al.
(141) studied 20 male patients treated with isotretinoin with an initial dose of
two mg/kg/day. They measured plasma lipids and lipoprotein levels before
and during the treatment. Isotretinoin induced elevations that were 67%
greater for plasma triglyceride and 16% greater for cholesterol. Increases ot
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C 56% and 22% were found for very-low-density lipoprotein and low-density
lipoprotein, respectively. Similarly, in a study of 60 patients, 17% had
elevations in triglycerides, cholesterol, and Iow-density lipoprotein (142). This
concurred with two other smaller studies; one of 18 patients (143) and the
other of seven patients only (144). In another study 0f 30 patients, Georgala
et al. (145) also found elevated levels of plasma lipids and liver enzymes in
patients treated with isotretinoin. In addition, high-density lipoprotein levels
were significantly reduced at the end of the treatment, prompting the authors
to suggest that isotretinoin can be used as a lipoprotein reducing agent in the
future (145). A major problem with the studies above is the small sample
size. Furthermore, little is known about the long-term effects of isotretinoin
on conditions compatible with elevated plasma cholesterol and triglyceride
levels, although these studies found levels returned to baseline in the month
following termination of treatment.
Because of the health risks elevations of plasma cholesterol and triglyceride
levels may pose, isotretinoin guidelines have emphasized the importance 0f
monitoring these levels throughout the treatment. However, the need for
such routine tests has been a matter of debate. Barth et al. (146) conducted
a retrospective analysis of 209 patients who had been treated with
isotretinoin. They found significant elevations of triglycerides and plasma
cholesterol at eight and 16 weeks, but pointed out that those with elevated
plasma cholesterol had higher levels prior to initiation of treatment. As for
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triglyceride levels, they reached their peak at eight weeks into the treatment,
and did flot increase thereafter. No significant change was observed for liver
function. in another retrospective study of 1292 patients treated with
isotretinoin, only 1.5% of patients were found to have abnormai triglyceride
leveis (147). Furthermore, no Iaboratory abnormaiities necessitated
discontinuation of the drug (147). Supporting these resuits, Altman et al.
(148) found few statistically significant elevations in plasma lipids and liver
enzymes in 141 patients treated with isotretinoin; only one patient had
elevations that warranted discontinuation of the drug.
2.8.5.6 PSYCHIATRIC EFFECTS 0F ISOTRET1NOIN
The role of isotretinoin in the occurrence of depression, suicidai ideation, and
suicide is a controversiai issue that has received massive media attention.
The debate has been fueied by case reports and case series linking
isotretinoin to depression, and by signais detected in adverse reaction
databases. The few controlled studies that have investigated the relationship
found no association, but were dismissed because of methodoiogical flaws.
The present section will describe the current literature, and will end by
describing the bioiogical plausibiiity of such an association.
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Ç) 2.85.61 CASE REPORTS
A total of 11 case reports have been published from 1986 to 2005 (38,149-
158), although one of them reported depressive mood changes in two-year
old child treated with isotretinoin for nodulocystic acne (159). The first report
was by Lindemayr (149). He describes the case of a subject who took 800
mg of isotretinoin and attempted suicide. However, it is unknown whether the
subject attempted suicide because of isotretinoin intoxication, or whether
isotretinoin intoxication was a means to attempt suicide. A similar case of
isotretinoin intoxication was reported by Hepburn in 1990 (160).
In 1989, Villalobos et aI. (151) reported a case in which isotretinoin induced
hallucinations, paranoia, and incoherence. When isotretinoin therapy was
discontinued, symptoms subsided. However, symptoms reappeared with
readministration of isotretinoin. Other case reports have reported that
discontinuation of isotretinoin therapy results to a return to normal
functioning. These include a report by 00ff and Wisner (161) in which a
patient with a previous history of bipolar disorder experienced an
exacerbation of her psychosis following administration of isotretinoin. She
returned to her normal state after discontinuing the therapy. In a detailed
report by Ng et al. (157), a 17-year old man is descrïbed having symptoms cf
acute depression two weeks after beginning an isotretinoin treatment. The
depressive symptoms improved as the dose was reduced and the patient
C was treated with a selective serotonin reuptake inhibitor (SSRI). lnterestingly,
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the depressive symptoms worsened as the dose was increased. Despite an
improvement in acne severity, the depressive symptoms leU the patient ta an
unsuccessful suicide attempt.
Depression and suicidai ideation are not the only psychiatric effects reporled
in case reports. In 1999, Middelkoop (156) reported a patient with
depression, but who also experienced withdrawn behavior and social
impairment, decreased appetite, ioss of interest, fatigue, as well as changes
in personality and behavior. This patient committed suicide after four months
on the treatment. It must be noted that the patient had no history cf
depression or famiiy depression.
Based on case reports, depression may occur as early as one day (162) to
four months (38) after the initiation of an isotretinoin treatment. Some may
even experience symptoms of depression one month after completing the
treatment regimen (153).
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2.S5.62 CASE SERES
The first case series was pubiished in 1983 (5), a year after isotretinoin was
marketed in the US, and the same year it was introduced in Canada. Hazen
et ai. (5) reported depressive symptoms in siX of 110 (5.5%) patients treated
with isotretinoin one to two mg/kg per day. The average age of the cases
was 28.5 years. The depressive symptoms were described as malaise,
crying spelis, and forgeffulness, ail of which started two weeks after initiating
the isotretinoin treatment. Ail except one patient completed the treatment.
In 1984, Bruno et al. (163) compared the toxicity cf two isotretinoin dosage
regimens in 94 patients with severe cystic acne. Patients in the low dosage
group received isotretinoin dosages ranging from 0.1-0.22 mg/kg/day,
whereas patients in the high dosage group received dosages ranging from
0.75-1.21 mg/kg/day. By the end of the 1 6-week treatment period, 11% of
patients in 10w dosage group and 11% in the high dosage group reported
depressive symptoms. The average onset of depressive symptoms in both
groups was after one month of isotretinoin therapy. The authors did not
observe a dose-related difference in the onset of depressive symptoms.
In 1988, Bigby and Stem (135) reviewed 104 suspected adverse reactions
related to isotretinoin use that had been recorded in the Adverse Drug
C Reaction Reporting System between 1982 and 1985. 0f the 104 reports, 23
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(22%) were related to the central nervous system. These included reports of
headache, depression, dizziness, personality disorder, and pseudotumor
cerebri. Three cases were related to depression, where two appeared to
have a temporal relationship with isotretinoin.
In 1990, Scheinman et ai. (164) investigated 700 patients treated with
isotretinoin who received the treatment for various conditions that included
acne, basal celi carcinoma, and psoriasis. Seven patients (one percent)
spontaneously reported having depressive symptoms. Symptoms inciuded
crying speiis, fatigue, malaise, and forgetfuiness. One patient (0.14%)
reported suicidai ideation. When patients were dechallenged to the drug, the
symptoms subsided within one week after termination and resumed after
being rechaiienged. Five of the seven patients were females, and two were
maies where their ages ranged from 22 to 47 years with a mean of 32 years.
The average dose was 0.7 mg/kg/day. Five of the seven patients deveioped
depression during a first course of isotretinoin therapy. Oniy two patients had
a previous history of depression.
Duke and Guenther (165) published a case series on two adolescents who
dispiayed depressive symptoms, irritabiiity, disobedience, appetite and sleep
disturbances. The first case is of a 1 5-year old girl who developed behavioral
changes one month after initiating an isotretinoin treatment (40 mg/day).
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Ç Behavioral changes included cutting her hair off on one side of her head,
personality changes, and left her home. She also developed sleep
disturbances, irritability, and became withdrawn. She also threatened to cut
her wrists and set her clothes on fire. Her behavior returned to normal after
several months of being off isotretinoin. The girl had no history of depression
prior to the initiation of treatment. The second case is of a 17-year old boy
initially treated with 80 mg/day of isotretinoin, which was later reduced to 40
mg/day because of side effects. As with the f irst case, the boy developed
behavioral changes one month after initiation of treatment. He displayed
mood swings, depression, decreased appetite, weight loss and moved out of
his parent’s house. The physician terminated the treatment three months
after initiation. The boy’s symptoms returned to normal three days after the
end of treatment. The boy had no history of depression prior to the initiation
of treatment.
In 1998, Byrne et al. (166) reported about three patients, aged 18 to 28
years, who developed depression and related symptoms after initiating an
isotretinoin treatment. The first is a female patient who exhibited depressed
mood, irritability, aggression, agitation, decreased sleep, decreased appetite,
reduced concentration, anhedonia, and early morning wakening. These
symptoms eventually led to the breakdown of her marnage. She had no
personal or family history of depression. Five weeks after isotretinoin was
discontinued coupled with an antidepressant treatment, her symptoms
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C subsided. The second case pertains to a patient who attempted suicide while
on isotretinoin. He had no personal or family history of depression. Aher
discontinuation of isotretinoin and administration of an antidepressant there
was an improvement in mood over four weeks. The third patient also
developed depression and had suicidai tendencies during an isotretinoin
treatment. Discontinuation of isotretinoin and treatment with antidepressants
Ied to an improvement in symptoms.
A summary of the case reports and case series is presented in Table 6
below.
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2.85.63 ADVERSE DRUG EVENT REPORTING SYSTEMS
Adverse drug event reporting systems (ADERS) represent another source of
information regarding the association between isotretinoin and depression.
ADERS are databases maintained by governments that receive drug-related
adverse event reports. Because such reports are voluntary, these databases
underestimate the true frequency of adverse events reiated to a particular
drug. Furthermore, their value is diminished when the baseline rate of an
outcome is high. Causality is often impossible to estabiish since both the
adverse event and drug exposure are reported at the same time. In addition,
spontaneous reports often Iack consistency which limits their interpretabiiity.
Despite these limitations, adverse events recorded in ADERS may point to a
potentiai signal that may warrant further investigation. The following section
will review adverse events reported to the World Health Organization (WHO),
the UK Medicines Control Agency (MCA), the Adverse Event Reporting
System (AERS) of the FDA, and the Canadian ADERS.
In 1999, Middeikoop (156) investigated the relationship between six anti
acne medications and suicide, suicide attempt, and suicidai ideation using
the WHO and the UK MCA ADERS. The six medications were isotretinoin,
minocycline, doxycycline, tetracycline, ethinyl estradiol/cyproterone acetate,
and oxytetracycline. From 1965 to 1998, there were 170 cases of suicide,
suicide affempt, and suicide ideation reiated to isotretinoin reported to the
WHO ADERS, compared to a total of eight reports for the other anti-acne
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medications. There were 47 cases of suicide, 67 suicide attempts, and 56
suicidai ideations. The numbers were even more dramatic in the UK MCA
ADERS, where virtually ail reports of suicide, suicide attempt, and suicidai
ideation were reiated to isotretinoin despite the smalier number of
prescriptions (Table 7).
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In 2001, Wysowski et al. (173) analyzed reports cf depression, suicidai
ideation, suicide attempt, and suicide in US isotretinoin users that were
voluntarily submitted to the FDA’s AERS database from the time of its
marketing in 1982 to 2000. A total of 431 reports were found, that included
both hospitalized and non-hospitalized cases.
One hundred one cases were hospitalized for depression, suicidai ideation,
suicide attempt, and suicide. 0f those, 85 were hospitalized whiie using
isotretinoin and 25 after stopping the medication. The median time of onset
of symptoms in those who were currently using isotretinoin was one month
from the start cf therapy. In those who stopped isotretinoin, the median time
of onset of symptoms was three months. There were 284 non-hospitaiized
cases, where 128 (45%) reports were received after suicide and depression
were added as warnings on the product iabeiing in 1998. The authors did flot
specify the median time cf onset of symptoms in non-hospitaiized cases.
Thirty-seven cases were repcrted to have commiffed suicide, 24 while using
isotretinoin and 13 after stopping the treatment. Using data mining
techniques, only six reports of suicide were expected compared to the 37
reported (173).
In comparison to ail medications in the AERS database, isotretinoin was
ranked fourth and fifth in the number of reports 0f depression and serious
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depression, respectiveiy (173). It was also ranked tenth in t[9e number of
reports of suicide attempt. The authors noted that of ail top ranked
medications, isotretinoin was the only one not to have psychoactive
properties and a psychiatric indication.
In Canada, Wooltorton (174) reported that there has been 222 adverse
events reported to Health Canada from 1983, the year isotretinoin was
marketed in Canada, up f0 2002. 0f those, 56 (25%) were psychiatric and
included depression and suicidai ideation.
28.56.4 PACKAGE LABEL CHANGES AND OTHER WARNiNGS
The case reports, case series, and signais detected in ADERS have
prompted several governments to modify the isotretinoin package iabeiing to
include psychiatric events as potentiai side effects. In March 1997, France
was the first to modify their iabel which specificaiiy mentioned depression
and suicide (175). The US modified their packaging Iabei in Fbruary 1998,
foiiowed by Canada in May 2000 (176). In March 2001, a Dear Heaith Care
Professional Letter was sent f0 Canadian physicians (177). This ietter
advised physicians f0 ciosely monitor patients undergoing isotretinoin
therapy for psychiatric symptoms during the course of the treatrnent (177).
C
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Ç) 2.85,65 OBSERVATIONAL STUDIES
Several observational studies have been conducted to determine whether
there was an association between isotretinoin and depression. The majority
of these studies were either uncontrolled, had small sample sizes, or
suffered from other methodological problems. These observational studies
are reviewed in the present section. A summary of these studies is also
presented in Table 8.
In 1999, Kellet and Gawkrodger (31) conducted a prospective study on 34
patients with chronic acne undergoing isotretinoin therapy (one mg/kg/day).
These patients were recruited by a consultant dermatologist in an outpatient
clinic. Patients were followed for 16 weeks, and their emotional status was
determined at four different points in time during the treatment (T1-T4). The
authors used the Hospital Anxiety and Depression Scale (HAD) to measure
anxiety and depression. Clinically significant depression is defined as having
a HAD score greater than 10. At T4, only 15 patients responded to
questionnaires. The authors found an improvement in depressive symptoms
in patients treated with isotretinoin. Specifically, there were 6/34 (18%)
patients with a HAD score greater than 10 at baseline compared to 0/15
(0%) at the end of treatment. Thus, the authors concluded that isotretinoin
does flot cause depressive symptoms, and in fact, it is associated with an
improvement of such symptoms. However, this study does have several
limitations. The first is the small sample size. The authors did flot have the
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necessary power ta capture rare psychiatric events. Second, only 15 out of
the initial 34 patients completed the study, which translates to a 56% drop
out rate. The authors did not state any reason why patients dropped out of
the study. The study may be biased if patients dropped out of the study
because they experienced the outcome. Third, the authors only presented
unadjusted analyses. No attempt was made ta control for possible
confaunders that cauld have potentially biased the results. Finally, the
isotretinoin cohort was not compared ta another cohort treated with an agent
known ta have no psychiatric effects. Thus, rates af depressian among
patients receiving isatretinoin cauld nat be campared with patients receiving
an alternative treatment.
In 2000, HulI and Demkiw-Bartel (178) published a study where they
praspectively fallawed 124 users af isotretinain fram 1991 ta 1996 far any
type af side effect. Patients were treated far 16 weeks atone mg/kg per day
and a questionnaire was administered manthly to record any side effects that
may appear during the treatment. The majarity af patients had
mucacutaneaus or musculaskeletal side effects. OnIy four percent af patients
reparted depressian, althaugh symptams were reparted ta remain consistent
thraughaut the treatment. This study was limited by its small sample size. It
was alsa Iimited in that it anly recarded reports 0f depressian, and did nat
enquire about suicide attempts or suicides during and after the treatment.
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Ç Finally, there was no comparator group to which rates of depression could
be compared.
To date, Jick et al. (179) conducted the largest population-based study on
the isotretinoin-depression association. Data were obtained from two
databases, the Canadian Saskatchewan Database and the United Kingdom
General Practice Research Database (GPRD), from 1983 to 1997. The
Canadian Saskatchewan Database contains over one million people who
benefit from health care coverage in the province of Saskatchewan. The
GPRD on the other hand, has in its banks over four million people. General
practitioners who have agreed to provide data for research purposes
continuously enter patient data through a computerized system.
The authors determined the rates of depression, psychotic symptoms,
suicide and suicide attempts using two cohoris, one from the Saskatchewan
database and one from the GPRD. Two analyses were conducted on each
cohort. In the first analysis, a cohort of patients treated with isotretinoin (7195
from the Saskatchewan database, and 340 from the GPRD) was compared
to a cohort of patients treated with systemic antibiotics (13700 from
Saskatchewan database, and 676 from the GPRD). The systemic antibiotics
included tetracycline, erythromycin, clindamycin, minocycline, or doxycycline,
received within 30 days tollowing an acne diagnosis. Patients were
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J categorized as either being currently exposed, recently exposed, or non
exposed. Patients currently exposed were defined as those receiving
isotretinoin or a systemic antibiotic from the first prescription through three
months after receiving the Iast prescription. Recent users were defined as
those who received their Iast prescription four to six months before. Non
exposed patients were those who received their Iast prescription more than
six months before. Cases of depression, suicide or suicide attempts were
defined using diagnostic codes (International Classification of Diseases,
ninth revision (lCD-9): 296-301). The authors calculate relative risks (RR) by
comparing cases of depression, suicide or suicide affempts in the currently
exposed and recent users groups to the non-exposed group. In the second
analysis, isotretinoin users were evaluated by comparing rates of neurotic
and psychotic disorders in the six months after the first prescription to the six
months before the prescription.
In the Saskatchewan database, RRs (95% confidence interval [Cl]) of
neurotic and psychotic disorders in current and recent isotretinoin users were
1.0 (0.7, 1.3) and 0.9 (0.6, 1 .4), respectively. RRs (95% Cl) of suicide and
attempted suicide in current and recent isotretinoin users were 0.9 (0.3, 2.4)
and 1.1 (0.2, 3.7), respectively. In the GPRD, ARs (95% Cl) of neurotic and
psychotic disorders in current and recent isotretinoin users were 1 .8 (0.4,
5.2) and 1.8 (0.3, 6.1), respectively. There was only one suicide attempt in
the GPRD, and that patient was unexposed. In the Saskatchewan database,
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Ç RRs (95% CI) comparing post- to pre-treatment rates of neurotic and
psychotic disorders were 1 .2 (0.9, 1 .7) in current users and recent users 1 .0
(0.6, 1.5). In the GPRD, the RRs (95% CI) were 1.3 (0.2, 5.7) in current
users and 1.1 (0.2, 5.7) in recent users.
The authors of the study described above concluded that isotretinoin users
were flot a greater risk of depression or psychosis than systemic antibiotic
users. Aithough this was a large population-based study, it does have
several limitations. The first limitation was that cases were identified using
diagnostic codes alone. Therefore, it is possible that some cases were
misclassified as non-cases. The authors did flot take into account the use of
psychoactive medications, such as antidepressants. The resuit is a bias of
the RRs towards the nulI, possibly explaining the lack 0f association
observed in this study. Others have also criticized the study for flot including
lCD-9 codes 309 (adjustment reactions) and 311 (depressive disorder, flot
classified elsewhere) (180). Second, the authors adjusted for previous
psychiatric history using data recorded six months up to five years before the
first isotretinoin prescription. It is possible that they did flot capture ail
psychiatric events that have occurred, especially in those with less than one
year recorded medical history. Therefore it is likely that some residual
confounding occurred, which wouid have once again biased the ARs
towards the nuli. Third, the authors did flot consider dosage or duration of
the isotretinoin in their models. Thus, it is unknown whether there is a dose-
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response relationship between isotretinoin and psychotic disorders,
depression or suicide. Fourth, the authors did flot affempt to adjust for acne
severity, which is a potential confounder of the isotretinoin-depression
association. Fifth, the poiflt estimates of the RRs in the GPRD were higher
than in the Saskatchewan database. In tact, the RRs in the GPRD were 1.8
in current and recent users of isotretinoin, indicating an 80% increase in risk.
Aside from the methodological problems mentioned above, the Iack of
statistical significance of these estimates may also be due to a lack of power
due the small sample size of the GPRD cohort (n=340). Finally, this study
was criticized for being sponsored by the manufacturer of the drug (181).
In 2001, McLane et al. (182) published a study where they evaluated 14
adverse events in patients participating in two isotretinoin trials. The first trial
consisted of 67 patients who received isotretinoin one mg/kglday as a single
dose with food for 16 to 20 weeks. Patients were asked to grade the severity
of adverse events using a 10cm visual analog scale (VAS). The second trial
consisted of 300 patients who received isotretinoin one mg/kg/day in two
equally divided doses and followed for 20 weeks. Patients used a VAS to
rate the severity of adverse events. No patient in the f irst trial reported any
psychiatric problems, while 0.3% reported experiencing psychiatric problems
in the second trial. The authors provide no other information, and do not
describe the type of psychiatric disorders experienced by their patients.
C
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C’ Furthermore, this study had small sample sizes and did flot compare the
isotretinoin cohoris to other groups.
From December 1998 to Match 2000, Ng et al. (183) prospectively followed
215 patients who were prescribed isotretinoin or antibiotics/topical
treatments. The isotretinoin group (n=174) received 40 mglday, followed by
a one mg/kg/day inctease for one month according to patient toletability.
Patients in the antibiotic/topical tteatment group (n=74) received 100-200
mg/day cf minocycline combined with a topical treatment of either adapalene
0.1%, tretinoin 0.05% or isotretinoin 0.05% gel. Patients were evaluated for
depressive symptoms using the 21-item Beck Depression lnventory (BDI),
and quality of life using the World Health Organization Quality of Life 100-
item questionnaire (WHOQOL-BREF). Assessments were pertormed at
baseline, one month, three months and at end of treatment or six months.
The mean change in BDI scores did flot significantly differ between the
isotretinoin and minocycline/topical treatments groups. There were also no
changes in quality of life scores between the two treatment groups. The
incidence of isotretinoin patients with moderate depressive symptoms
remained relatively the same throughout the treatment, and there was no
correlation between isotretinoin dose and depression score (183). Although
this is a well-conducted study, the authors acknowledged that it is Nmited by
its small sample size. lnterestingly, f ive patients from the isotretinoin group
were withdrawn from the study because of worsening of mood. This did flot
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occur in the minocycline/topical treatments group. The authors dismissed
any association between these mood changes and administration of
isotretinoin.
In 2003, Hersom et aI. (184) published a study investigating the prescription
order of isotretinoin and antidepressants among incident users of both drugs.
They employed the sequence symmetry method which works by calculating
the ratio (adjusted risk ratio) of the number of patients who filled an
isotretinoin prescription first versus second to an antidepressant. Their data
was collected from the Quintiles Informatics Database from 1999 to 2000,
and included 2821 patients aged 12 to 49 years of age. Patients were
categorized into two groups: the causal group and the non-causal group. The
causal group was composed of patients who received an isotretinoin
prescription first and an antidepressant second. Similarly, the non-causal
group was composed of patients who received an antidepressant f irst and
isotretinoin second. A risk ratio is calculated by dividing the number of
patients in the causal group to the number of patients in the non-causal
group. The authors also performed a prescription sequence analysis using
minocycline, a systemic antibiotic used in the treatment of acne known to
have no psychiatric effects. The authors found no asymmetries between the
casual and non-causal group, indicating that there is no association between
isotretinoin and depression. As expected, the same resuits were obtained for
mi nocyci i ne.
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Ç The prescription sequence symmetry analysis is a variant of the case
crossover analysis, where cases serve as their own controls thereby
automatically adjusting for time-dependent confounders (185). However, an
inherent assumption cf this study design is that medications must have a
clear indication. This is not the case in the study conducted by Hersom et al.
(184). Antidepressants are increasingly being prescribed for conditions other
than depression. They include premenstrual dysphoric disorder, obesity, and
smoking cessation (186). Thus, t is possible for a person to be treated with
an antidepressant for smoking cessation, then undergo an isotretinoin
treatment for acne, develop depression and require a new antidepressant
treatment. Such a patient would be excluded from the discordant pair
analysis because an antidepressant prescription preceded and followed the
isotretinoin prescription. The failure to include this patient in the causal group
would dilute the risk ratio towards the nulI.
In 2004, Ferahbas et al. (187) published a study of 45 patients with severe
acne recruited by a consultant dermatologist in an outpatient clinic. Patients
were treated with 0.5 to one mg/kg/day of isotretinoin for up to 16 weeks.
Anxiety was measured using the Clinical Anxiety Scale and depression with
the Montgomery-Asberg Depression Rating Scale. Both questionnaires were
administered before and after treatment. Only 23 (51%) of patients
completed the final assessment. The authors found a statistically significant
decrease in anxiety scores, whereas depression scores also decreased but
P a g e $1
did flot reach statistical significance. The authors also reported that no
patients attempted nor committed suicide. This study has several important
limitations. No real conclusions can be drawn based on the small sample
size. Furthermore, only 23 patients completed the final assessment. It is
possible that those who experienced psychiatric effects withdrew from the
study, which would have overestimated the positive psychological impact of
isotretinoin in the remaining sample. Finally, there was no comparison group
to which the anxiety and depression scores could have been compared.
Kellet and Gawkrodger (188) recruited 33 patients who consulted a
dermatologist during routine clinical practice. The patients had flot
responded to conventional acne therapy. They were administered the 21-
item BDI and the 20-item Beck Hopelessness Scale (BHS) at baseline, eight
weeks (half-way through the treatment), and at the end of the 16-week
treatment. Twenty-two (67%) patients completed the final assessment. At
eight weeks into the treatment, patients displayed improvements in
depressive symptoms compared to baseline. These improvements were flot
observed during the second phase of the treatment.
From October 1998 through December 2001, Chia et al. (189) recruited 132
patients with moderate-to-severe acne aged 12 to 19 years from two
outpatient clinics. AIl patients with a history of major depression were
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Ç excluded from the study. Patients were assigned ta either an isotretinoin
therapy (one mg/kg/day) or a topical antibiotic or topical retinoid and a
systemic antibiotic. Patients were not randomized ta the treatment options,
but rather the allocation of treatment was based on the physician’s
assessment of the patient’s clinical history of acne. Depressive symptoms
were recorded at baseline, and three ta four months after initiation of
therapy. Depressive symptoms were assessed using the 20-item Center for
Epidemiologic Studies Depression Scale (CES-D). A score greater than 17 is
indicative of clinically significant depression. One hundred one patients
completed the study. At baseline, 14.3% of the isotretinoin group and 19.2%
of the standard therapy group had a CES-D score greater than 17. At follow
up, 8.2% of the isotretinoin group and 15.4% of the standard therapy group
had a CES-D score greater than 17. This difference was not statistically
significant. The results of this study appear ta indicate that there is no
association between isotretinoin and depression. Furthermore, it appears
from these results that isotretinoin may have beneficial effects in reducing
symptoms of depression in patients with moderate-to-severe acne. However,
a careful look into the methods employed in this study reveal several
methodological problems. First, the sample size appears to be too small ta
detect cases of clinically significant depression. Second, there was a 23%
loss ta follow-up, and it is unknown whether this might have been related ta
the outcome. That is, those who experienced a clinically significant
depression may have stopped their treatment and withdrawn from the study.
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Furthermore, the authors fail to indicate which treatment groups lost the most
patients, and only provide percentages and no raw data in their resuits.
Third, the authors conducted multiple logistic regressions controlling for
baseline CES-D and sex. They did not consider acne severity in their
models, despite it being a potential confounder.
In 2007, Cohen et al. (190) published a study of 200 patients at least 14
years of age recruited from a community dermatology practice who were
treated with either isotretinoin or other anti-acne agents. One hundred
patients were treated with isotretinoin, and the remaining 100 were treated
with either topical or oral agents. Depression was measured using the Zung
Depression Status lnventory and the CES-D at baseline, and after 2 months
into the treatment. The authors found no association between isotretinoin
and depression. However, this study had several important limitations. First,
the authors did not provide any sample size calculations, and it thus
unknown how they derived their sample size. Second, it is unclear that the
analyses were adjusted for potential confounders, such as age, sex, socio
economic status. Finally, depression was measured at baseline and two
months into the treatment. It is possible patients experienced depression at a
subsequent time in their treatment.
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2.85.66 BIOLOGICAL PLAUS{BILITY
Since isotretinoin and Vitamin A share similar chemical structures, many side
effects cf isotretinoin are similar to Vitamin A when taken in large doses
(192). Hypervitaminosis A has been shown to induce irritability and
depressive symptoms (133,193,194). One study found that exposure to
retinoic acid resuits in hippocampal celI loss in mice (195). In humans,
hippocampal volume has been shown to be inversely related to depression
(196), indirectly supporling the hypothesis that isotretinoin may cause celI
loss in this region of the brain. Another study found that daily intake cf one
mg/kg cf isotretinoin for six weeks in young male mice (similar doses used
in humans) was associated with depression-like behavior (197). Recently,
Bremner et al. (198) assessed brain function in patients with acne treated
with isotretinoin and antibictics. They found that isotretinoin decreased
metabolism in the orbitofrontal cortex, a region cf the brain known to be
invclved in depression. This effect was not observed in patients treated with
antibictics. More research is needed to elucidate the exact mechanisms
through which isotretinoin may induce depression.
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C
Because acne can be treated with a number of therapeutic treatments, it is
informative to compare the cost of isotretinoin to that of other treatments.
Along with this une of thinking, we must look at the short- and long-term
costs of such treatments. In one study of 180 patients with severe acne not
treated with isotretinoin, the authors calculated the costs of ail drugs,
investigations, physician visits and Ioss productivity over a one-year period.
They found that the average total cost of non-isotretinoin treatments was
69% of the theoretical cost with isotretinoin (199).
Although isotretinoin may be more costly in the short-term, one must also
look at the costs in the Iong-term. Because isotretinoin is able to maintain
long-term treatment f ree remissions and permanent remissions (103,110), it
would be expected to save costs in the long-term. An Australian study
estimated the theoretical costs of treating patients over 2.5 years either with
isotretinoin or with systemic antibiotics combined with two topical agents
(200). The costs investigated included drugs, investigations and physician
visits. They found that antibiotic therapy would have cost 35% more than
isotretinoin over a 2.5-year period. However, the authors assumed there
were no further courses of isotretinoin therapy after an initial course of
treatment. Therefore, the long-term costs associated with isotretinoin may be
8$
have underestimated in this study since it has been shown that over 23% of
isotretinoin users require at least two courses of the drug (101).
Cunliffe et aI. (201) investigated the actual costs over a three-year period for
364 patients treated with isotretinoin. These costs were compared to the
Iong-term theoretical costs associated with systemic antibiotic therapy over
the same time period. The theoretical costs included the price of the therapy,
hospital visits and investigations. The mean three-year costs of an
isotretinoin treatment were £732 for patients with moderate acne, and £803
for patients with severe acne. These costs included patients who required
repeat courses of isotretinoin during the study period. In contrast, the mean
theoretical costs associated with systemic antibiotic use were £1520 for
patients with moderate acne, and £1856 for patients with severe acne.
Cost analyses of isotretinoin have been criticized for failing to measure the
cost of important factors associated with the drug (202). Since isotretinoin
can have a teratogenic effect on the fetus, women on the drug are subjected
to pregnancy tests prior and during the treatment, contraceptive counseling,
diagnostic techniques (such as ultrasound), genetic counseling for women
with exposed pregnancies, termination costs for women who elected to
remove the fetus, diagnostic tests to determine the health of live births
following an exposed pregnancy, and of course life-time health costs for
189
babies born with major malformations (202). However, it has also been
argued that the costs of avoiding pregnancy while using isotretinoin are not
likely to be important factors (203). This is because many female patients
would be using a form of contraception anyway and many isotretinoin
patients are males and thus would not need to go through pregnancy
prevention measures (203).
The objectives of Study 1 were to:
1. Describe the patterns and trends of isotretinoin utilization between
1984 and 2003.
2. Describe the characteristics of isotretinoin users within that same
time period.
3. Identify and quantify predictors of isotretinoin use.
4. Describe the impact of guidelines on isotretinoin utilization between
1984 and 2003.
3.2 HYPOTHESES STUDY 1
Previous US studies that have investigated the use of isotretinoin found that
most treatments were initiated without prior consideration of conventional
treatments. We hypothesized a similar situation in Quebec, especially since
our study population was insured for their medications by the RAMQ drug
plan, and thus had a relatively easy access to isotretinoin. We hypothesized
however, that the different guidelines and programs implemented over the
years would have an impact on prescribing patterns.
G
3.1 OBJECTIVES STUDY 1
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C 3.3 OBJECTIVES STUDY 2
The objectives of Study 2 were to:
1. Determine the incidence of patients initially treated with isotretinoin
experiencing an acne relapse as defined by requiring further
treatment with an anti-acne medication (either a second
isotretinoin treatment or another anti-acne medication).
2. ldentify and quantify predictors of experiencing an acne relapse.
3. ldentify and quantify predictors of receiving a second isotretinoin
treatment.
3.4 HYPOTHESIS STUDY 2
Several studies have determined the rate of acne relapse in patients initially
treated with isotretinoin. However, these studies had several limitations, ail of
which were described in Section 2.8.3. As a result, the acne relapse rates
reported in these studies may not have been accurate, and in some cases
underestimated. Given that we assembled the Iargest isotretinoin cohort to
date, followed for up to 20 years, we hypothesized a relatively high acne
relapse rate in patients initialiy treated with isotretinoin.
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0 3.5 OBJECTIVE STUDY 3
The objective ot Study 3 was to determine whether there is an association
between isotretinoin use and depression in patients with acne vulgaris.
3.6 HYPOTHESIS STUDY 3
Case reports and adverse reaction databases have signaled a possible
association between isotretinoin and depression. Observational studies
conducted on the subject found null resuits, but had several methodological
limitations. Based on reports of depression in patients with no personal or
family history of the condition, and reports of positive dechallenge and
rechallenge to isotretinoin, we hypothesized that there is an association
between isotretinoin use and depression.
o
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Ç 3.7 OBJECTIVE STUDY 4
The objective of Study 4 was to use the case-time-control design to
determine whether an exposure time-trend confounded the association
between isotretinoin and depression.
3.8 HYPOTHESIS STUDY 4
Using a case-crossover design, we found an association between
isotretinoin and depression. However, an association derived from the case
crossover design may be biased if there is an underlying exposure time
trend. To account for this possibility, we performed a case-time-control study.
In theory, this design should correct for any exposure time-trend that may
have confounded the association in the case-crossover design. Since the
point estimates obtained in the case-crossover design were relatively high,
we hypothesized that an exposure time-trend could not account for ail of the
association.
4.1.1 RAMQ DATABASES
In Quebec, the Régie de l’Assurance Maladie du Québec (RAMQ) is the
government body that administers the province’s health-related matters. Ail
heaithcare services (other than hospitalizations) are recorded in the RAMQ
administrative databases, which are composed of a set of daims files. The
medical daim file contains patient characteristics (including age, gender, and
place cf residence), prescriber information (including age, gender, medical
specialty, year cf graduation, and place of graduation), and data regarding
outpatient medical visits (this includes services received in emergency
rooms). It aise includes information on the date and type cf services
received, and diagnoses are classified according to the International
Classification of Diseases, Ninth revision (lCD-9) (204). The pharmaceutical
daims file contains information on the date a medication is dispensed,
formulation, dose, duration cf prescription, as weII as quantity dispensed. It
also includes the subjects’ insurance status, whether they are welfare
recipients or adherents to the RAMQ drug plan. Medications prescribed
during hospitalizations are net included in the database. Prier to January 1,
1997, the RAMQ covered those who were 65 years and older, and welfare
recipients and their children for their medications. After January 1, 1997, the
RAMQ drug plan was modified te also include workers and their
spouses/children who did flot have access to a private medication insurance
4.1 DATA SOURCES
Ç program (adherents). Approximately 50% of ail Quebec residents are
covered by the RAMQ drug plan (205). AIl RAMQ daims files can be linked
via an encrypted patient identification number. Both the medical and
pharmaceutical daims databases have been validated and shown to be
accu rate for certain diagnoses (206,207).
41.2 MED-ÉCHO DATABASES
Med-Écho (Maintenance et Exploitation des Données pour l’Etude de la
Clientèle Hospitalière) is Quebec’s hospital discharge database that has
been in place since 1980. It contains hospitalization-specific data on ail
Quebec residents. The database includes patient demographic information
(age and sex), admission diagnosis, up to 15 secondary diagnoses, duration
of stay, dates of admission and discharge, type of hospital where the
services were rendered, as well as ail services received during the
hospitalization (this excludes services received in emergency rooms and
outpatient clinics). Ail diagnoses in Med-Écho are coded according to the
lCD-9 classification system (204). Medical diagnoses recorded in Med-Écho
have been shown to be valid and precise (208). The RAMQ and Med-Écho
databases can be linked using the patient’s encrypted identification number.
o
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0 4.2 STUDY POPULATION
The study population for the fout studies described in this thesis was
composed of ail Quebec residents insured by the RAMQ drug plan who
received at least one isotretinoin prescription, in either the 10 mg or 40 mg
formulation (drug identification numbers 582344 and 582352, respectively),
between January 1, 1984 and December 31, 2003. A total of 30,496 Quebec
residents insured by the RAMQ drug plan were exposed to isotretinoin at
least one during the study period.
Approval was obtained from the CHU Sainte-Justine Ethics Committee
(Appendix I) and the Commission d’accès à l’information du Québec
(Appendix li).
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C 4.3 METHODS FOR STUDY 1
4.3.1 STUDY COHORT
The cohort for Study 1 was selected from the study population described in
section 4.2. To be included in Study 1, subjects had to be between 13 and
45 years on the first day 0f the first isotretinoin prescription. These ages
were chosen because isotretinoin is primarily prescribed during this age
range. Subjects were also required to be continuously insured by the RAMQ
drug plan for at least 12 months before and at least six months after the first
day of the first isotretinoin prescription. This was deemed an appropriate
time window to assess the use ot healthcare services and medications,
which are important markers of comorbidity. Furthermore, an isotretinoin
treatment typically lasts between four and five months (93), and thus six
month coverage after the first prescription would ensure that subjects would
be covered for their medications during the isotretinoin treatment. Finally, ail
subjects who received an isotretinoin in the 12 months prior to index date
were excluded. Therefore those included in this study were considered
incident users of isotretinoin. In the event that a subject had more than one
isotretinoin treatment fitting the criteria described above, the first isotretinoin
treatment present in a subject’s record was considered for analysis.
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C 4.3.2 TREATMENT DURATION AND MEAN DAILY DOSAGE
it was of interest to determine the median treatment duration of an
isotretinoin treatment. Isotretinoin is typically prescribed at 30-day intervals.
Therefore, an isotretinoin treatment was defined as receiving consecutive
prescriptions with less than 30 days between renewals. The total treatment
duration was calculated by adding the durations 0f ail dispensations. The
mean daily dosage (milligrams/day) was calculated by dividing to the
cumulative dosage of isotretinoin prescribed (milligrams) during a given
treatment by the total duration of treatment (days).
4.3.3 PREVIOUS ANTI-ACNE MEDICATIONS
We documented the types and number of anti-acne medications patients had
received in the 12 months immediately prior to the index date. Both topical
and systemic agents were considered: tretinoin, tazarotene, benzoyl
peroxide, clindamycin, doxycyciine, tetracycline, minocycline, erythromycin,
azithromycin, and acne-specific oral contraceptives (Diane-35TM). Adapalene
and benzoyl peroxide/erythromycin combination were flot included since they
are flot reimbursed by the RAMQ drug prescription plan. The drug
identification numbers used to identify the anti-acne medications above are
presented in Appendix lii. Since systemic antibiotics are used to treat several
conditions, it was necessary to ensure that these were prescribed for acne.
Therefore, an acne diagnosis (lCD-9 code: 706.1) must have been present in
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the database within 30 days of the dispensing of the systemic antibiotic. In
the event of a missing acne diagnosis, we used procedure codes related to a
dermatology visit within 30 days of the dispensing of the medication. These
procedure codes are presented in Appendix IV.
4.3.4 CHARACTERISTICS 0F ISOTRETINOIN USERS AND
PREDICTORS 0F UTILJZATION
Descriptive statistics were used to summarize the characteristics of the study
cohort. Because of the teratogenic risks associated with isotretinoin and thus
the differential management 0f males and females, we determined whether
there were demographic and treatment differences between genders.
Student’s t-tests and chi-square tests were used to compare continuous and
categorical variables, respectively. When normality was not observed, the
Mann-Whitney U test was used to compare median values between groups.
We also conducted univariate and multiple unconditional Iogistic regressions
to determine factors associated with treatment duration 20 weeks. Both
patient and prescriber characteristics were considered in the models. In
addition, since our cohort spanned a 20-year period, it was necessary to
adjust the model for the different practices and guidelines issued throughout
the years. We therefore considered four different time periods: 1) the pre
PPP years, 2) implementation of the PPP in 1988, 3) Canadian Acne
Treatment Guidelines issued in 1995 (85) and 4) the new Canadian
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Consensus Guidelines on Treatment of Acne and Prevention of Scaring
issued in 2000 (86,209).
4.3.5. INTERRUPTED TIME-SERIES MODELING
The study cohort spanned a 20-year period (from 1984 to 2003), which
presented a unique opportunity to evaluate whether the implementation of
the PPP in October 1988, and the Dear Healthcare Professional Letter
(DHPL) regarding isotretinoin’s possible psychiatric risks issued in Match
2001, had any impact on prescribing patterns.
Interrupted time-series modeling, fitst ptoposed by Box and Tiao (210), were
used to determine whether the PPP and the DHPL had any impact on the
number of new isotretinoin users in the months that followed their
introduction. Linear regression would not have been an appropriate analysis
since it assumes independence between consecutive observations. With
regards to prescribing patterns, this assumption is flot likely to be valid since
they are highly influenced by current practices and guidelines.
In interrupted time-series models, dummy variables are created with O and 1
representing pre- and post-interventions, respectively. The impact of the
C implementation of PPP in October 1988 on prescribing patterns was based
I 101
on 57 pre-intervention and 15 post-intervention months (from January 1984
ta December 1989), and the impact cf the DHPL issued in Match 2001 was
based on 134 pre-intervention and 22 post-intervention months (from
January 1990 to December 2002). The interventions were assumed ta have
a graduai, permanent impact and thus each model contained both abrupt (w)
and graduai () effect parameters. impact of the PPP was assessed in
temale patients, whereas impact of the DHPL was assessed in bath genders.
Autoregressive integrated moving average (ARIMA) was used ta modei the
time-series and predict post-intervention rates with 95% confidence intervais.
To stabiiize the variabiiity within the series, Box-Cox transformations were
employed. When trend was observed, we differenced rates between
successive months. Seasonal troughs were observed at every mid-summer
and were therefore removed by differencing rates using a seasonal period of
12 months. Ta identify models, we examined the estimated autocorreiation
and partia’ correlation functions of the stationary series. Ljung-Box test and
Akaike’s information criterion were used as guides for choosing the best
modei. in ail chosen models, normality and stabiiity of the variance cf the
residuals was ascertained.
Incident isotretinoin users were expressed as the number cf users per
Q 100,000 persans insured by the RAMQ drug prescription plan per calendar
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year. Given the fact that our cohort only included users of isotretinoin, and
thus trends in time could reflect the increase in the number of people insured
and not an increase in the number of users, we had to define a common
denominator. To do this, the total number of patients eligible in the RAMQ
drug prescription plan for each calendar year from 1984 to 2003 was
obtained from the RAMQ’s annual statistics (211). These statistics include
the mean number 0f beneficiaries for each calendar year stratified by age
and gender.
Q 4.4 METHODS FOR STUDY 2
4.4.1 STUDY COHORT
The members of the study cohort from Study 1, composed of 17,351 first
time isotretinoin users, were followed from the end of their isotretinoin
treatment until they experienced an acne relapse (defined as receiving an
anti-acne medication, isotretinoin or other), they were no longer insured by
the RAMQ drug plan, or the end of the study period (June 30, 2003),
whichever came first. Detailed descriptions of the methods used to conduct
Study 2 are described below.
4.4.2 STUDY DESIGN
A nested case-control design was used in Study 2 to determine predictors of
experiencing an acne relapse (defined as receiving an anti-acne medication,
isotretinoin or other) after being initially treated with isotretinoin. This design
allowed the use of incidence density sampling, whereby a patient could
serve as a control for more than one case. Moreover, cases could serve as
controls before they become cases.
Two nested case-control analyses were conducted using a SAS incidence
density program that was adapted for the purposes of the present study
(212). The first nested case-control analysis determined predictors of
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receiving an anti-acne medication (isotretinoin or other) after being initialiy
treated with isotretinoin. The second nested case-control analysis
determined predictors 0f receiving a second isotretinoin treatment. For both
nested case-control analyses, f ive controls were randomly selected from the
cases’ risk set and matched to each case on the time accrued from the end
of the first isotretinoin treatment to the acne relapse.
44.3 COHORT ENTRY AND EXIT
The date of entry in the cohort for the first nested case-control started the
day after the end of the first isotretinoin treatment. This is because it was
possible to receive an anti-acne medication at any time after the first
isotretinoin treatment.
With regards to the second nested case-control study, the date of entry in
the cohort for ail patients started only 30 days after the end 0f their first
isotretinoin treatment. This is because an isotretinoin treatment was defined
as filiing consecutive prescriptions with fewer than 30 days between
renewals. Therefore by design, there were no isotretinoin prescriptions in the
30 days after the end cf the first treatment. This was done to avoid immortal
bias (213), where the person-time at which patients were flot at risk of
receiving an isotretinoin prescription was excluded. Patients in both nested
case-control analyses were followed until they became cases, were no
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longer covered by the RAMQ drug plan, or until June 30, 2003, whichever
came first.
4.4.4 CASE AND CONTROL DEFINTION
4.4.4.1 DEFINITION FOR FIRST NESTED CASE-CONTROL STUDY
Cases for the f irst nested case-control analysis consisted of patients who
experienced an acne relapse and required furiher treatment with an anti
acne medication (isotretinoin or other). For those cases, the index date was
the calendar date of the dispensing of the anti-acne medication (isotretinoin
or other). Eligible controls were patients who were stiil present in the cohort
at the time of the cases’ index date and had not received any anti-acne
medications (isotretinoin or other) prior to that date.
An acne-relapse was defined as receiving any of the following anti-acne
medications: isotretinoin, tretinoin, tazarotene, benzoyl peroxide, topical
clindamycin, topical erythromycin, systemic doxycycline, systemic
tetracycline, systemic minocycline, systemic erythromycin, systemic
azithromycin, and acne-specific oral contraceptives (Diane-35TM) (Appendix
III). Adapalene and benzoyl peroxide/erythromycin combination were not
considered since they are not reimbursed by the RAMQ drug plan. Systemic
antibiotics are prescribed for a variety of conditions, it was thus necessary to
ascertain that those considered as acne treatments were truly for acne.
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Therefore, an acne diagnosis (lCD-9 code: 706.1) must have been present in
the database within 30 days of the dispensing of the systemic antibiotic to be
considered an anti-acne treatment. In the event of a missing acne diagnosis,
we used dermatologic procedure codes recorded within 30 days of the
dispensing of the medication (Appendix IV).
4.4.4.2 DEFINTION FOR SECOND NESTED CASE-CONTROL STUDY
Cases for the second nested case-control analysis consisted of patients who
experienced an acne relapse severe enough to require a second isotretinoin
treatment. As such, the index date was the calendar date of the dispensing
ot the second isotretinoin treatment. Eligible controls were patients who were
stili present in the cohort at the time of the cases’ index date and had not
received any isotretinoin prescriptions prior to that date.
4.4.5 POTENTIAL PREDICTORS
Potential predictors for both nested case-control analyses were assessed in
four different time periods. The time periods were at the 1) index date, 2)
between the end of the first isotretinoin treatment and index date (follow-up
period), 3) during the first isotretinoin treatment, and 4) in the 12 months
prior to the f irst isotretinoin treatment. The predictors considered in the four
time periods related to patient socio-demographic information (age, gender,
place of residence, adherent of the RAMQ drug plan/welfare recipient),
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Ç healthcare and medication utiNzation (visits to the physician, emergency
depariment visits, ail cause hospitalizations, and number 0f different types cf
medications) as weii as prescriber information (specialty, gender of
prescriber, and whether isotretinoin was prescribed by more than two
physicians during the first treatment). Other predictors for requiring furiher
treatment with an anti-acne medication (isotretinoin or other) included
isotretinoin average daily dose during the first treatment stratified according
to its 40 mg formulation, and median duration cf the first isotretinoin
treatment (121 days).
Since our cohort spanned a 20-year period, we also adjusted the models on
the calendar time periods of the different Canadian programs and guidelines
promulgated over the years. We considered the following three programs
and guidelines. The first was the Pregnancy Prevention Program (PPP)
implemented in October 1988, whose goal was to prevent isotretinoin
exposed pregnancies in femaies of childbearing age. The second were the
Canadian Acne Treatment Guidelines published in 1995 (209).These
guidelines recommended up to three courses of systemic antibiotics before
considering isotretinoin. The third were the Canadian Consensus Guidelines
on Treatment of Acne and Prevention of Scarring published in 2000 (86).
These guidelines recommended that isotretinoin be prescribed primarily to
patients with scarring acne, regardless 0f severity.
C
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4.4.6 STATISTICAL ANALYSIS
Descriptive statistics were used to summarize the characteristics of the study
population. Kaplan-Meier survivai analyses were performed to determine the
time until receipt of an anti-acne medication (isotretinoin other). Rate ratios
(RR) along with 95% confidence intervals (95% Cl) were estimated using
conditional Iogistic regression. Crude and adjusted RRs were calculated for
both nested case-control analyses. Ail analyses were conducted using SAS
version 8.2 (SAS institute mc, Cary, North Carolina).
4.5 METHODS FOR STUDY 3
4.5.1 STUDY BASE
As with Studies 1 and 2, Study 3 was conducted among a population-based
cohort of patients who had received at Ieast one isotretinoin prescription from
January 1, 1984 to December 31, 2003 within the RAMQ drug plan.
4.5.2 STUDY DESIGN
A case-crossover design was used to determine whether there is an
association between isotretinoin and depression. This design was developed
by Maclure (214) in 1991 to study the transient effect of brief exposures on
rare acute events. The case-crossover design is similar to a matched case
control study where cases serve as their own controls by assessing
exposure at different points in time. The time intervals in which exposure is
assessed are the risk and control periods. The risk period is a time interval
immediately prior to the event. The risk period must take into account the
following parameters: induction time, effect period, and an exposure time
window. The induction time can be defined as the time between the last
component of a causal pathway (the trigger) and the onset of an event. Most
case-crossover studies have assumed a minimum induction time of zero
(185), although incubation periods have been accounted for in certain
situations (215). The effect period is the time between the minimum and
maximum induction times in the population. In situations where the minimum
jllo
Ç induction time is zero, the effect period is equal to the maximum induction
time. Finally, the risk period is equal to the minimum exposure time window
necessary for the event to occur, plus the etfect period. When the exposure
is instantaneous, such as point exposures, the risk period equals the effect
period. When the exposure is not instantaneous, such as prolonged drug
exposures, the risk period is longer than the effect period.
The control period is a time interval of equal length prior, and not overlapping
with the risk period, that provides an expected frequency of exposure for
each study subject. Similar to matched case-control studies, case-crossover
studies allow selecting one or several control periods for each risk period. In
addition, since patients serve as their own controls, time-independent
variables are automatically adjusted by design. However, variables that
change with time must be adjusted for in analyses. The analysis of a case
crossover study is essentially the same as that of a matched case-control
study, where the individual patient is the stratifying variable. In a matched
case-control study, concordant and discordant pairs are formed between
case and control subjects. In a case-crossover study, concordant and
discordant pairs are formed between risk and control periods. In both
designs, the odds ratio is calculated by the ratio of discordant pairs.
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4.5.3 CASE DEFINITION
According to the Diagnostic and Statistical Manuai 0f Mental Disorders,
fourth edition (DSM-IV) (216), clinical depression occurs when an individual
experiences at ieast five 0f nine symptoms for a period 0f two weeks or
more, for most of the time almost every day. Because of this stringent
definition, the validity of using administrative databases to identify cases of
depression can be put into question. Hence, using diagnostic codes alone s
not sufficient. Furthermore, identification of cases using antidepressants
alone can also be problematic, since depression is flot the sole indication for
these agents. Therefore, cases were defined according to the toilowing
algorithm. We identified ail subjects with a first diagnosis or hospitalization
for depression (lCD-9 codes: 296.2, major depressive disorder, single
episode; 298.0, depressive type psychosis, 300.4, neurotic depression;
309.0, brief depressive reaction; 309.1 prolonged depressive reaction; 311,
depressive disorder, flot elsewhere classified) during the study period (1984-
2003). In addition to having been diagnosed or hospitalized for depression,
cases were required to have filled an antidepressant prescription (American
Hospital Formulary System code: 28:16.04) within the 30 days following their
diagnosis or hospitaiization. The index date was defined as the calendar
date of the diagnosis or hospitalization for depression.
Furthermore, cases had to be covered by the RAMQ drug plan for at least 12
months prior to the index date. This was deemed necessary to ensure that
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drug exposure information was available during the time periods of interest.
In addition, cases had to have at least one diagnosis of acne vulgaris (lCD-9
code: 706.1) at any time in the 12 months prior to the index date. This
criterion ensured that cases had acne and thus had an exposure opportunity
to receiving isotretinoin. Finally, cases were excluded if they had received an
antidepressant prescription in the 12 months prior to the index date. Since by
design, the index date was defined as the subject’s first diagnosis or
hospitalization for depression in their medical history, none had any
diagnoses or hospitalizations for depression at any time prior to the index
date. Thattime period ranged from a minimum of 12 months up to 20 years.
4.54 TIME WINDOWS
Determining the length of the risk and control periods necessitates
knowledge of the duration of exposure necessary to alter the risk for an
outcome, as weII as the induction period in which the outcome is presumed
to develop. In daims data, the induction period is furiher defined as the time
it takes after exposure for the outcome to develop, become noticed by the
healthcare professional, and then be recorded in the administrative database
(217). In the case of isotretinoin, depression has been reported as early as
one day, two weeks, one month, and up to four months after initiation of
treatment (5,156,165,218). Furthermore, depression is an insidious outcome
which results in a time lag between actual onset of symptoms and clinical
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Ç diagnosis. Thus, the Iength of the time window for the risk period should take
into account these factors.
Assuming a minimum induction time of zero, the effect period should equal
the maximum induction time. For isotretinoin, the maximum induction time
was hypothesized to be four months based on data found in the literature
(5,156,165,219). In addition to this induction time, a time lag 0f one month
was hypothesized to exist between the actual onset of depression and its
clinical diagnosis. Patients undergoing isotretinoin treatment are typically
seen by their treating physicians at one-month intervals. As such, if
depressive symptoms do appear, physicians would be expected to diagnose
them at one of those follow-up visits. Therefore, the risk period was set to be
a total of five months. A five-month control window was separated from the
risk window by a two-month washout period. A two-month washout period
was chosen because product guidelines suggest initiating a second course
of isotretinoin in those who have not responded to the treatment only eight
weeks after the completion of a first course (92). This is because
improvements continue to occur during that time period despite having
terminated the treatment.
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0 4.5.5 POTENTJAL CONFOUNDERS
In a case-crossover design, each patient serves as his own contrai which
eliminates time-independent confounders (such as age, sex, socioeconomic
status). Thus such variables were flot included in the modeis. Characteristics
that change with time (i.e. time-dependent confounders) must be adjusted for
and therefore included in the models. The following potential time-dependent
confounders were recorded in each time window and adjusted for in the
models: non-dermatologic visits, dermatologic visits, at ieast one ail-cause
hospitalization, at least one emergency department visit, and comorbidity.
Dermatologic visits were defined as consuiting a dermatoiogist and/or being
diagnosed with acne vuigaris (lCD-9 code: 706.1). Comorbidity was
assessed using the total number of different types of medications prescribed,
other than isotretinoin. The number of different types of medications has
been shown ta be a good predictor cf healthcare utilization, similar ta other
comorbidity measures (220).
4.56 STATIST1CAL ANALYS1S
Descriptive statistics were used ta describe the characteristics of the cases.
Relative risks (RR) along with 95% confidence intervals (Cl) were estimated
using conditional logistic regression with the individual case as the stratifying
variable, In a first analysis, exposure ta isotretinoin was entered as a
dichotomous variable in the models (exposed at ieast once during each
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specific time window, yes or no). The length cf an isotretinoin prescription is
typicaiiy 30-days. In a second analysis, we determined whether there was a
dose-response cf isotretinoin on the incidence of depression. The cumulative
dose in milligrams cf isotretinoin dispensed was calculated in each time
window and entered as quartiles in the modeis. Crude and adjusted models
were calculated for ail situations. Analyses were two-sided and p 0.05 was
considered significant. SAS version 8.2 (SAS Institute, Cary, NO) was used
to conduct the analyses.
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Q 4.6 METHODS FOR STUDY 4
4.6.1 CASE-CROSSOVER AND CASE-TiME-CONTROL DESIGNS
Using a case-crossover design, a statistically significant association between
isotretinoin use and depression was found in Study 3. An assumption of the
case-crossover design is that there is no exposure time-trend during the time
periods of interest. Often this is not the case. Aggressive marketing of a
medication may Iead to an increase in its prescribing. Conversely, there are
instances that may lead to sudden decreases in prescribing, such as when
there is a shift in treatment guidelines. In either situation, a bias is introduced
in the model because of the exposure time-trend. Thus, time-trend alone
could explain an association or lack of association between a medication and
an outcome.
The case-time-control introduced by Suissa in 1995 (221), is an extension of
the case-crossover design whose goal is to correct for any exposure time
trend. A control group is selected around the same calendar period as the
cases, in which a control-crossover is performed. The control-crossover
provides an estimate of the exposure time-trend. The odds ratio (OR) of the
case-crossover is then divided by the OR of the control-crossover to produce
an OR adjusted for exposure time-trend (case-time-control). The OR of the
control-crossover is determined using the same time window scheme as in
the case-crossover.
g e I 117
In the case-time-control design, we used the same cases that were used in
the case-crossover design. As for controls, they were seiected according to
the following algorithm. We first identified ail subjects who were non-cases.
For each subject in the non-case pool, we generated a random index date
between the first and last day of their coverage in the RAMQ drug plan.
Subjects had to be covered at least 12 months prior to the index date, and
have at least one acne diagnosis (lCD-9: 706.1) during that same time
period. Subjects were excluded of they had received an antidepressant
prescription in the 12 months prior to the index date, or a diagnosis or
hospitalization for depression (lCD-9 codes: 296.2, 298.0, 300.4, 309.0,
309.1, 311) at any time prior to the index date. Up to 10 controls were
matched to cases on age (± three years), sex, and calendar year (± one
year).
Exposure to isotretinoin was assessed using the same time window scheme
as in the case-crossover design. Similarly, we adjusted the model for non
dermatologic visits, dermatologic visits, ail-cause hospitalizations,
emergency depariment visits, and comorbidity measured in the risk and
control periods independently.
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0 4.6.3 STAflSTICAL ANALYSIS
Descriptive statistics were used to describe the characteristics of cases and
controls in the different study designs. For the case-crossover design,
relative risks along with 95% confidence intervals (Cl) were estimated using
conditional logistic regression using the individual subject as the stratifying
variable. For the case-time-control, a conditional logistic regression was
fitted with time (risk versus control periods) as the dependent variable and
the exposure and an interaction term (the product of the exposure and case
group) as the independent variables. In the adjusted model, interaction terms
were added for each of the corresponding confounders. SAS version 8.2
(SAS Institute, Cary, NO) was used to carryout the analyses.
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5.1 PATTERNS AND UTILIZATION 0F ISOTRETINOIN FOR ACNE
FROM 1984 TO 2003: IS THERE NEED FOR CONCERN?
Laurent Azoulay1’2 MSc, Driss Oraichi2 PhD, Anick Bérard1’2 PhD
1Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada.
2Research Center, Sainte-Justine Hospital, Montreal, Quebec, Canada.
Manuscript published in the European Journal of Clinical Pharmacology
2006 Aug;62(8):667-74.
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5.1.1 ABSTRACT
Objectives: To 1) describe the patterns and trends of isotretinoin utilization
between 1984 and 2003, 2) describe the characteristics cf isotretinoin users
within that same time period, 3) identify and quantify predictors cf isotretinoin
use, and 4) describe the impact of guidelines on isotretinoin utilization
between 1984 and 2003.
Methods: Using the Régie de l’Assurance Maladie du Québec (healthcare
utilization, med ications) and Med-Écho (hospital izations) administrative
databases, we conducted a descriptive study on a population-based sample
of first-time isotretinoin users f rom 1984 to 2003. We determined the
characteristics cf these users, predictors cf an isotretinoin treatment 20
weeks, and impact cf guidelines on the number of new isotretinoin users.
Guidelines included the implementation of the Pregnancy Prevention
Program (PPP - 1988) and the Dear Healthcare Professional Letter
regarding possible psychiatric risks issued to Canadian physicians (DHPL -
2001).
Results: Mean (SD) age was 23.9 (7.6) years; 50% males, 52% welfare
recipients, 77% urban dwellers, and 55% of prescriptions were written by
dermatologists. Sixty-four percent 0f patients did not receive any anti-acne
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Ç medications in the 12 months prior to receiving isotretinoin. Thirty-five
percent of patients had an isotretinoin treatment 20 weeks suggested by
product guidelines. The odds ratio of having a treatment 20 weeks
significantly increased after the implementation of the PPP and other
guidelines. There was no statistically significant decrease in the number of
new isotretinoin users following the implementation of the PPP and DHPL.
Conclusion: These data suggest inappropriate isotretinoin utilization, even
more so after guidelines were promulgated.
o
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Ç 5.1 lNTRODUCflON
Since its introduction in the US in 1982 and Canada in 1983, isotretinoin has
become a popular therapeutic agent for patients with severe recalcitrant
nodular acne. One study conducted in the US found that isotretinoin was
prescribed 5.8 million times out of 35 million physician visits for acne (17% of
visits) [1J. A second study conducted in the US found that isotretinoin
prescriptions have more than doubled between 1992 and 2000 [2]. Despite
being the most efficacious drug in the treatment of severe nodular acne,
isotretinoin also acts as a potent teratogen [3, 4, 5, 6, 7, 8]. Additionally,
m ucocutaneous, ophthalmologic, neuromuscular, and gastrointestinal side
effects have been documented [9].
Given the extent of its use and its documented risks, it is imperative to
understand who uses isotretinoin and under what circumstances it is being
prescribed. A concern in the US has been its increased prescribing to
patients with mild-to-moderate acne between 1992 and 2000 [21. In addition,
47% to 72% of patients do not receive conventional therapies prior to
commencing isotretinoin as suggested by product guidelines [10].
Furthermore, new off-label indications such as gram-negative folliculitis,
recalcitrant rosacea, pyoderma faciale, generalized lichen planus, psoriasis,
cutaneous lupus erythematosus and acne fulminans for the drug have
become a concern [11].
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Since its marketing in Canada in 1983, several guidelines have been issued.
In 1988, a Pregnancy Prevention Program (PPP) was implemented ta
prevent isotretinoin-exposed pregnancies in females of childbearing age. In
1995, the Canadian Acne Treatment Guidelines were published [12]. These
guidelines recommended up ta three courses of systemic antibiotics, each
lasting four ta six months, before considering isotretinoin. The Canadian
Consensus Guidelines on Treatment of Acne and Prevention of Scarring
became available in 2000. Their focus was that prescriptions should be given
primarily on the presence of scarring regardless of severity [13, 14]. In
addition ta its known teratogenic risk and various side effects, case reports
have suggested a possible association between isotretinoin and depression
[15, 16, 17, 18]. This Ied Health Canada along with the manufacturer of the
drug ta issue a Dear Healthcare Professional Letter (DHPL) to Canadian
physicians warning them of possible psychiatric risks associated with
isotretinoin in 2001 [19].
Although population-based studies on isotretinoin have been previously
published [20, 21], none have specifically examined its utilization from the
time of its introduction into the market. Furthermore, no study has
investigated the impact of the guidelines mentioned above on prescribing
patterns over a 20-year period. As such, population-based data spanning
this time period would provide an accurate representation 0f isotretinoin
utilization. We therefore sought to 1) describe the patterns and trends of
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Ç isotretinoin utilization between 1984 and 2003, 2) describe the
characteristics cf isotretinoin users within that same time period, 3) identify
and quantify predictors cf isctretinoin use, and 4) describe the impact cf
guidelines on isotretincin utilization between 1984 and 2003.
5.1.3 METHODS
5.1,3.1 DATA SOURCES
We conducted a populaticn-based study on a cohort cf patients who had
received at ieast cne isctretinoin prescription from January 1, 1984 to June
30, 2003 in the province cf Quebec. Data were obtained frcm both the Régie
de l’Assurance Maladie du Québec (RAMQ) and the Quebec’s hcspital
discharge (Med-Écho) administrative databases. The RAMQ insures ail
Quebec residents fer medical services. The RAMQ drug prescription plan
insures apprcximately 50% cf Quebec residents [22], which inciudes perscns
65 years and eider, weifare recipients and their chiidren, and ail wcrkers and
their spcuse/chiidren whc dc net have access te a private insurance
prcgram.
The medical and pharmaceuticai databases cf the RAMQ were iinked by a
unique patient identificaticn number. The medical daims database includes
information on the date and type cf services received, and diagncses are
ciassified according te the International Classification cf Diseases, Ninth
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Ç revision (lCD-9) [23]. The pharmaceutical daims database contains
information on the date medications were dispensed, formulations, doses,
duration of prescriptions, and quantities dispensed. Medications prescribed
during hospitalizations are flot inciuded in the database. Both the medical
and pharmaceuticai daims databases have been validated and shown to be
accurate [24, 25].
The unique patient identification number was also used to link the RAMQ to
the Med-Écho administrative databases. Med-Écho contains hospitalization
data on ail Quebec residents. This data inciudes patient demographic
information, physician characteristics, admission diagnostic, length of stay,
as well as ail services received during the hospitalization. Medical diagnoses
recorded in Med-Écho have been shown to be valid and precise [26]. The
study protocol was approved by the Sainte-Justine Hospital Ethics
Committee and the Commission d’accès à l’information du Québec.
5.1.3.2 STUDY COHORT
Ail Quebec residents who received at least one isotretinoin prescription
(Drug identification numbers: 582344 (10 mg) and 582352 (40 mg)) between
January 1, 1984 and June 30, 2003 within the RAMQ drug prescription plan
and who met the following inclusion criteria were included in the present
C study: a patient must have been between 13 and 45 years of age and
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continuously insured by the RAMQ drug prescription plan for at least 12
months before and at least six months after the first day of the tirst
isotretinoin prescription within the study period (index date). A patient was
excluded if he/she had received a prescription for isotretinoin in the 12
months prior to index date.
5.1.3.3 INDiCATION FOR ISOTRETINO1N
According to the product labeling, isotretinoin is indicated for patients with
severe recalcitrant nodular acne who have flot responded to conventionai
therapy [27]. Since the lCD-9 classification system does not distinguish
between the different acne severities, it was not possible to determine
whether isotretinoin was being prescribed for severe recalcitrant nodular
acne. However, ail diagnostic codes entered within 30 days of the index date
were considered. Any lCD-9 code other than 706.1 (acne vulgaris) was
considered an off-label indication.
5.1.3.4 TREATMENT DURATION AND MEAN DAILY DOSAGE
The duration of an isotretinoin treatment was defined as fiiling consecutive
prescriptions with fewer than 30 days between renewals. The RAMQ
pharmaceutical daims database contains information on the duration
associated with a given drug prescription. Therefore, the cumulative
treatment duration was caiculated by adding the durations of ail
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dispensations of isotretinoin as prescribed by the physician. The
recommended duration 0f an isotretinoin treatment is between 15 to 20
weeks (105 to 140 days) [28]. The mean daily dosage in miiligrams/day was
calculated for ail patients.
5i.35 PREVIOUS ANTI-ACNE MEDICATIONS
We documented the types and number of anti-acne medications patients had
received in the 12 months immediately prior to the index date. Both topical
and systemic agents were considered: tretinoin, tazarotene, benzoyl
peroxide, clindamycin, doxycycline, tetracycline, minocycline, erythromycin,
azith romycin, and acne-specific oral contraceptives (Diane-35TM). Adapalene
and benzoyi peroxide/erythromycin combination were not included since they
are flot reimbursed by the RAMQ drug prescription plan. Since systemic
antibiotics are used to treat several conditions, it was necessary to ensure
that these were prescribed for acne. Therefore, an acne diagnosis (lCD-9
code: 706.1) must have been present in the database within 30 days of the
dispensing of the systemic antibiotic. In the event of a missing acne
diagnosis, we used procedure codes reiated to a dermatology visit within 30
days of the dispensing of the medication.
o
1129
5i.3.6 STATISTICAL ANALYSIS
5.1.3,6.1 CHARACTERISTIOS 0F ISOTRETINOIN USERS AND
PREDICTORS 0F UTILIZATION
Descriptive statistics were used to summarize the characteristics of the study
cohort. Because of the teratogenic risks associated with isotretinoin and thus
the differential management of males and females, we determined whether
there were demographic and treatment differences between genders.
Student’s t-tests and chi-square tests were used to compare continuous and
categorical variables, respectively. When normality was not observed, the
Mann-Whitney U test was used to compare median values between groups.
We also conducted univariate and multiple unconditional logistic regressions
to determine factors associated with treatment duration 20 weeks. Both
patient (socio-demographic data, healthcare utilization, and markers of
comorbidity such as the number of different medications dispensed) and
prescriber characteristics (age, gender, and specialty) were considered in
the models. In addition, since our cohort spanned a 20-year period, it was
necessary to adjust the model for the different practices and guidelines
issued throughout the years. We therefore considered four different time
periods: 1) the pre-PPP years, 2) implementation of the PPP in 1988, 3)
Canadian Acne Treatment Guidelines issued in 1995 [12] and 4) the new
Canadian Consensus Guidelines on Treatment of Acne and Prevention of
Scaring issued in 2000 [13, 14]. Ail analyses were conducted using SAS
version 8.2 (SAS Institute Inc., Cary, North Carolina).
.
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5.1362 ISOTRETINOIN UTILIZATION AND IMPACT 0F
GUIDELINES
Incident isotretinoin users were expressed as the number of users per
100,000 persons insured by the RAMQ drug prescription plan per calendar
year. Given the fact that our cohort only included users of isotretinoin, and
thus trends in time could reflect the increase in the number of people insured
and not an increase in the number of users, we had to define a common
denominator. To do this, the total number 0f patients eligible in the RAMQ
drug prescription plan for each calendar year from 1984 to 2003 was
obtained from the RAMQ’s annual statistics [29]. These statistics include the
mean number of beneficiaries for each calendar year stratified by age and
gender.
An impact in prescribing patterns was defined as an increase or decrease in
the number of isotretinoin users following an intervention. The interventions
considered were 1) the introduction of the PPP in October 1988, and 2) the
DHPL about possible psychiatric risks issued in March 2001. lnterrupted
time-series analyses, first proposed by Box and Tiao [30], were used to
determine whether these interventions had any impact on the prescribing
patterns in the months that followed their introduction. In interrupted time
series models, dummy variables are created with O and 1 representing pre
and post-interventions, respectively. Intervention 1) was based on 57 pre
Q intervention and 15 post-intervention months (from January 1984 to
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Ç December 1989), and intervention 2) was based on 134 pre-intervention and
22 post-intervention months (from January 1990 to December 2002). The
interventions were assumed to have a graduai, permanent impact and thus
each model contained both abrupt (w) and graduai (Ô) eftect parameters.
Impact of the PPP was assessed in female patients, whereas impact of the
DHPL was assessed in both genders.
Autoregressive integrated moving average (ARIMA) was used to model the
time-series and predict post-intervention rates with 95% confidence intervais.
To stabiiize the variabiiity within the series, Box-Cox transformations were
empioyed. When trend was observed, we differenced rates between
successive months. Seasonal troughs were observed at every mid-summer
and were therefore removed by differencing rates using a seasonai period cf
12 months. To identify modeis, we examined the estimated autocorrelation
and partial correlation functions of the stationary series. Ljung-Box test and
Akaike’s information criterion were used as guides for choosing the best
modei. In au chosen models, normaiity and stability of the variance of the
residuais was ascertained.
51.4 RESULTS
0f the 30,496 Quebec residents that had received at ieast one isotretinoin
ç prescription between January 1, 1984 and June 30, 2003 within the RAMQ
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drug prescription plan, a total of 17,351 patients met inclusion criteria, and
were thus included in this analysis - these patients were considered new
isotretinoin users. Specitically, 12,908 (74.4%) had one isotretinoin
treatment, 2997 (17.3%) had two, and 1446 (8.3%) had three or more during
the 20-year study period. Only the first isotretinoin treatment was considered
in the following analyses.
5.1.4.1 INDICATION FOR ISOTRETINOIN
Seventy-nine percent of patients had a diagnosis for acne in the 30 days
prior to the index date, while the remaining had either dermatologic
diagnoses other than acne (9.8%), or other diagnoses (11.2%).
5.1.4.2 PATIENT AND PRESCRIBER CHARACTERISTICS
Table 1 presents unadjusted patient and prescriber characteristics. From
1984 to 2003, isotretinoin was similarly prescribed to males and females
(8715 (50.2%) vs. 8636 (49.8%), respectively). Females were 4.5 years
older than males at the index date, were more often living in urban seffings
as compared to males, and consulted physicians more often than males in
the 12 months prior to the index date as well as were taking less anti-acne
medications other than isotretinoin than males (p < 0.05). Emergency
department (ED) visits were more common among males than females in the
12 months prior to the index date (p = 0.0006). With regards to
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hospitalizations, they were more common among females than in males in
the 12 months prior to the index date (p < 0.0001). The majority of
prescriptions for isotretinoin at index date were written by male physicians
(76.8%), and dermatologists (54.7%).
5.1.4.3 PREVIQUS ANTACNE TREATMENTS
Some 36.9% of males and 34.4% of females had received at Ieast one anti
acne medication in the 12 months prior to the index date before actually
receiving their first isotretinoin prescription (Table 2). The most common type
of anti-acne medication prescribed was systemic antibiotics (74.7%), in both
males (74.5%) and females (74.8%).
5.1 4.4 TREATMENT CHARACTERISTICS
Table 3 presents treatment characteristics. The median treatment duration
was 121 days for both males and females. There were 6099 (35.2%)
patients who had treatment duration equal to or greater than the 20 weeks
(140 days) suggested by product guidelines. Mean daily dosage was greater
in males than females (49.4 mg versus 42.7 mg, p < 0.0001).
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51.45 PREDICTORS 0F INAPPROPRIATE ISOTRETINOiN USE
Table 4 displays predictors of having a treatment duration 20 weeks, which
is considered inappropriate. In multivariable analyses, the following
decreased the likelïhood of having an isotretinoin treatment duration 20
weeks: older age, male gender, urban dwellers, welfare recipients, having
two ED visits in the 12 months prior to the index date, and being treated by
older male physicians. In contrast, the following increased the likelihood of
having an isotretinoin treatment duration 20 weeks in multivariable
analyses: receiving anti-acne medications concomitantly during the
isotretinoin treatment, receiving anti-acne medications or other types cf
medications in the 12 months prior to the index date, having the first
isotretinoin prescription written by a dermatologist, and being prescribed
isotretinoin by two physicians during the isotretinoin treatment. Moreover,
the estimated odds ratios for treatment durations 20 weeks significantly
increased following the implementation of the PPP (after 1988).
5L4.6 IMPACT 0F GUIDELINES
No significant impact of guidelines on the number of new isotretinoin users
was noted in this study. The estimated interrupted time-series parameters for
the implementation of the PPP in October 1988 in females users were w = -
2.09 (p = 0.008) and 6 = -0.21 (p = 0.642). Since 6 was not statistically
significant while w was, only an abrupt, permanent impact remains plausible.
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With regard to the DHPL issued in March 2001, neither w = -0.15 (p = 0.610)
nor 6 = -0.10 (p = 0.996) were statistically significant in female users,
indicating no impact. The same was true for male users; w -0.46 (p =
0.475) and 6 -0.06 (p = 0.967).
51.5 DISCUSSION
To our knowledge, this is the first population-based study to specifically
investigate isotretinoin utilization over a 20-year period (1984 to 2003). Our
data indicate inappropriate isotretinoin utilization, even more so atter the
implementation 0f the PPP and introduction 0f other guidelines. Specifically,
over 35% of patients had undergone an isotretinoin treatment longer than the
20 weeks suggested by the product guidelines. In addition, 64% of patients
had not received any anti-acne medication in the 12 months prior to the
index date. In the province of Quebec, the implementation of the PPP in
1988 and the DHPL issued in 2001 do flot appear to have had any impact on
prescribing patterns.
Isotretinoin is intended for severe recalcitrant nodular acne, and as such, it
would be expected that ail patients receiving the drug are acne patients.
Stem [311 found that 97% of prescriptions for isotretinoin were indicated for
acne. However, in the present study, we found that 79% of patients received
an acne diagnosis in the 30 days prior to the index date. Although
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G isotretinoin is prescribed for other dermatologic and non-dermatologic
conditions [9, 1 1], we believe our prevalence to be an underestimate given
that diagnoses are often missing in administrative databases.
Dermatologists prescribed 55% of the isotretinoin prescriptions, a figure that
is weII below what has been reported in the literature [1, 31], although Chen
et aI. [32] found that 52% of prescriptions were written by dermatologists in a
southern California HMO. In the present study, the Iow frequency of
prescriptions written by dermatologists could be due to the universal
healthcare system that is in place in the province of Quebec. Because of the
high demand for such professionals, the waiting time to consult a
dermatologist could be several weeks. As such, non-dermatologists,
especially general practitioners become the best alternative. Unfortunately, a
Canadian report suggested that non-dermatologists were not familiar with
the components of the PPP, raising the concern of unintended isotretinoin
exposed pregnancies in females of childbearing age [33]. In addition, non
dermatologists may not be familiar with the numerous side effects associated
with isotretinoin treatment, and thus may not have the proper training to
counsel patients when symptoms appear.
We found that 35% of patients had treatment duration longer than the 20
Q weeks suggested by the product guidelines. This in itself is a troubling
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finding since it unnecessarily prolongs exposure to a potent agent.
Interestingly, receiving at least one anti-acne medication in the 12 months
prior to isotretinoin was a predictor of having treatment duration longer than
20 weeks. One possibility is that those who received such medications have
severe forms of acne that are resistant to conventional therapy, and thus
would require longer isotretinoin treatment durations. In addition, the odds
ratio 0f having treatment duration 20 weeks increased after the
implementation of the PPP and other guidelines. This indicates that the
implementation ot the PPP and other guidelines were associated with longer
treatment durations, contrary to what might have been expected.
Furthermore, receiving isotretinoin from 2 or more physicians during the
isotretinoin treatment more than doubled the odds of having treatment
duration 20 weeks, indicating that unity 0f care is a marker for appropriate
prescribing and utilization.
It is expected that patients with severe recalcitrant nodular acne obtain
therapeutic treatments prior to commencing an isotretinoin treatment. In fact,
Canadian consensus guidelines have suggested that isotretinoin should only
be prescribed to those patients who did not respond to conventional therapy,
including systemic antibiotics [12]. In 2000, new Canadian Consensus
Guidelines on Treatment of Acne and Prevention of Scaring have suggested
a more aggressive approach, primarily focusing on the presence of scarring
regardless of severity [13, 14]. Our data indicate a sub-optimal rate of
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cD physician adherence to guidelines. Over 64% of ail patients had not received
any anti-acne medication in the 12 months prior to the index date. in
contrast, Chen et al. [32] found that 39% of patients had not received any
anti-acne medication in the 6 months prior to the first isotretinoin
prescription. Our iower prevaience of anti-acne medication utilization may
indicate one of two things. First, isotretinoin is being utilized as a first une
agent instead ot being prescribed after having exhausted ail other
conventionai therapies. Second, the absence of anti-acne medications in the
12 months prior to the index date may potentially be a proxy for acne
severity, indicating that isotretinoin is being prescribed to patients with mild
or moderate acne. We were not able to document the use of over-the
counter (OTC) anti-acne agents since they are not reimbursed by the RAMQ
drug prescription plan. However, we believe that adequate treatment of
severe nodular acne requires systemic agents, which for the most part are
covered by the RAMQ drug prescription plan. Furthermore, given the tact
that members of our cohort were ail insured by the RAMQ drug prescription
plan for their medications and thus had no incentive to buy medications
OTC, the likelihood of OTC anti-acne medication use is minimal.
5,L5.1 IMPACT 0F GUIDELINES
Our resuits indicate that impiementation of the PPP (1988) did not have a
graduai, permanent effect on the number of new isotretinoin users. The PPP
requires a strict follow-up of temale patients throughout the treatment, and
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thus would normally deter both physicians and patients from using
isotretinoin. Likewise, the DHPL (2001) on possible psychiatric risks
associated with isotretinoin utilization did flot have a graduai, permanent
effect on the number of new isotretinoin users. Our data suggest that both
these interventions did flot appear to have any effect in clinical practice.
Several factors may explain this iack of effect. it is possible physicians were
flot fully familiar with the new guidelines when they were implemented, that
they disagreed with them altogether, or that they lacked motivation in
implementing them (inertia of previous practice) [34]. Future research should
focus on the barriers to physician adherence to practice guidelines in relation
to isotretinoin.
Despite its various side effects, isotretinoin remains the most effective drug
in the treatment of severe acne. However, our study suggests inappropriate
utilization since its introduction into the market more than 20 years ago. This
problem may be exacerbated by the introduction of cheaper generic
compounds which are likely to increase its availability. As such, more
effective strategies should be put in place to improve its current utilization.
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In the 12 months rior to index date:
(able 1. Characterïstics of patients andprescribers
Patient characteristics
At index date:
Age (years) (mean, SD)
Urban dwellers (n, %)t
Welfare recipients (n, ¾)
Total
(n=1 7351)
Males
(n=871 5)
Females
(n=8636) P-value1’
Anti-acne medications (n, %)t
Other medications (n, %)
Visits to the MD (n, %)
None
1
Visits to the ED (n, %)
None
1
Hospitalizations (n, %)t
None
1
23.9 (7.6)
12,363 (77.0%)
9023 (52.0%)
6195 (35.7%)
13,857 (79.9%)
975 (5.6%)
1821 (10.5%)
14,555 (83.9%)
12,640 (72.8%)
2664 (15.4%)
2047 (11.8%)
15,472 (89.2%)
1468 (8.5%)
411 (2.4%)
21 .6 (6.8)
6053 (75.4%)
4499 (51.6%)
3220 (36.9%)
6375 (73.1%)
701 (8.0%)
1222 (14.0%)
6792 (77.9%)
6252 (71.7%)
1426 (16.4%)
1037 (11.9%)
8097 (92.9%)
483 (5.5%)
135 (1.6%)
26.1 (7.6)
6310 (78.6%)
4524 (52.4%)
2975 (34.4%)
7485 (86.7%)
274 (3.2%)
599 (6.9%)
7763 (89.9%)
6388 (74.0%)
1238 (14.3%)
1010 (11.7%)
7375 (85.4%)
985(11.3%)
276 (3.2%)
<0 .0001
0 .0208
0 .7924
0.0006
<0.0001
<0.0001
0.0006
<0.0001
Prescriber characteristics at index
date
Age (years) (mean, SD)tt 53.3 (10.7) 54.9 (10.6) 47.9 (9.1) < 0.0001
Males (n, ¾) 13,317 (76.8%) 6813 (78.2%) 6504(75.3%) < 0.0001
Number of patients treated by:
Dermatologists (n, %) 9465 (54.7%) 4490 (51.7%) 4975 (57.8) < 0.0001
General practitioners (n, %) 7529 (43.5%) 4042 (46.5%) 3487 (40.5%)
Others (n, %) 308 (1.8%) 160(1.8%) 148 (1.7%)
Abbreviations: SD, standard deviation; MD, medical doctor; ED, emergency department.
‘Comparing males and females.
tPercentage based on 16,058 patients with available data; 8028 maIes and 8030 females.
tCalculated in the 12 months immediately preceding the first isotretinoin prescription.
ttBased on 17,240 patients with available data; 8663 maIes and 8577 females.
Percentage based on 17,302 patients with available data; 8692 maIes and 8610 temales.
Note: Percentages may flot add up to 100% due to rounding.
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ibIe 2. Anti-acne medications dispensed in the 12 months immediately preceding the index date
. .
. Total Males FemalesAnti-acne medications (n=67 95) (n=3220) (n=2975) P-value
Systemic antibioticst 4625 (74.7%) 2399 (74.5%) 2226 (74.8%) 0.7721
Miscellaneous agentst 1478 (23.9%) 866 (26.9%) 612 (20.6%) < 0.0001
Topical retinoidst 1017 (16.4%) 472 (14.7%) 545 (18.3%) 0.0001
Topical antibioticst 805 (13.0%) 400 (12.4%) 405 (13.6%) 0.1636
At least any one of the 35.7% (35.0, 36.4) 36.9% (36.2, 37.7) 34.4% (33.7, 35.2) 0.0006
agents above
The categories above are flot mutually exclusive since a patient may have received more than one type
of medication.
‘1Comparing males and females.
Percentages were calculated by dividing the number of patients in each category by the total number of
patients received at least one acne medication (n=6195).
9Defined as the percentage of patients who had received at least one these medications along with 95%
confidence intervals.
À
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ble 3. Characteristics related to the isotretinoin treatment
Total Males Females
(n=17,351) (n=8715) (n=8636) -va ue
duration, days (median, 121 (66-155) 121 (66-156) 121 (66-154) 0.3666
Treatment duration (n, %)
140 days 6099 (35.2%) 3096 (35.5%) 3003 (34.8%) 0.2996
150 days 4866 (28.0%) 2480 (28.5%) 2386 (27.6%) 0.2247
l8odays 2362(13.6%) 1231 (14.1%) 1131 (13.1%) 0.0482
Mean daily dosage (mg/day) (mean, SD) 46.1 (22.2) 49.4 (24.5) 42.7 (19.0) < 0.0001
Isotretinoin Rxs in a treatment (mean,
4.1 (2.5) 4.2 (2.6) 4.1 (2.4) 0.0008
Abbreviations: Qi -Q3, 25th percentiIe75th percentile; SD, standard deviation; Rx, prescription.
“Comparing males and females.
Mann-Whitney U test was used to compare median values between males and females.
tPatients with at Ieast one anti-acne medication other than isotretinoin during their treatment.
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3bIe 4. Predictors of an isotretinoin treatment duratïon 20 weeks
0 Adjusted OR (95%Crude OR (95/0 CI) CI)
Age 0f patients, years 0.97 (0.97, 0.98) 0.98 (0.97, 0.98)
Male patients 1.03 (0.97, 1.10) 0.92 (0.85, 0.99)
Urban dwellers 0.79 (0.73, 0.85) 0.87 (0.81, 0.95)
Welfare recipients 0.53 (0.49, 0.56) 0.75 (0.69, 0.81)
In the 12 months immediately prior to the first
isotretinoin prescription:
At least one anti-acne medication 1.48 (1.39, 1.58) 1.22 (1.14, 1.32)
At leastone non anti-acne medication 1.02 (0.94, 1.10) 1.12 (1.03, 1.23)
Number of visits to the physician
None 1.00 (Reference) 1.00 (Reference)
7 1.20(1.01, 1.41) 1.13(0.94, 1.35)
2 1.16 (1.01, 1.33) 1.04 (0.89, 1.23)
Number of emergency department visits
None 1.00 (Reference) 1.00 (Reference)
1 0.98 (0.90, 1.07) 0.94 (0.86, 1.04)
2 0.85 (0.77, 0.93) 0.81 (0.73, 0.90)
Number of hospitalizations
None 1.00 (Reference) 1.00 (Reference)
1 0.89(0.80, 1.00) 1.04 (0.92, 1.18)
2 0.58 (0.46, 0.73) 0.78 (0.60, 1.02)
Time periods
January 1, 1984 — September 30, 7 988 1.00 (Reference) 1 .00 (Reference)
October 1, 1988— December 31, 7994 1.30 (1.14, 1.49) 1.24(1.05, 1.47)
Januaryl, 1995— December3l, 1999 2.38 (2.14, 2.65) 1.66 (1.42, 1.94)
January 7, 2000 — June 30, 2003 2.79 (2.51, 3.1 1) 1.70 (1 .45, 2.01)
Age of physician, years 0.96 (0.96, 0.97) 0.97 (0.97, 0.98)
Treated by male physicians 0.68 (0.63, 0.73) 0.92 (0.85, 0.99)
Treated by dermatologists 0.96 (0.90, 1.02) 1.17 (1.09, 1.26)
Isotretinoin prescribed by 2 physicians 2.36 (2.10, 2.66) 2.42 (2.13, 2.77)
Concomitant anti-acne medications 1 .44 (1.29, 1.62) 1.41 (1.25, 1.60)
Mean daily dosage (mg/day) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00)
Abbreviations: OR, odds ratio; CI, confidence interval; SD, standard deviation.
tAdjusted for the covariates in the table.
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:5.2.1 SUMMARY
Background: Previous studies on predictors of acne relapse in patients
treated with isotretinoin had either small sample sizes, short follow-up
periods, or lacked population-based data.
Objectives: To identify and quantify (1) predictors of acne relapse, and (2)
predictors of receiving a second isotretinoin treatment.
Methods: Using the RAMQ and Med-Écho administrative databases, a
population-based cohort of 17,351 first-time isotretinoin users was
assembled between 1984 and 2003. A nested case-control analysis was
performed to determine predictors of acne relapse (as defined by receiving
an anti-acne medication). A second nested case-control analysis was
performed to determine predictors of receiving a second isotretinoin
treatment. The index date of cases was the calendar date of dispensing of
an anti-acne medication (isotretinoin or other). Five controls were matched to
each case on follow-up time. Rate ratios were estimated using conditional
logistic regression.
Results: 7100 (40.9%) subjects experienced an acne relapse. These were
matched to 35,500 controls. Being male, <16 years of age, living in urban
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area, isotretinoin cumulative doses greater than 2450 mg and an isotretinoin
treatment longer than 121 days were statistically associated (p<0.05) with
acne relapse. The publishing of the different Canadian acne guidelines had
no impact on the incidence of acne relapse (p>0.05). 4443 (25.6%) subjects
required a second isotretinoin treatment. These were matched to 22,215
controls. There was a greater probability of receiving a second isotretinoin
treatment after the publishing of the Canadian acne guidelines (p<0.05).
Conclusion: A relatively high rate of subjects experienced an acne relapse
afte r an isotretinoin treatment.
o
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Since its introduction in the market more than 20 years ago, isotretinoin has
revolutionized the treatment of severe nodular acne. However despite its
remarkable eftectiveness, isotretinoin bas important side effects. It is a
teratogen if taken during the first trimester of pregnancy.1 In Canada, a
pregnancy prevention program was implemented in 1988, but failed to
prevent isotretinoin-exposed pregnancies.2 Other side effects may be
mucocutaneous, ophthalmologic, neuromuscular, and gastrointestinal
problems.3 In addition, an association between isotretinoin and depression
has recently been found (Azoulay et al., submitted for publication).
Given isotretinoin’s safety profile, it is important to determine which patients
wiII benefit most from this treatment versus those who wiIl not. As such,
determining predictors of experiencing an acne relapse may be of great
prognostic value to physicians who treat patients with acne.. This is
particularly important in countries such as Canada that have no restrictions
as to which physicians may prescribe isotretinoin. Since its introduction in
the US in 1982 and Canada the following year, several observational studies
have examined predictors of experiencing an acne relapse after being
initially treated with isotretinoin. The relapse rates varied between studies,
ranging from 5.6% to 65.4%.415 There are several possible explanations for
this large discrepancy. First, these studies had small sample sizes, ranging
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Q between 52 and 299 patients.415 Second, some studies had short foiiow-up
periods, and may have thus underestimated the relapse rate. Finally, relapse
was flot defined consistently across the different studies.
Given the limitations described above and lack of popuiation-based data on
the subject, we sought to (1) determine the characteristics of subjects initialiy
treated with isotretinoin experiencing an acne relapse as defined by requiring
further treatment with an aflti-acfle medication (either a second isotretinoin
treatment or another anti-acne medication), (2) identify and quantify
predictors of experiencing an acne relapse, and (3) identify and quantify
predictors of receiving a second isotretinoin treatment.
5.2.3 METHODS
5.2.3.1 DATA SOURCES
Data were obtained from the Régie de l’Assurance Maladie du Québec
(RAMQ) and Quebec’s hospital discharge (Med-Écho) administrative
databases. Ail Quebec residents are covered by the RAMQ for medical
services. Prior to January 1, 1997, the RAMQ drug plan covered those who
were 65 years and older, and welfare recipients and their chiidren. After
January 1, 1997, the RAMQ drug plan was changed to also include workers
and their spouses/children who do flot have access to a private medication
ifisurance program. The RAMQ drug plan covers approximately 50% of
Ç Quebec residents.16
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Ç The medicai and pharmaceutical databases of the RAMQ were iinked by a
unique patient identification number. The medicai daims database includes
information on the date and type of services received, and diagnoses are
ciassitied according to the International Classification of Diseases, Ninth
revision (lCD-9).17 The pharmaceuticai daims database contains information
on the date medications were dispensed, formulations, doses, duration of
prescriptions, and quantities dispensed. Medications prescribed during
hospitalizations are flot included in the database. Both the medicai and
pharmaceuticai daims databases have been vaiidated and shown to be
accurate for certain diagnoses.18’19
The unique patient identification number was aiso used to Iink the RAMQ to
the Med-Écho administrative databases. Med-Écho contains hospitalization
data on ail Quebec residents. This data includes patient demographic
information, physician characteristics, admission diagnostic, iength of stay,
as well as ail services received during the hospitalization. Medical diagnoses
recorded in Med-Écho have been shown to be vaiid and precise.2°
The study protocol was approved by the CHU Sainte-Justine Ethics
Committee and the Commission d’accès à l’information du Québec.
C
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5.2.3.2 STUDY COHORT
We identified ail Quebec residents who received a f irst isotretinoin treatment
between January 1, 1984 and June 30, 2003 within the RAMQ drug plan. An
isotretinoin treatment was defined as filling consecutive prescriptions with
fewer than 30 days between renewais. These subjects were between 13 and
45 years of age on the first day of the first isotretinoin prescription within the
study period. They were required to be continuously insured by the RAMQ
drug plan for at least 12 months before and at least six months after the first
day of the first isotretinoin prescription. Based on the criteria above, we
identified 17,351 first-time isotretinoin users. A detailed description of the
cohort has been described previously.21
5.2.3.3 STUDY DESIGN
Two nested case-control analyses were conducted using a SAS incidence
density program22 that was adapted for the purposes of the present study.
The first nested case-control analysis determined predictors of receiving an
anti-acne medication (isotretinoin or other) after being initially treated with
isotretinoin. The second nested case-control analysis determined predictors
of receiving a second isotretinoin treatment. With incidence density
sampling, a subject could serve as a control for more than one case.
Moreover, cases could serve as controls before they become cases. For
both nested case-control analyses, controls were matched to cases on the
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time since the end cf their first isotretinoin treatment. Five controls were
randomly matched to each case.
5.2.3.4 FOLLOW-UP
The date of entry in the cohort for the first nested case-control started the
day after the end of the first isotretinoin treatment. This is because it was
possible to receive an anti-acne medication at any time after the first
isotretinoin treatment. As for the second nested case-control study, the date
of entry in the cohort for ail subjects started only 30 days after the end of
their f irst isotretinoin treatment. This is because an isotretinoin treatment was
defined as filling consecutive prescriptions with fewer than 30 days between
renewals. Therefore by design, there were no isotretinoin prescriptions in the
30 days after the end 0f the first treatment. This was done to avoid immortal
bias,23’24 where the person-time at which subjects were not at risk 0f
receiving an isotretinoin prescription was excluded. Subjects in both nested
case-control analyses were foiiowed until they became cases, were no
longer covered by the RAMQ drug plan, or until June 30, 2003, whichever
came first.
5.2.3.5 CASES AND CONTROLS
Cases for the f irst nested case-control analysis consisted cf subjects whoQ
experienced an acne relapse and required further treatment with an anti-
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C acne medication (isotretinoin or other). For those cases, the index date was
the calendar date of the dispensing of the anti-acne medication (isotretinoin
or other). Eligible controls were subjects who were still present in the cohort
at the time of the cases’ index date and had flot received any anti-acne
medications (isotretinoin or other) prior to that date. The anti-acne
medications considered were isotretinoin, tretinoin, tazarotene, benzoyl
peroxide, topical clindamycin, topical erythromycin, systemic doxycycline,
systemic tetracycline, systemic minocycline, systemic erythromycin, systemic
azithromycin, and acne-specific oral contraceptives (Diane-35TM). Adapalene
and benzoyl peroxide/erythromycin combination were flot considered since
they are flot reimbursed by the RAMQ drug plan. Given that systemic
antibiotics are prescribed for a variety of conditions, it was necessary to
ascertain that those considered as acne treatments were truly for acne.
Therefore, an acne diagnosis (lCD-9 code: 706.1) must have been present in
the database within 30 days of the dispensing of the systemic antibiotic to be
considered an anti-acne treatment. In the event of a missing acne diagnosis,
we used dermatologic procedure codes recorded within 30 days of the
dispensing of the medication.
Cases for the second nested case-control analysis consisted of subjects who
experienced an acne relapse severe enough to require a second isotretinoin
treatment. As such, their index date was the calendar date of the dispensing
of the second isotretinoin treatment. Eligible controls were subjects who
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C were stiil present in the cohort at the time of the cases’ index date and had
not received any isotretinoin prescriptions prior to that date.
5.2.3.6 POTENTIAL PREDICTORS
Potential predictors for both nested case-control analyses were assessed in
four different time periods. The time periods were at the 1) index date, 2)
between the end of the first isotretinoin treatment and index date (follow-up
period), 3) during the first isotretinoin treatment, and 4) in the 12 months
prior to the f irst isotretinoin treatment. The predictors considered in the four
time periods related to subject socio-demographic information (age, gender,
place of residence, adherent of the RAMQ drug plan/welfare recipient),
healthcare and medication utilization (visits to the physician, emergency
department visits, ail cause hospitalizations, and number of different types of
medications) as well as prescriber information (speciaity, gender of
prescriber, and whether isotretinoin was prescribed by more than two
physicians during the first treatment). Other predictors for requiring further
treatment with an anti-acne medication (isotretinoin or other) included
median duration of the first isotretinoin treatment (121 days) and isotretinoin
cumulative dose. The latter was entered as quartiles in the models. A
cumulative dose of 2450 mg was considered equivalent to close to a two
month’s supply of isotretinoin, assuming an ave rage dosage of 46 mg/day.21
C
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C Since our cohort spanned a 20-year period, we also adjusted the models on
the calendar time periods of the different Canadian programs and guidelines
promulgated over the years. We considered the following three programs
and guidelines. The first was the Pregnancy Prevention Program (PPP)
implemented in October 1988, whose goal was to prevent isotretinoin
exposed pregnancies in females of childbearing age. The second were the
Canadian Acne Treatment Guidelines published in 199525 These guidelines
recommended up to three courses of systemic antibiotics before considering
isotretinoin. The third were the Canadian Consensus Guidelines on
Treatment of Acne and Prevention of Scarring published in 2000. These
guidelines recommended that isotretinoin be prescribed primarily to patients
with scarring acne, regardless of severity.26’27
5.2.3.7 STATISTICAL ANALYSIS
Descriptive satistics were used to summarize the characteristics of the study
population. Kaplan-Meier survival curves were constructed to model the time
from the end on the first isotretinoin treatment until receipt of an anti-acne
medication (isotretinoin or other). Rate ratios (RR) along with 95%
confidence intervals (95% Cl) were estimated using conditional logistic
regression. Crude and adjusted RRs were calculated for both nested case
control analyses. AIl analyses were conducted using SAS version 8.2 (SAS
Institute mc, Cary, North Carolina).
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5.2.4 RESULTS
5.2.4.1 PREDICTORS 0F RECEl VING AN ANT1-ACNE MEDICATION
0f the 17,351 first-time isotretinoin users in the cohort, a total of 7100
(40.9%, 95% Ci: 40.4%, 41.4%) subjects (cases) required further treatment
with an anti-acne medication (isotretinoin or other). There was a total of
36,911 person-years of foliow-up, where the rate of receiving an anti-acne
medication was 192/1000 persons per year. Hait of the cohort received an
anti-acne medication within 58.8 months (4.9 years) after the end cf their
isotretinoin treatment (Figure 1).
A total of 35,500 controls were matched to the 7100 cases. The
characteristics of the cases and controls were similar (Table 1). isotretinoin
was dispensed to 4011 (56.5%) subjects, whereas 3089 (43.5%) required
other anti-acne medications (Table 2). Out cf the latter group, 432 (14.0%)
received isotretinoin during the remainder cf their follow-up.
Table 3 displays crude and adjusted RRs of receiving an anti-acne
medication (isotretinoin or other) after being initially treated with isotretinoin.
Maie subjects and those under 16 years cf age were more likeiy to receive
an anti-acne medication. Subjects living in urban areas were also more likeiy
to receive an anti-acne medication. The impiementation of the PPP and
publishing of other guidelines were not statistically associated with receiving
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an anti-acne medication. Subjects who had received isotretinoin cumulative
doses greater than 2450 mg compared to those who received cumulative
doses less than 2450 mg during their first treatment were less likely to
receive another anti-acne medication. Those whose f irst isotretinoin
treatment was 121 days were also less likely to receive another anti-acne
medication.
5.2.4.2 PREDICTORS 0F RECEIVING A SECOND ISOTRETINOIN
TREATMENT
0f the 17,351 first-time isotretinoin users in the cohort, 12,908 (74.4%) had
one treatment, 2997 (17.3%) had two treatments, and 1446 (8.3%) had three
or more isotretinoin treatments during the follow-up period. Thus a total of
4443 (25.6%, 95% Cl: 25.1%, 26.0%) had two or more isotretinoin
treatments during the study period. There was a total of 48,802 person-years
of follow-up, where the rate of receiving a second isotretinoin treatment was
91/1000 persons per year. Nearly ail subjects who received a second
isotretinoin treatment did so within 25.4 months after the end of their first
treatment (Figure 2).
There were 4443 cases and 22,215 controls in the nested case-control
analysis. The characteristics of cases and controls were similar (Table 4).
Table 5 presents crude and adjusted RRs of predictors of receiving a second
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isotretinoin treatment. In adjusted analyses, subjects under 16 years cf age,
as well as males were more Iikely to receive a second isotretinoin treatment.
The chances of receiving a second isotretinoin treatment increased after the
implementation 0f the PPP and the publishing 0f the different guidelines.
Subjects who had received isotretinoin cumulative doses greater than 2450
mg compared to those who received cumulative doses less than 2450 mg
during their first treatment were less likely to receive a second isotretinoin
treatment. Likewise, subjects who had an isotretinoin treatment 121 days
were less likely to receive a second isotretinoin treatment.
5.2.5 DISCUSSION
In a cohort of first-time isotretinoin users, 41% of subjects experienced an
acne relapse necessitating further treatment with an anti-acne medication
(isotretinoin or other). Twenty-six percent of subjects experienced a relapse
severe enough to receive a second isotretinoin treatment at some point
during their follow-up. Younger age, male gender, living in an urban area,
and several healthcare utilization variables were associated with receiving an
anti-acne medication (isotretinoin or other). Guidelines published over the
years had no impact on the incidence of acne relapse. However, subjects
were more Iikely to receive isotretinoin after the publishing of these
guidelines.
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Forty-one percent of the cohort experienced an acne relapse necessitating
further treatment with an anti-acne medication. This figure is similar to what
has been published previously.1214 Male subjects and those under the age of
16 were more likely to require furiher treatment with an anti-acne medication.
Compared to subjects living in rural areas, those living in urban areas were
more likely to require further treatment. A possible explanation for this finding
is that subjects living in urban areas had a greater accessibility to physicians
than those living in rural areas, and were thus more likely to consult a
physician and receive an anti-acne medication. Subjects who visited an
emergency department or who were hospitalized after the end of their
isotretinoin treatment were less likely to experience an acne relapse. It s
possible that these subjects had other serious medical conditions that may
have prevented them from receiving an anti-acne medication. Furthermore,
subjects who had isotretinoin treatment durations longer than the median
(121 days) were less likely to experience an acne relapse, as well as those
who had cumulative doses greater than 2450 mg. This is consistent with
other studies that have investigated cumulative dose on the incidence of
acne relapse.6’1°
lnterestingly, the acne guidelines published over the years had no impact on
the incidence of acne relapse. This suggests one of two possibilities. The
first is that these guidelines may not have been adequate in preventing
relapses in subjects initially treated with isotretinoin. As such, future research
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should determine the effectiveness of such guidelines on patient outcomes.
The second is that physicians did flot fully adhere to these guidelines. If true,
it may be due to Iack of awarefless, Iack of familiarity with new guidelines,
disagreement, or inertia of previous practice.28
Twenty-six percent of the cohort required a second isotretinoin treatment at
some point during the follow-up. This estimate is similar to what has been
published previously.8’1° Most were dispensed isotretinoin within the first two
years after the end of their first treatment. In contrast to the first analysis,
subjects were more Iikely to receive a second isotretinoin treatment in the
years after the implementation of the PPP and other guidelines. The PPP
and the other guidelines were meant to increase physician awareness of
isotretinoin’s potential side effects so as to restrict its use to patients who
most need it. It appears that such guidelines had no impact on prescribing
patterns. This could be due to the increasing prescribiflg of isotretinoin to
subjects with mild or moderate acne,29 or the fact that it is increasingly being
used as a first une agent.21’30’31
There are a number ot differences between the present study and the ones
published previously. First, the present study is the Iargest to date with a
sample size exceeding seventeen thousand first-time isotretinoin users.
C Previous studies had smaller sample sizes.45 Second, the majority
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previous studies recruited patients from specialized settings such as
dermatology clinics and hospitals.4’5’79’12’1315 Although the motivation for
using patients from these settings was to facilitate recruitment, it does limit
the generalizability of their resuits. Although the subjects included in the
present study came from restricted socio-economic backgrounds, they were
treated by physicians who also treat patients from higher socio-economic
backgrounds. Thus ail residents of the province of Quebec have access to
the same medical care regardless of their socio-economic status. As a result,
it is unhikely that subjects trom Iower socio-economic backgrounds would be
treated differently than subjects trom higher socio-economic backgrounds
given the fact that both groups were reimbursed for their medications. Thus,
we believe our cohort is representative of the acne population. Third, we
were able to follow subjects for up to 20 years since the end of their first
isotretinoin treatment. This long-term follow-up is essential for an accurate
detection of relapses. Fourth, administrative databases contain complete
information on healthcare services received and medications dispensed.
Thus, we were able to control for important variables that are seldom
collected in field studies. In addition, we considered predictors of receiving
an anti-acne medication in four different time periods, from 12 months prior
to the first isotretinoin treatment to the index date.
Despite the strengths mentioned above, the present study does have some
limitations inherent in the use of administrative databases. Administrative
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Ç databases provide information oniy on those subjects who fiiled their
prescriptions. Therefore, the number of subjects who experienced a relapse
and did flot consult a physician is unknown. It is aiso unknown the number of
subjects who were prescribed an aflti-acne medication but did flot fui them at
the pharmacy, or the number of subjects who used over-the-counter (OTC)
products to treat their acne. Although these are possibilities, they are unhikely
for the following two reasofls. First, it is reasonable to assume that subjects
who were previously treated for their acne would seek further treatment had
they experienced an acne relapse. Not consulting a physician for an acne
relapse may be indicative that the relapse was not severe enough to warrant
further intervention. Second, ail subjects included in this study were covered
for their medications by the RAMQ drug plan. Thus, the cost of the
medications is not likely to have been a major factor for not getting anti-acne
medications, had they been prescribed. The use of OTC products is also
likely to have been minimal. Because of their insurance status, subjects were
more likely to get a prescription for products also found OTC (such as
benzoyi peroxide).
Another limitation was that acne relapse was defined as receiving either a
topical or systemic anti-acne medication. The inclusion of topical agents in
this definition could have included subjects with mild acne who would flot
have been defined as relapsers in a clinical study. However, topical agents
accounted for less than 20% of ail anti-acne medications prescribed.
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Furthermore, the majority 0f these agents are also prescribed for moderate
acne (e.g. tretinoin, benzoyl peroxide). With regards to anti-acne medications
flot reimbursed by the RAMQ drug plan (e.g. adapalene), the exclusion of
these agents is flot likely to have had an impact on the acne relapse rate.
Although such agents may be covered by some private insurance programs,
physicians will typically prescribe medications they know are covered by their
patient’s insurance program. Thus, it is likely that physicians would replace
an anti-acne medication flot covered by a given insurance program by one
that is. Other limitations 0f this study were that we were not able to directly
adjust for acne severity, or the site 0f acne. This is because the lCD-9
classification does not specify the severity or the location of the acne.
However, we did use anti-acne medication dispensing information in time
periods before the index date, cumulative dose and length of the first
isotretinoin treatment as proxies for acne severity.
Isotretinoin is an effective medication associated with long-term remissions
in patients with acne. However, it remains that 41% of patients may
experience an acne relapse necessitating further treatment with anti-acne
medications. Several patient characteristics have been found to be
associated with acne relapses. These data could be 0f prognostic value to
clinicians who treat patients with acne.
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Q Table J. Characteristïcs of cases and controls for the antî-acne medïcationanalysis
Characteristics Cases (n=7,JOO) Controls (n=35,500)
Age (mean, SD) 25.2 (8.1) 25.5 (7.9)
Males (n, ¾) 3770 (53.1%) 17,833 (50.2%)
Welfare recipients (n, %) 3993 (56.2%) 16,982 (52.2%)
Urban dwellers (n, ¾) 5732 (80.7%) 26,678 (78.2%)
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Table 2. Type of antï-acne medicatïons dïspensed (n=7100)
n (¾)
Systemïc retinoids
Isotretinoin
Systemic antibïotics
Minocycline
Tetracycline
Doxycycline
Erythromycin
Cli ndamyci n
Azithromycin
Anti-microbial and hormonal agents
Benzoyl peroxide
Acne-specific oral contraceptives
Topical retïnoïds
Tretinoin
Tazarotene
Topïcal antibiotics
Eryth ro myci n
Cli ndamyci n
Treatment combinations
Systemic antibiotic plus topical antibiotic
Systemic antibiotic plus topical retinoid or benzoyl peroxide
Two topical agents
Two systemic antibiotics
Acne-specific oral contraceptives plus system ic antibiotic
4011(56.5%)
678 (9.6%)
264 (3.7%)
185 (2.6%)
136 (1.9%)
94(1.3%)
90 (1.3%)
406 (5.7%)
176 (2.5%)
468 (6.6%)
0 (0.0%)
366 (5.2%)
1(0.01%)
90 (1 .3%)
78 (1.1%)
46 (0.6%)
6(0.1%)
5(0.1%)
I 174
Time periods
Jan uary 1, 1984
— Septem ber 30, 1988
October 1, 1988 — Decem ber 31, 1994
Jan uary 1, 1995
— Decem ber 31, 1999
Jan uary 1, 2000 — June 30, 2003
1.00 (Reference)
1.44 (1.30, 1.58)
1.22 (1.11, 1.33)
1.14 (1.05, 1.24)
1.40
1.14
1.09
1.01
(1.26,
(1.07,
(1.01,
(0.94,
1.54)
1.20)
1.16)
1.09)
1 .00 (Reference)
1.07 (0.97, 1.19)
1.02 (0.92, 1.13)
1.04 (0.94, 1.16)
Between the end of the first treatment and index date
Number of different types of medications
Visits to the physician
None
Visits to the emergency department
None
Hospitalizations
None
1.09 (1.09, 1.10)
1.00 (Reference)
4.00 (3.71, 4.32)
1 .00 (Reterence)
1.13 (1.06, 1.22)
1.00 (Reference)
1.46(1.33,1.61)
1.08 (1.07, 1.09)
1.00 (Reference)
3.83 (3.53, 4.15)
1 .00 (Reference)
0.80 (0.74, 0.87)
1 .00 (Reference)
0.86 (0.76, 0.96)
During the first isotretinoin treatment
Number of different types of medications
At least one anti-acne medication
Visits to the physician
None
Visits to the emergency department
None
Hospital izations
None
Age ot treating physician, years
Treated by male physician
Treated by dermatologist
2 isotretinoin prescribers
Cumulative dose
<2450 mg
2450 — 4840 mg
4840
— 7584 mg
7584mg
Treatment du ration 121 davs
1 .04 (1 .02, 1 .05)
1.82 (1.66, 1 .99)
1 .00 (Reterence)
0.93 (0.86, 1.01)
1.00 (Reference)
0.96 (0.89, 1.05)
1.00 (Reference)
1.09 (0.93, 1.26)
1.00(1.00,1.01)
1.03 (0.97, 1.10)
1.03 (0.98, 1.08)
1.00 (0.90, 1.10)
1.00 (Reference)
0.76 (0.71, 0.81)
0.62 (0.58, 0.67)
0.52 (0.49, 0.56)
0.65 (0.61, 0.68)
0.98 (0.96, 0.99)
1.71 (1.55, 1.89)
1 .00 (Reference)
0.89 (0.82, 0.97)
1.00 (Reference)
1.00 (0.92, 1.10)
1 .00 (Reference)
0.91 (0.77, 1.07)
0.99 (0.99, 1 .00)
1.03 (0.96, 1.10)
1.09 (1.03, 1.16)
1.09 (0.98, 1.22)
1 .00 (Reference)
0.82 (0.76, 0.88)
0.75 (0.68, 0.83)
0.63 (0.57, 0.70)
0.83 (0.76, 0.89)
TbIe 3. Predictors of receiving an anti-acne treatment after being initially treated wïth isotretinoin
At index date
<16 years of age
Male gender
Urban dweller
Welfare recipient
Crude Rate Ratio
(95% Cl)
Adjusted Rate Ratio’
(95% Cl)
1.31 (1.19, 1.44)
0.89 (0.85, 0.94)
1.16(1.09,1.24)
1.15(1.09,1.21)
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T”Ie 3. Predïctors of receÏvÏng an antï-acne treatment after being initïally treated with isotretinoin
...ntinuation)
12 months prior to the fïrst isotretinoin treatment
Number of different types of medications 1.00 (1.00, 1.00) 1.00 (1.00, 7.00)
At least one anti-acne medication 1.34 (1.27, 1.41) 1 .36 (1 .29, 1.44)
Visits to the physician
None 1.00 (Reference) 1.00 (Reference)
1.27 (1.13, 1.44) 0.86 (0.76, 0.99)
Visits to the emergency department
None 1.00 (Reference) 1 .00 (Reference)
1.05 (0.99, 1.11) 0.98(0.92,1.05)
Hospitalizations
None 1.00 (Reference) 1 .00 (Reference)
1.11 (1.03,1.20) 0.94(0.86,1.02)
Abbreviation: SD, standard deviation.
tAdjusted for the covariates in the table.
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Table 4. Characterïstics of cases and controls for the isotretinoin analysis
Characteristics Cases (n=4443) Controls (n=22,215)
Age, years (mean, SD)
Males (n, ¾)
Adherents (n, %)
Urban dwellers (n, %)
24.8 (7.9)
2235 (50.3%)
2518 (56.7%)
3534 (79.5%)
25.3 (7.9)
10,792 (48.6%)
12,287 (55.3%)
17,383 (78.9%)
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Time perïods
January 1, 1984— September 30, 1988
October 1, 1988 — Decem ber 31, 1994
Jan uary 1, 1995 — Decem ber 31, 1999
Jan uary 1, 2000 — June 30, 2003
1.00 (Reference)
1.16 (1.03, 1.31)
1.10 (0.99, 1.22)
1.06 (0.96, 1.17)
1 .00 (Reference)
1.10(0.97,1.24)
1.22 (1.09, 1.37)
1.29 (1.15, 1.46)
Between the end of the first treatment and index date
Num ber of different types of medications
At Ieast one anti-acne medication
Visits to the physician
None
Visits to the emergency department
None
H ospital izations
None
1.09 (1.08, 1.09)
2.06 (1.87, 2.27)
1 .00 (Reference)
2.75 (2.52, 3.01)
1.00 (Reference)
1.05 (0.96, 1.15)
1.00 (Reference)
1.13 (1.00, 1.29)
1.11 (1.10, 1.12)
1.51 (1.36, 1.68)
1 .00 (Reference)
2.71 (2.46, 2.98)
1 .00 (Reference)
0.78 (0.70, 0.86)
1 .00 (Reference)
0.76 (0.65, 0.88)
During the fïrst isotretinoin treatment
Number of different types of medications
At Ieast one anti-acne medication
Visits to the physician
None
Visits to the emergency department
None
Hospital izations
None
Age of treating physician, years
Treated by male physician
Treated by dermatologist
2 isotretinoin prescribers
Cumulative dose
<2450 mg
2450 — 4840 mg
4840 — 7584 mg
7584 mg
Treatment duration 121 days
1.00 (0.98, 1.01)
1.08 (0.95, 1.22)
1.00 (Reference)
0.74 (0.67, 0.81)
1 .00 (Reference)
0.92 (0.83, 1.02)
1 .00 (Reference)
0.99 (0.82, 1.21)
1.01 (1.00, 1.01)
1.15(1.06,1.24)
1.00 (0.93, 1.06)
0.88 (0.77, 1.00)
1.00 (Reference)
0.71 (0.65, 0.77)
0.54 (0.50, 0.59)
0.41 (0.37, 0.45)
0.52 (0.48, 0.55)
0.95 (0.93, 0.98)
0.94 (0.82, 1.08)
1 .00 (Reference)
0.81 (0.73, 0.89)
1 .00 (Reference)
1.03 (0.91, 1.15)
1 .00 (Reference)
1.04 (0.84, 1.29)
1.00 (1.00, 1.00)
1.20 (1.10, 1.31)
1.08 (1.00, 1.16)
1.09 (0.94, 1.26)
1.00 (Reference)
0.85 (0.77, 0.93)
0.80 (0.71, 0.90)
0.62 (0.54, 0.71)
0.69 (0.62, 0.76)
Ie 5. Predictors of receiving a second ïsotretinoin treatment
Crude Rate Ratio Adjusted Rate Ratiot
(95% Cl) (95% CI)
At index date
<16 years of age 1.30 (1.16, 1.46) 1.26 (1.12, 1.43)
Male gender 1.07 (1.01, 1.14) 1.32 (1.22, 1.41)
Urban dweller 1.04 (0.96, 1.12) 0.94 (0.86, 1.02)
Welfare recipient 1.14 (1.06, 1.21) 1.08 (0.99, 1.17)
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TbIe 5. Predictors of receiving a second isotretinoin treatment (continuation)
months prior to the first isotretïnoin treatment
Number of different types cf medications 1 .00 (1.00, 1.00) 0.99 (0.99, 0.99)
At leastone anti-acne medication 1.13 (1.06, 1.21) 1.15 (1.07, 1.24)
Visits to the physician
None 1.00 (Reference) 1.00 (Reference)
1.14(0.99,1.32) 0.90(0.77,1.06)
Visits te the emergency depariment
None 1.00 (Reference) 1.00 (Reference)
1.05 (0.98, 1.13) 0.98 (0.90, 1.06)
Hospitalizations
None 1.00 (Reference) 1.00 (Reference)
1.02 (0.92, 1.12) 0.95 (0.85, 1.06)
Abbreviation: SD, standard deviation.
tAdjusted for the covariates in the table.
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53.1 ABSTRACT
Objective: To determine whether isotretinoin increases the risk cf
depression in patients with acne vulgaris.
Methods: A case-crossover study was performed among subjects who
received 1 isotretinoin prescription between 1984 and 2003. Data were
obtained from the Régie de l’Assurance Maladie du Québec (RAMQ) and
Quebec’s hospital discharge (Med-Écho) administrative databases. Cases
were defined as those with a first diagnosis or hospitalization for depression
(lCD-9 codes: 296.2, 298.0, 300.4, 309.0, 309.1, and 317.0) during the study
period (1984-2003), and who filled a prescription for an antidepressant in the
30 days following their diagnosis or hospitalization. The index date was the
calendar date cf the diagnosis or hospitalization for depression. Cases were
covered by the RAMQ drug plan and had 1 acne diagnosis in the 12
months prior to the index date. Those who received an antidepressant in 12
months prior to the index date were excluded. Exposure to isotretinoin in a 5-
month risk period immediately prior to the index date was compared to a 5-
month control period. Relative risks (RR) along with 95% confidence
intervals (Cl) were estimated using conditional logistic regression.
Resuits: 0f the 30,496 subjects in the initial cohort, 126 (0.4%) cases met
inclusion criteria. The crude RR was 2.00 (95% Cl: 1.03, 3.89). After
I 183
adjusting for potential time-dependent confounders, the RR was 2.68
(95%Cl: 1.10, 6.48).
Conclusion: This s the first controlled study to find a statistically significant
association between isotretinoin and depression. Because depression could
have serious consequences, close monitoring of isotretinoin users s
indicated.
.
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Isotretinoin is an effective medication in the treatment 0f severe recalcitrant
nodular acne. Therefore, the expected resuit of a successful treatment would
be improvements in quality of lite, and decreases in rates of anxiety and
depression.5 However over the past two decades, case reports have
suggested a controversial association between isotretinoin and depression.6
10
Observational studies investigating th is association have prod uced
contradictory resuits. Whereas in some studies no association was found
between isotretinoin and depression,11’12 one study tound that it increases
the use of mental health services.13 Against this backdrop, the US Food and
Drug Administration has received reports of 394 cases ot depression, and 37
suicides in patients exposed to isotretinoin between 1982 and 2000.1415 In
the US Adverse Event Reporting System (AERS), isotretinoin is the fifth
most common medication Iinked to depression, and the tenth most common
Iinked to suicide reports.’4 Using data mining techniques, Wysowski et al.14
estimated that 6 suicide reports would be expected to be reported in the
AERS by chance compared with the 37 actually reported. In Canada, out of
the 222 isotretinoin adverse events archived in the Health Canada adverse
drug reaction database between 1983 and 2003, 56 (25%) were
psychiatric.16
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These reports have prompted several governments to modify their
isotretinoin package labeling ta include depression as a possible side effect
cf the drug. These modifications were first introduced in France in March
1997,17 the US in February 1998 and Canada in May 2000.15 In 2001, a Dear
Health Care Professional Letter was sent to Canadian physicians advising
them to closely monitor patients presenting with depression or depressive
symptoms during the course cf an isotretinoin treatment.18
Given the contradictory resuits in the current literature and the repeated
signais reported in adverse drug reaction databases, the association
between isotretinoin and depression warrants furiher investigation.
Therefore, the objective of the present study was to determine whether there
is an association between isotretinoin and depression in patients with acne
vulgaris.
5.3.3 METHODS
5.3.3.1 DATA SOURCES
Data were obtained from the Régie de l’Assurance Maladie du Québec
(RAMQ) and Quebec’s hospital discharge (Med-Écho) administrative
databases. Ail Quebec residents are covered by the RAMO for medical
services. Prior ta January 1, 1997, the RAMQ drug plan covered those who
were 65 years and older and welfare recipients and their children. After
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Q January 1, 1997, the RAMQ drug plan was changed to also inciude workers
and their spouses/chiidren who do not have access to a private insurance
program. The RAMQ drug plan covers approximately 50% of Quebec
residents.19
The medical and pharmaceutical databases of the RAMQ were linked by a
unique patient identification number. The medical daims database includes
information on the date and type of services received, and diagnoses are
classified according to the International Classification of Diseases, Ninth
revision (ICD-9).2° The pharmaceutical daims database contains information
on the date medications were dispensed, formulations, doses, duration of
prescriptions, and quantities dispensed. Medications prescribed during
hospitalizations are not inciuded in the database. Both the medical and
pharmaceutical daims databases have been validated and shown to be
accurate for certain diagnoses.21’22
The unique patient identification number was also used to link the RAMQ to
the Med-Écho administrative databases. Med-Écho contains hospitalization
data on ail Quebec residents. This data includes patient demographic
information, physician characteristics, admission diagnostic, length of stay,
as well as ail services received during the hospitalization. Medical diagnoses
recorded in Med-Écho have been shown to be valid and precise.23
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Ç The study protocol was approved by the CHU Sainte-Justine Ethics
Committee and the Commission d’accès à l’information du Québec.
5.3.3.2 STUDY DESIGN
We employed a case-crossover design first introduced by Maclure in 1991 24
In the case-crossover design, cases serve as their own controls by
assessing exposure at different time intervals. The time intervais in which
exposure is assessed are the risk and control periods. The risk period is a
time interval immediately prior to the event. The control periods are time
intervais that are prior and equal in length to the risk period, and provide an
expected baseline frequency of exposure for each study subject in the
absence of the outcome. Since cases serve as their own controls, time
independent confounders (known and unknown) are automatically adjusted
by design. Confounders that change over time must be adjusted for in the
analyses.
5.3.3.3 CASE DEFINITION
Cases were selected from a cohort of subjects who received at least one
isotretinoin prescription between January 1, 1984 and December 31, 2003.
Incident cases of depression were defined according to the following
algorithm. We identified ail subjects with a f irst diagnosis or hospitalization
for depression (lCD-9 codes: 296.2, major depressive disorder, single
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Ç episode; 298.0, depressive type psychosis, 300.4, neurotic depression;
309.0, brief depressive reaction; 309.1 prolonged depressive reaction; 311,
depressive disorder, flot elsewhere classified) during the study period (1984-
2003). In addition to having been diagnosed or hospitalized for depression,
cases were required to have filled an antidepressant prescription (American
Hospital Formulary System code: 28:16.04) in the 30 days following their
diagnosis or hospitalization. The index date was detined as the calendar
date of the diagnosis or hospitalization for depression.
Furthermore, cases had to be covered by the RAMQ drug plan for at least 12
months prior to the index date. This was deemed necessary to ensure that
drug exposure information was available during the time periods of interest.
In addition, cases had to have at Ieast one diagnosis of acne vulgaris (lCD-9
code: 706.1) at any time in the 12 months prior to the index date. This
criterion ensured that cases had acne and thus had an exposure opportunity
to receiving isotretinoin. Finally, cases were excluded if they had received an
antidepressant prescription in the 12 months prior to the index date. Since
the index date was defined as the subject’s first diagnosis or hospitalization
for depression in their entire recorded medical history, none had any
diagnoses or hospitalizations for depression at any time prior to the index
date. That time period ranged from a minimum of 12 months up to 20 years.
C
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0 5.3.3.4 TIME WINDOWS
The risk period was hypothesized to be a total of 5 months based on data
found in the literature.6’2526 A five-month control window was separated from
the risk window by a two-month washout period (Figure 1). A two-month
washout period was chosen because product guidelines suggest initiating a
second course of isotretinoin in those who have flot responded to the
treatment only eight weeks after the completion of a first course.27 This is
because improvements continue to occur during that time period despite
having terminated the treatment.
5.3.3.5 POTENTIAL CON FOUNDERS
By design, the case-crossover method adjusts for time-independent
confounders, such as socioeconomic status or gender. However, the
following potential time-dependent confounders were recorded in each time
wifldow and adjusted for in the models: dermatologic visits, non-dermatologic
visits, 1 hospitalization, 1 emergency depariment visit, and comorbidity.
Dermatologic visits were defined as consulting a dermatologist and/or being
diagnosed with acne vulgaris (lCD-9 code: 706.1). Comorbidity was
assessed using the total number of different types of medications prescribed,
other than isotretinoin. The number of different types 0f medications has
been shown to be a very good predictor of healthcare utilization, similar to
other comorbidity measures.28
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5.3.3.6 STATISTICAL ANALYSES
Descriptive statistics were used to describe the characteristics cf the cases.
Relative risks (RR) along with 95% confidence intervals (Cl) were estimated
using conditional Iogistic regression with the individual case as the stratifying
variable. In a first analysis, exposure to isotretinoin was entered as a
dichotomous variable in the models (exposed at least once during each
specific time window, yes or no). In a second analysis, we determined
whether there was a dose-response 0f isotretinoin on the incidence 0f
depression. The cumulative dose in milligrams of isotretinoin dispensed was
calculated in each time window and entered as quartiles in the models.
Crude and adjusted models were calculated for ail situations. Analyses were
two-sided and p 0.05 was considered significant. SAS version 8.2 (SAS
Institute, Cary, NO) was used to conduct the analyses.
53.4 RESULTS
0f the 30,496 subjects in the initial cohort, 126 (0.4%) cases met the
inclusion criteria. This corresponded to 126 risk periods matched to 126
control periods. The mean age of cases was 28.1 (SD: 9.0) years, over 60%
were males, and most were urban dweilers (Table 1).
Most cases were diagnosed with neurotic depression (65%), tollowed by
brief depressive reaction (15%), depressive disorder (9%), major depressive
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C disorder (6%), depressive type psychosis (3%), and prolonged depressive
reaction (2%). The most trequently prescribed antidepressants were
selective-serotonin reuptake inhibitors (48%), tricyclics (37%), New
Antidepressants (13%) and monoamine oxidase inhibitors (2%). Depression
was diagnosed by psychiatrists (49%), general practitioners (47%) and other
physicians (4%) (data flot shown).
5.3.4.1 ISOTRETINOIN AND DEPRESSION
The number cf cases exposed to isotretinoin in the 5-month risk and control
periods were 41 (32.5%) and 28 (22.2%), respectively. Twenty-six cases
were exposed in the risk and notthe contrai period, versus 13 exposed in the
control and not the risk period (crude RR = 26/13 = 2.0) (Table 2). The
adjusted RR of isotretinoin associated with depression was 2.68 (95% CI:
1.10, 6.48) (Table 3).
To assess whether our resuits could be explained by surveillance bias due ta
increased physician awareness cf isotretinoin’s possible psychiatric effects,
we stratified the cases according to the calendar date cf Canadian label
change addressing isotretinoin’s possible psychiatric risks. There were no
differences in the RRs of cases diagnosed or hospitalized for depression
after the label change (affer May 2000) than cases diagnosed or hospitalized
for depression before the label change (before May 2000) (data not shown).
1192
Ç 5.3.4.2 CUMULATIVE DOSE
Although the effect sizes were large, none of the cumulative doses of
isotretinoin in the adjusted model reached statistical significance (Table 4).
5.3.5 DISCUSSION
To our knowledge, the present controlled study is the first to detect an
association between isotretinoin and depression in patients with acne
vulgaris. The risk of depression in subjects with no previous history of the
condition increases close to 3-fold after being exposed to isotretinoin.
Because depression could have serious consequences, our resuits advocate
for close monitoring of patients undergoing isotretinoin therapy. This may be
done by administering psychiatric assessments prior and during therapy.
To date, Jick et al.11 conducted the Iargest population-based study
investigating the association between isotretinoin and depression, psychotic
symptoms and suicide. They used data collected between 1983 and 1997 in
the Saskatchewan database and the United Kingdom General Practice
Research Database. In their primary analysis, the authors compared a
cohort of patients with acne treated with isotretinoin to another cohort treated
with systemic antibiotics. No association was found between isotretinoin and
depression, psychotic symptoms or suicide. Unlike the study conducted by
Jick et al.,11 it was not possible to determine whether there is an association
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between isotretinoin and suicide, given that we had access only to inpatient
and outpatient medical visits. However, with regards to depression, there are
several reasons why our resuits differ from that study. First, we used a strict
case definition where cases were required to have both a diagnosis or
hospitalization for depression and an antidepressant. This leU to the
inclusion of 126 cases. Despite this small sample size, the associations
obtained were large enough to be statistically significant. In contrast, Jick et
al.11 identified cases of depression using diagnostic codes alone, and thus it
is possible that some cases were misclassified as non-cases which could
have biased the RRs towards the nulI. Second, we identified incident cases
of depression. The cases identified in the present study had no diagnoses or
hospitalizations for depression for a minimum of 12 months up to 20 years
prior to the index date. In contrast, Jick et aL11 adjusted for previous
psychiatric history using data recorded 6 months up to 5 years before the
first isotretinoin prescription. Therefore it is Iikely that some residual
confounding occurred, which would have once again biased the RRs
towards the nuil. Finally, one of the strengths of the case-crossover design is
that cases serve as their own controls. As such, known and unknown time
independent confounders are automatically adjusted by design.
In daims data, the length of the risk and control periods necessitates
knowledge of the duration of exposure required to alter the risk for an
outcome, to become noticed by the physician, and then be recorded in the
194
Ç administrative database.29 Depression has been reported as eariy as 1 day
and up to 4 months after initiating an isotretinoin treatment.6’25’26’3°
Therefore, the maximum induction time was hypothesized to be 4 months.
Furthermore, patients undergoing isotretinoin treatment are typically seen by
their treating physicians at 1-month intervals. As such, if depressive
symptoms do appear, physicians would be expected to diagnose them at
one of the follow-up visits. For these reasons, the risk period was set to be 5
months in length. This time window also concords with the recommended
duration of an isotretinoin treatment.31’32
5.3.5.1 DOSE-RESPONSE RELATIONSH1P
Although the effect measures relating cumulative dose of isotretinoin to
depression were large, none reached statisticai significance. This is Iikeiy
due to the small number of cases in each cumulative dose stratum. Studies
with greater sample sizes would be needed to determine the exact dose
response relationship between isotretinoin and depression.
Acne has been associated with depression, suicidai ideation, and suicide in
patients.3334 Acne is thus an important confounder of the isotretinoin
depression association. The presence of acne was intrinsically controiled by
requiring cases to have at least one acne diagnosis in the 12 months prior to
the index date. Due to the retrospective nature of the study and Iack of
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clinical data, it was flot possible to directiy adjust for acne severity. However,
the possibility of confounding by acne severity is unhikely for the following
four reasons. First, ail cases had at least one acne diagnosis in the 12
months prior to their index date. This indicates that cases received medical
attention for their acne, and were thus iikely to have received an anti-acne
medication. Receiving an anti-acne treatment should to the very ieast
stabilize the severity of acfle, and it is therefore unlikely that it may have
worsened during the study period. Second, although there is a correlation
between acne and depression, previous studies found no correlation
between acne severity and depression,35’36 thus puffing into question
whether severity is a true confounder. Third, isotretinoin is a highly effective
medication whose utilization is associated with drastic reductions in acne
lesions. In theory, the clearing of acne lesions shouid be associated with
improvements in depressive symptoms and quaiity of lite. Fourth, there is
evidence that isotretinoin is being prescribed to patients with mild or
moderate acne,37 or as a first une treatment.27’38 Thus, flot ail patients
receiving isotretinoin have severe nodular acne. We nonetheiess affempted
to control for acne severity by adjusting our modeis for dermatologic visits in
the risk and control periods, aithough such analyses wouid have been
subject to some residual confounding.
The present study has limitations inherent in the use of administrative
databases. Variables such as smoking, aicohol consumption, and iliicit drug
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Ç use are flot available in administrative databases. Although these variables
are likely to be associated with depression, it is unclear how they would be
related to the use of isotretinoin. Furthermore, these variables are unlikely to
have changed over a 12-month period. Given their time-independent nature,
they would be automatically adjusted by design in a case-crossover study.
Administrative databases report only on medications dispensed, and
therefore it is unknown whether medications are actually taken by patients.
However, given that isotretinoin is typically prescribed for 30-day intervals,
renewals between successive prescriptions is indicative of patient
adherence.38 One major advantage of administrative databases is that they
are not prone to recail bias. As such, they provide accurate information on
the number, types and dosages of medications dispensed over a specific
time period. Coding errors may be present in administrative databases. If
that were the case, non-differential misclassification of the outcome would
resuit biasing the RRs towards the nuli. If coding errors did occur in our data,
then the estimates obtained would actually be underestimates of the true
RR.
There are several studies that have pointed to a possible biological
association between isotretinoin and depression. Isotretinoin and vitamin A
share similar chemical structures, as such many side effects of isotretinoin
are similar to Vitamin A when taken in large doses.39 Hypervitaminosis A has
C been shown to induce irritability and depressive symptoms.4042 One study
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found that exposure to retinoic acid resuits in hippocampal celi loss in
mice.43 In humans, hippocampal volume has been shown to be inversely
related to depression7 indirectly supporting the hypothesis that isotretinoin
may cause celi loss in this region of the brain. Another study found that daily
intake of 1 mg/kg of isotretinoin for 6 weeks in young male mice (similar
doses used in humans) was associated with depression-like behavior.45
Recently, Bremner et al.46 assessed brain function in patients with acne
treated with isotretinoin and antibiotics. They found that isotretinoin
decreased metabolism in the orbitofrontal cortex, a region of the brain known
to be involved in depression. This effect was not observed in patients treated
with antibiotics. More research is needed to elucidate the exact mechanisms
through which isotretinoin may induce depression.
Depression is Iikely to be a rare side effect of isotretinoin therapy. The
present study supports close monitoring of patients during the treatment for
possible signs of such symptoms. Current guidelines should possibly be
modified to include psychiatric assessments of patients prior and during
isotretinoin therapy.
o
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Table 1. Characteristïcs of cases (n=1 26)
Characteristics
At the index date
Age, years, mean (SD) 28.1 (9.0)
Males, n (¾) 47 (37.3%)
Welfare recipients, n (¾) 88 (70.0%)
Urban dwellers, n (¾) 106 (84.1%)
In the 72 months prior to the index date
Dermatologic visits, mean (SD) 1.1 (1.3)
Non-dermatologic visits, mean (SD) 6.2 (7.1)
At Ieast one visit to the emergency department, n (¾) 42 (33.3%)
At Ieast one hospitalization, n (¾) 24(19.1%)
Number of different medications other than isotretinoin, mean (SD) 5.5 (4.0)
Abbreviations: SD, standard deviation.
Defined as consulting a dermatologist and/or being diagnosed with acne during a visit to
the MD (lCD-9 code: 706.1).
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Exposed
Risk period Notexposed
15 26
. 13 72
Crude RR = 26/13 = 2.0
C Table 2. Two-by-two table of cases exposed in the risk and control periods
Control perïod
Exposed Not exposed
O
o
P
I2
06
T
ab
le
3.
R
is
k
o
f
de
pr
es
sï
on
a
s
s
o
c
ia
te
d
w
ith
e
x
po
su
re
to
is
ot
re
tin
oï
n
u
si
ng
5-
m
on
th
ri
sk
a
n
d
c
o
n
tr
ol
pe
ri
od
s
C
ru
de
re
la
tiv
e
ri
sk
A
dj
us
ted
re
la
tiv
e
ri
sk
t
(9
5%
c
o
n
fi
de
nc
e
in
te
rv
al
)
(9
5%
c
o
n
fi
de
nc
e
in
te
rv
al
)
E
xp
os
ur
e
to
is
ot
re
tin
oi
n
2.
00
(1
.03
, 3
.8
9)
2.
68
(1
.10
,6
.4
8)
N
on
-d
er
m
at
ol
og
ic
al
v
is
its
1.
21
(1
.10
,1
.3
4)
1.
13
(1
.01
, 1
.2
5)
D
er
m
at
ol
og
ic
v
is
its
1.
09
(0
.90
,1
.3
0)
0.
81
(0
.62
,1
.0
5)
A
tl
ea
st
on
e
ho
sp
ita
liz
at
io
n
2.
44
(1
.13
,5
.3
1)
1.
73
(0
.65
,4
.5
8)
At
le
as
to
n
e
e
m
e
rg
en
cy
de
pa
rim
en
tv
isi
t
1.
81
(0
.98
,3
.3
4)
0.
94
(0
.43
,2
.0
4)
N
um
be
r o
fd
iff
er
en
tm
e
di
ca
tio
ns
o
th
er
th
an
is
ot
re
tin
oi
n
1 .
40
(1
.
20
,
1.
63
)
1.
34
(1
.
1
1,
1.
61
)
tA
dju
ste
d f
or
th
e
c
o
v
a
ri
at
es
in
th
e
ta
bl
e.
D
ef
in
ed
a
s
c
o
n
su
lti
ng
a
de
rm
at
ol
og
is
t a
n
d/
or
be
in
g
di
ag
no
se
d
w
ith
a
c
n
e
du
rin
g
a
v
isi
t t
o
th
e
M
D
(lC
D-
9
c
o
de
:
70
6.
1)
.
o
o
F
a
12
07
T
ab
le
4.
R
is
k
o
f
de
pr
es
si
on
a
s
s
o
c
ia
te
d
w
ith
is
ot
re
tin
oï
n
c
u
m
u
la
tiv
e
do
se
u
si
ng
5-
m
on
th
ri
sk
a
n
d
c
o
n
tr
ol
pe
ri
od
s
C
ru
de
re
la
tiv
e
ri
sk
A
dj
us
ted
re
la
tiv
e
r
is
k
(9
5%
c
o
n
fi
de
nc
e
in
te
rv
al
)
(9
5%
c
o
n
fi
de
nc
e
in
te
rv
al
)
C
um
ul
at
iv
e
do
se
of
is
ot
re
tin
oi
n
O
m
g
R
ef
er
en
ce
(1
.00
)
R
ef
er
en
ce
(1
.00
)
30
0—
12
00
m
g
0.
52
(0
.05
,5
.4
2)
0.
79
(0
.05
,1
3.
86
)
12
00
—
24
00
3.
09
(1
.04
,9
.1
5)
3.
24
(0
.89
,1
1.
79
)
24
00
—
48
00
m
g
2.
55
(0
.81
,8
.0
1)
3.
13
(0
.84
,1
1.
64
)
48
00
m
g
1.
46
(0
.53
,4
.0
0)
2.
14
(0
.62
,7
.4
3)
N
on
-d
er
m
at
ol
og
ic
al
v
is
its
1.
21
(1
.10
,1
.3
4)
1.
13
(1
.0
1,
1.
26
)
D
er
m
at
ol
og
ic
v
is
its
1.
09
(0
.90
,1
.3
0)
0.
82
(0
.62
,1
.0
7)
At
le
as
to
n
e
ho
sp
ita
liz
at
io
n
2.
44
(1
.13
,5
.3
1)
1.
69
(0
.63
,4
.5
3)
At
le
as
to
n
e
e
m
e
rg
en
cy
de
pa
rtm
en
tv
isi
t
1.
81
(0
.98
,3
.3
4)
0.
92
(0
.42
,2
.0
2)
N
um
be
r
of
di
ff
er
en
tm
e
di
ca
tio
ns
o
th
er
th
an
is
ot
re
tin
oi
n
1.
40
(1
.20
,1
.6
3)
1.
33
(1
.10
,1
.6
0)
tA
dju
ste
d
fo
rt
he
c
o
v
a
ri
at
es
in
th
e
ta
bl
e.
D
ef
in
ed
a
s
c
o
n
su
lti
ng
a
de
rm
at
ol
og
is
ta
n
d/
or
be
in
g
di
ag
no
se
d
w
ith
a
c
n
e
du
rin
g
a
v
isi
tt
o
th
e
M
D
(lC
D-
9
c
o
de
:
70
6.
1)
.
G!
I
CQQ.
0 h
L()
o
L.
Q.
o
L.
4-
o
_______
_LC)Q I
Ci)4-
Q
o
P e 209
0 5.4 ISOTRETIN0IN AND THE RISK 0F DEPRESSION: A
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C
:5.4.1 ABSTRACT
isotretinoin is the most effective treatment for severe nodular acne. Over the
years however, it has been associated with depression, suicidai ideation,
and suicide. Using a iarge cohort of subjects who received 1 isotretinoin
prescription from 1984 to 2003 in the province of Quebec, the authors
identified 126 incident cases of depression on which they conducted a case
crossover study. There was 2- to 3-foid increase in the risk of depression in
subjects exposed ta isotretinoin. This was the first study ta find a statisticaily
significant association between isotretinoin and depression. However, this
association may have been confounded by exposure time-trends. The case
time-controi design is an extension of the case-crossover which was
deveioped to correct for such exposure time-trends. Thus, the objective of
the present study was ta determine whether there was an exposure time
trend, and adjust for it using the case-time-control design. This required
seiecting a contrai group with no previous history of depression. A total of
1149 contrais were matched ta cases on age, sex, and caiendar year. The
adjusted odds ratio of depression reiated ta isatretinoin exposure in the
case-time-contrai design was 1.56 (95% confidence interval: 0.66, 3.73).
Aithough it did flot reach statisticai significance, the relativeiy large odds ratio
is suggestive 0f an association. Severai assumptions and conditions inherent
ta the use of the case-time-control design are emphasized.
C
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Isotretinoin is the most effective treatment for severe nodular acne, capable
of inducing long-term remissions (1-3). However, it is a well known teratogen
(4, 5), and has been associated with a number of side effects (6). Over the
years, case reports and adverse reaction databases have signaled a
possible association with depression (7-10). This was reported as early as
1983 (7), a year after the medication was marketed in the US, and the same
year it was introduced in Canada.
Although several observational studies have investigated whether there was
an association between isotretinoin and depression, none found a Iink (11 -
14). However, these studies were either uncontrolled, had small sample
sizes, or suffered from methodological problems such as case
ascertainment. Using a case-crossover design, we were the first to find a
statistical Iy significant association between isotretinoin and depression
(Azoulay et al., University of Montreal, in press). The case-crossover design
offered two important methodological advantages. First, there was no need
to select a separate control group, since patients served as their own
controls. This eliminated the possibility of control selection bias. Second, the
design automatically adjusted for known and unknown time-independent
confounders.
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Ç Despite these advantages, the case-crossover design does have a few
limitations. First, it does flot adjust for confounders that change over time.
Thus known time-dependent confounders must be adjusted for in analyses.
Second, an assumption of the case-crossover design is the absence of a
time-trend in the exposure. Often this is flot the case, such as when a
medication is aggressively marketed leading to an increase in its utilization,
or during pregnancy for example, a Urne when there is a decrease in the
prescribing of certain medications (15). In either situation, a bias is
introduced in the model because of the exposure time-trend. Thus, time
trend alone can explain an association or lack of association between an
exposure and an outcome. With regards to isotretinoin, its prescribing has
been shown to have significantly increased over the years (16). Its utilization
outside its intended indication (16), and the tact that it is being used as a f irst
me treatment for acne might explain such increases (17, 18). As a result, the
association observed with the case-crossover design may have been biased
by an exposure time-trend. This would have overestimated, and possibly
explained the association observed between isotretinoin and depression.
The case-time-control introduced by Suissa in 1995 (19), is an extension of
the case-crossover design whose goal is to correct for any exposure time
trend. Therefore, the objective of this study was to determine the impact of
an exposure time-trend on the association between isotretinoin and
C
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depression by comparing the point estimates from the case-crossover and
case-time-control designs.
5.4.3 MATER1ALS AND METHODS
5.4.3.1 DATA SOURCES
Data for the isotretinoin cohort studied here were obtained from the Régie de
l’Assurance Maladie du Québec (RAMQ) and Quebec’s hospitai discharge
(Med-Écho) administrative databases. The RAMQ covers ail Quebec
residents for medical services, In addition, prior to January 1, 1997, the
RAMQ aiso covered those who were 65 years and older, and welfare
recipients and their chiidren for their medications. After January 1, 1997, the
RAMQ drug plan was modified to also inciude workers and their
spouses/children who did not have access to a private medication insurance
program (adherents). Approximateiy 50 percent of aIl Quebec residents are
covered by the RAMQ drug plan (20).
A unique patient identification number was used to link the medical and
pharmaceutical databases of the RAMQ. The medical database includes
information on the date and type of services received, and diagnoses are
ciassified according to the International Classification of Diseases, Ninth
revision (lCD-9) (21). The pharmaceutical database contains information on
the subject’s socioeconomic status (weifare recipient or adherent),
characteristics of the prescribing physicians, date medications were
dispensed, formulations, doses, duration of prescriptions, and quantities
dispensed. Medications prescribed during hospitalisations are flot included in
the database. Both the medicai and pharmaceutical daims databases have
been validated and shown to be accurate (22, 23).
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Q The RAMQ databases were also linked to the Med-Écho databases via the
unique patient identification number. Med-Écho contains hospitalisation data
on ail Quebec residents. This database includes patient demographic
information, physician characteristics, admission diagnoses, Iength of stay,
as well as ail services received during the hospitalisation. Medical diagnoses
(lCD-9 codes) recorded in Med-Écho have been shown to be valid and
precise (24).
The study protocol was approved by the CHU Sainte-Justine Ethics
Committee and the Commission d’accès à l’information du Québec.
5.4.3.2 STUDY POPULATION
The study population was composed of subjects from the province of
Quebec who received at least one isotretinoin prescription, in either the 10
mg or 40 mg formulation (drug identification numbers 582344 and 582352,
respectively) between January 1, 1984 and December 31, 2003.
5.4.3.3 CASE-CROSSOVER DESIGN
The case-crossover design was first introduced by Maciure in 1991 (25). In
this design, cases serve as their own controls by determining exposure at
different time intervals. Thus, this design removes the need of selecting a
separate control group. The time intervals in which exposure is assessed are
the risk and control periods. The risk period is a time interval immediately
G prior to the event. The control period is a time interval prior and equal in
1215
Iength to the risk period, and provides an expected baseline frequency 0f
exposure for each study subject in the absence of the outcome. This design
was originally designed to study transient exposures with acute effects.
However, it is possible to use the case-crossover for prolonged exposures
and insidious outcomes by increasing the length of the risk and control
periods (26, 27). Given that cases serve as their own controls, time
independent confounders (known and unknown) are automatically adjusted
by design. Confounders that change over time must be adjusted for in
analyses.
Case definition has been described previously (Azoulay et al., University of
Montreal, in press). Briefly, within our study population, we identified ail
subjects with a first diagnosis or hospitalization for depression (lCD-9 codes:
296.2, 298.0, 300.4, 309.0, 309.1, 311) during the study period (1984-2003).
Subjects had to have received at least one antidepressant prescription in the
30 days following their diagnosis or hospitalization. Their index date was
defined as the calendar date of the diagnosis or hospitalization for
depression. They were required to be covered by the RAMQ drug plan at
Ieast 12 months prior to index, and have at least one acne diagnosis (lCD-9:
706.1) during that same period. Those with who filled an antidepressant in
the 12 months prior to the index date were excluded.
C
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We hypothesized the risk period to be a total of 5 months based on data
found in the literature (7, 28, 29). That time window also corresponds to the
recommended duration 0f an isotretinoin treatment (30, 31). The risk period
immediately followed the index date which was separated from a 5-month
control period by a 2-month washout period.
We adjusted for non-dermatologic visits, dermatologic visits, ail-cause
hospitalizations, emergency depariment visits, and comorbidity measured in
the risk and control periods independently. Dermatologic visits were defined
as either consulting a dermatologist, or being diagnosed with acne vulgaris
(lCD-9 code: 706.1) by a general practitioner. Comorbidity was assessed
using the total number of different types of medications prescribed, other
than isotretinoin.
5.4.3.4 CASE-TIME-CONTROL DESIGN
The case-time-control requires selecting a control group around the same
calendar period as the cases. Using these controls, a control-crossover is
pertormed using the same time window scheme as in the case-crossover, to
determine whether there is an exposure time-trend. Thus, the odds ratio
(OR) obtained with the case-crossover is divided by the OR of the control
crossover to produce an OR adjusted for exposure time-trend (case-time
Ç control). This design implicitly makes the assumption that the OR obtained
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Ç from the case-crossover is a product cf the OR relating the exposure to the
outcome and the OR produced by exposure time-trend. It also assumes that
the exposure time-trend 15 the same in the cases and controls.
In the case-time-control design, we used the same cases that were used in
the case-crossover design. As for controis, they were selected according to
the following algorithm. We first identified ail subjects who were non-cases in
the study population. For each subject in the non-case pooi, we generated a
random index date between the first and last day of their coverage in the
RAMQ drug plan. Subjects had to be covered at least 12 months prior to the
index date, and have at ieast one acne diagnosis (lCD-9: 706.1) during that
same time period. Subjects were excluded of they had received an
antidepressant prescription in the 12 months prior to the index date, or a
diagnosis or hospitalization for depression (lCD-9 codes: 296.2, 298.0,
300.4, 309.0, 309.1, 311) at any time prior to the index date. Up to 10
controls were matched to each case on age (±3 years), sex, and calendar
year (±1 year).
Exposure to isotretinoin was assessed using the same time window scheme
as in the case-crossover design. Similarly, we adjusted the model for non
dermatoiogic visits, dermatologic visits, ail-cause hospitalizations,
G
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C emergency department visits, and comorbidity measured in the risk and
contrai periods, independently.
5.4.3.5 STATIST1CAL ANALYSIS
Descriptive statistics were used ta summarize the characteristics cf cases
and contrais. For the case-crossover design, odds ratios (OR) with
corresponding 95 percent confidence intervals (CI) were estimated using
conditionai iogistic regression using the individual subject as the stratifying
variable. For the case-time-control, a conditional logistic regression was
f itted with time (risk versus contrai periods) as the dependent variable and
the exposure and an interaction term (the product cf the exposure and case
group) as the independent variables. Crude and adjusted ORs were
estimated for bath study designs. SAS version 8.2 (SAS institute, Cary, NC)
was used ta carryout the analyses.
C
P e g e 219
Q 5.4.4 RESULTS
5.4.4.1 CASE-CROSSOVER DESIGN
In the original case-crossover analysis, 126 cases met the inclusion criteria.
In the present study, 2 cases could flot be matched to suitable controls,
leaving 124 cases for analysis. This corresponded to 124 risk periods
matched to 124 controls periods. The characteristics 0f the cases are
presented in Table 1. The number of cases exposed to isotretinoin in the 5-
month risk and control periods was 41(32.5 percent) and 28 (22.2 percent),
respectively. Tweflty-six (21.0 percent) cases were exposed in the risk afld
flot the control period, versus 13 (10.5 percent) exposed in the control and
flot the risk period (crude OR = 26/13 = 2.00) (Table 2). After adjusting for
time-dependent confounders, the OR (95 percent CI) was 2.47 (1.06, 5.75)
(Table 2).
5.4.4.2 CASE-TIME-CONTROL DESIGN
A total of 1149 controls met the inclusion criteria. Despite matchiflg on age,
sex, and calendar year, controls appeared healthier than cases (Table 1).
In the control-crossover, the number exposed to isotretinoin in the 5-month
risk and control periods in the control-crossover analysis was 403 (35.1
Q percent) and 311 (27.1 percent), respectively. Two-hundred-ninety-eight(25.9 percent) controls were exposed in the risk and flot the control period,
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versus 206 (17.9 percent) exposed in the control and flot the risk period
(crude OR = 298/206 = 1.45) (Table 2). The adjusted case-time-control OR
(95 percent CI) determined by dividing the adjusted case-crossover OR by
the adjusted control-crossover OR was 1.56 (0.66, 3.73) (Table 2).
5.4.5 DISCUSSION
In the present study, we compared the point estimates obtained in the case
crossover design to the ones obtained in the case-time-control design. A
case-time-control OR close to unity would have been expected if the
association between isotretinoin and depression was solely due to an
exposure time-trend. The OR obtained using the case-time-control design
was 1 .56, although it did not reach statistical significance. This indicates that
trends in isotretinoin prescribing cannot account for the entirety of the
association. However, controls used in the case-time-control appeared
healthier than cases, and may have thus overestimated the exposure time
trend. These results emphasize the important assumptions and conditions
implicit in the use cf the case-time-control design.
The case-time-control design revealed an exposure time-trend in the use of
isotretinoin during the time periods of interest. This could be due to the
increasing prescribing cf isotretinoin to patients with mild or moderate acne
(16), or the tact that it is increasingly being prescribed as a first une agent
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Ç (17, 18, 32). The exposure time-trend however, did flot fully explain the
association between isotretinoin and depression. Although the point estimate
of the case-time-control was relatively high (OR=1.56), it did flot reach
statistical significance. Two factors can explain this Iack of statistical
significance. The first is the small sample size resulting in a Iack of statistical
power to detect an OR of this magnitude. The second is that in the case
time-control design, there is Ioss in precision caused by within-subject
correlations. This reduces the effective study size (19). In tact, the standard
error of the case-time-control design was larger than the one produced by
the case-crossover design.
The case-time-control design is only valid under certain conditions (33, 34).
Greenland showed that adjustment for exposure time-trend cannot be
universally valid (33). A caveat of the case-time-control design is that
unmeasured confounders are not different between cases and controls.
However, if any unmeasured confounder is differential between cases and
controls, so would be their use of the study medication. In such situations,
using controls to correct for an exposure time-trend would introduce a new
bias, which may be larger than the original time-trend bias (33). Although we
matched controls to cases on age, sex, and calendar year, there were
differences in their healthcare utilization in the 12 months prior to the index
date. The general health of the cases appeared to be worse than that of
controls. Therefore, it is possible that controls were more Iikely to use
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isotretinoin than cases because of their better health status. This
corroborates with our findings, where 22.2 percent af cases versus 27.1
percent of cantrois were exposed in the contrai period. Thus, using heaithier
controls is iikeiy ta have averestimated the expasure time-trend, and biased
the case-time-controi OR towards the nuli.
The bidirectional case-crossover is another method for correcting exposure
time trends that does flot require seiecting separate contrais (35). Using this
approach, expasures are determined bath before and after the outcome in
cases. The premise of this approach is that any time-trend before the
autcame wauid cancel aut with the time-trend after the outcome. This design
has been frequently used in enviranmentai epidemioiogy to determine the
seasonal variation of poilutants on heaith outcomes (36). However, an
important assumption of this modei is that the outcame does not affect
subsequent expasure. This may flot be the case for ail outcomes, such as
death, where subsequent expasure to a medication wiii flot accur. We did flot
perform a bidirectianai case-crossover far the faliawing twa reasons. First,
isotretinain is an effective medicatian where only 26 percent af subjects
require a second treatment course (3, 18). As such, it is unhikeiy for subjects
to have mare than ane treatment course. Second, if it is suspected that
isotretinoin triggered or caused depression, it is uniikeiy that it would be
prescribed again even if the subject’s acne reiapsed. it is more iikeiy that the
treating physician wouid cansider ather treatment options. Because of the
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Ç methodological limitations of the bidirectional case-crossover in investigating
our study question, we used the case-time-control to adjust for possible time
trends in the exposure (19).
The present study is an illustration of how self-matched designs can be
easily implemented using administrative databases. Provided the research
question is appropriate, self-matched designs may be particularly useful
when using administrative databases. First, there is no need to adjust for
time-independent confounders that are not recorded in administrative
databases. This net advantage over other conventional designs makes self
matched designs attractive alternatives when using these data sources.
Second, self-matched designs conducted by interviewing subjects are prone
to differential misclassification of exposure, which is a result of fading
memory over time (37). That is, subjects are more likely to remember their
exposure immediately prior to the outcome than any other time in their
exposure history. Thus exposure during the control periods is typically
underestimated, biasing the association away from the null. On the other
hand, self-matched designs conducted using administrative databases use
accurate information on the date medications were filled, their formulations
and dosages, duration of prescriptions, and quantities dispended. Therefore,
differential misclassification of exposure in self-matched designs is
minimized when using administrative databases.
C
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Ç The association between isotretinoin and depression has been a
controversial issue. This is part due ta the fact that acne itself can cause
depression, suicidai ideation and even suicide. Although our case-crossover
design intrinsicaliy controiied for the presence of acne, increasing trends in
isotretinoin prescribing couid have expiained the observed association. Our
resuits reveaied a moderate exposure time-trend, but which did flot expiain
the entirety of the association. Furthermore, siflce contrais appeared ta be
heaithier than cases, the exposure time-trend may have been overestimated,
biasiflg the case-time-control OR towards the nuil.
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Isotretinoin is the most effective medication for the treatment of severe
nodular acne. However it is a potent human teratogen (2), and has been
associated with several other important side effects (3). These side effects
have led to several label changes by regulatory agencies, and the issuing of
new guidelines that were meant to improve its utilization (209). Over the
years, case reports and signais from adverse reaction databases have
fueled concerns that isotretinoin may cause depression. Several
observational studies have been conducted on the subject, but failed to find
an association. However, these studies were either uncontrolled, had small
sample sizes, or suffered from other methodologicai limitations that rendered
their resuits inconciusive. Using a case-crossover design, the present study
is the first to find a statisticaliy significant association between isotretinoin
and depression.
An association between isotretinoin and depression raises a number of
questions regarding the way it is being utilized in the province of Quebec,
and possibiy the rest of Canada. Studies 1 and 2 presented in this thesis
determined to whom, by whom, and how many times isotretinoin was
prescribed. These studies also determined whether guidelines had any
impact on prescribing patterns. In Study 1, we found that 45% of ail
isotretinoin prescriptions were wriffen by non-dermatologists. Aithough it is
reiativeiy easy to diagnose severe acne, it is unknown whether non-
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dermatologists are fully aware of isotretinoin’s side effect profile. In the UK,
only consultant dermatologists are authorized to prescribe isotretinoin
because of their good knowledge of the medication. In the US, the iPLEDGE
program requires prescribers to be registered in a computerized database in
order to prescribe isotretinoin (131). Currently, there is no system in place in
Canada that monitors by whom, to whom, and how isotretinoin is being
prescribed. We also found that over 60% of patients did not receive any anti
acne medication in the year prior to their first isotretinoin treatment. This is
contrary to product guidelines, and suggests that isotretinoin is either being
prescribed as a first une treatment, or to patients with mild or moderate acne.
In either situation, a large proportion of patients are unnecessarily exposed
to a potent agent without consideration of other therapeutic options. The third
finding was that the Dear Healthcare Professional letter issued by Health
Canada regarding isotretinoin’s possible psychiatric risks in March 2001 had
no impact on prescribing patterns. This indicates that such warnings were
either not adequately promulgated, or that physicians do not give them the
attention that is required. Study 2 reinforced that notion, in that the different
acne treatment guidelines published over the years had no impact on the
incidence of acne relapse in patients initially treated with isotretinoin.
The resuits described above could be a result of Canada’s passive approach
to dealing with the prescribing of isotretinoin. As an example of this troubuing
trend, our research team recently published a study investigating the
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incidence of pregnancy during an isotretinoin treatment, and the impact 0f
the Pregnancy Prevention Program (PPP) on this incidence. The study
showed that the PPP had no impact on the incidence of pregnancies, as
wouid have been expected. Furthermore, the pregnancy rates were four
times greater than what has been published previously in the US (129).
Despite these alarming figures, officiais from Heaith Canada continue to
believe that there is no probiem in Canada (222). Their belief is that there is
no need to impiement a stringent program such as iPLEDGE (222). This
view was shared by the Canadian Dermatology Association (223).
Aithough isotretinoin’s teratogenecity can have grave consequences on the
mother and her unborn child, its psychiatric risks shouid theoretically push
for more rigorous regulations. This is because both men and women, young
and oid can be affected by this side effect. Furthermore, depression can
have an important socioeconomic burden. It can iead to household strain,
financial ioss, occupationai limitations, and impaired social reiationships
(224). Thus more needs to be done to better reguiate and monitor the use of
isotretinoin. This is iikeiy to get compiicated with the introduction of new
generics in the market. Their cheaper price and thus greater avaiiabiiity wiil
most iikeiy increase the use of isotretinoin.
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Ç The studies presented in this thesis have limitations inherent to the use 0f
administrative databases. Administrative databases, such as the RAMQ,
provide data on prescriptions filled. As such, it is unknown whether
medications were actually taken, or whether the patient correctly followed the
treatment regimen. However, administrative databases are not prone to
recail bias and thus provide accurate information on the type, formulation,
dosage, duration, and quantity of the medications prescribed. Furthermore,
the administrative databases we used allowed us to create the largest
isotretinoin cohort to date. This enabled us to conduct the largest studies on
isotretinoin utilization. This also enabled us to have sufficient statistical
power to detect a rare event such as depression in isotretinoin users.
This study generated new research questions that would need to be
addressed in future studies. A limitation of the present study was that we
lacked statistical power to determine whether there a dose-response
relationship between isotretinoin and depression. This is due to the tact that
there were not enough subjects in the cumulative dose strata. Thus, the
exact dose-response relationship between isotretinoin and depression needs
to be investigated in studies with larger sample sizes. Another limitation was
that it was not possible to determine whether there was an association
between isotretinoin and suicide. This is because the RAMQ and Med-Echo
administrative databases provide information on inpatient and outpatient
visits only. Thus, it was unknown how many patients commiffed suicide in
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the cohort. Future studies should investigate whether there is an association
between isotretinoin and suicide. Finally, our population was mainly
composed of subjects of 10w to moderate socioeconomic status. Although
the association between isotretinoin and depression is supported by some
biological data, future studies would have to investigate whether the
association is stili present in individuals of higher socioeconomic status.
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Isotretinoin is the most powerful agent for the treatment of severe nodular
acne. For this reason, it is Iikely to remain the mainstay treatment for severe
acne for a long time to corne. However, exposure to isotretinoin can eaU to
depression in certain patients. As a resuit, treating physicians need to be
aware of this association and be prepared to terminate the treatrnent if
symptoms appear. In some situations, termination of treatment may not be
enough, and psychotherapy and/or pharmacologic treatments may be
indicated.
Depression is frequently underdiagnosed and untreated (225). Therefore it
may be difficult to diagnose it within the context of a dermatologic visit. Thus,
psychiatric screening tests may be appropriate in patients undergoing
isotretinoin therapy. This can be done by adrninistering standardized
assessrnents, such as the Beck Depression lnventory or Hamilton Rating
Scale for Depression, before and during an isotretinoin treatrnent. Because
depression can have serious consequences, current guidelines should
possibly be rnodified to include these psychiatric assessrnents. Their
effectiveness at reducing the incidence of depression in patients undergoing
isotretinoin therapy should subsequently be evaluated in large prospective
cohort studies.
238
___ _____
z
(1) Stem RS. Medication and medical service utilization for acne 1995-
1998. J Am Acad Dermatol. 2000;43:1042-48.
(2) Mitchell AA, Van Bennekom CM, Louik C. A pregnancy-prevention
program in women of childbearing age receiving isotretinoin. N Engi
J Med. 1995;333:1O1-6.
(3) ElIis ON, Krach KJ. Uses and complications of isotretinoin therapy. J
Am Acad Dermatol. 2001 ;45:S150-S157.
(4) Physicians Desk Reference. Product labeling for isotretinoin. 55th
ed. eU. Montvale, NJ: Medical Economics Company, Inc.; 2001.
(5) Hazen PG, Carney JE, Walker AE, Stewart JJ. Depression--a side
effect of 13-cis-retinoic acid therapy. J Am Acad Dermatol.
1 983;9:278-79.
(6) Stupak, B. Safety issues surrounding
http://www. house
. Qov!stuak’accutane statement.shtm I
United States House of Representatives.
Accutane.
2002.
11 -6-2007.
s
I 239
(7) White GM. Recent flndings in the epidemiologic evidence,
classification, and subtypes of acne vulgaris. J Am Acad Dermatol.
1 998;39:S34-S37.
(8) Kligman AM. An overview of acne. J lnvest Dermatol. 1974;62:268-
87.
(9) Brown SK, Shalita AR. Acne vulgaris. Lancet. 1 998;351 :1871 -76.
(10) Fellowes HM, Billewicz WZ, Thomson AM. Is acne a sign of normal
puberty? A longitudinal study. J Biosoc 3d. 1981;13:401-7.
(11) Hunter JAA, Savin JA, DahI MV. Sebaceous and sweat gland
disorders. 3rd ed. Malden: Blackwell Science Ltd; 2002.
(12) Goulden V, Clark 3M, Cunhiffe WJ. Post-adolescent acne: a review
of clinicalfeatures. BrJ Dermatol. 1997;136:66-70.
(13) Cunliffe WJ, Gould D]. Prevalence of facial acne vulgaris in late
adolescence and in adults. Br Med J. 1979;1:1109-10.
(14) Seukeran DC, Cunliffe WJ. Acne vulgaris in the elderly: the
response to 10w-dose isotretinoin. Br J Dermatol. 1998; 139:99-101.
e 240
(15) Gollnick H, Cunhiffe W, Berson D, Dreno B, Finlay A, Leyden JJ et
al. Management of acne: a report from a Global Alliance to improve
Outcomes in Acne. J Am Acad Dermatol. 2003;49:S1 -37.
(16) BilIow JA, Berardi RR, DeSimone EM, Newton GD. Handbook of
Nonprescription Drugs. l3th eU. Washington DC: American
Pharmaceuticai Association; 2002.
(17) Walton S, Wyatt EH, Cunliffe WJ. Genetic control of sebum
excretion and acne--a twin study. Br J Dermatol. 1988; 118:393-96.
(18) Hay JB, Hodgins MB. Metabohism of androgens by human skin in
acne. BrJ Dermatol. 1974;91:123-33.
(19) Leyden JJ. Therapy for acne vulgaris. N Engi J Med.
1997;336:1 156-62.
(20) Russehi JJ. Topicai therapy for acne. Am Fam Physician.
2000;61 :357-66.
(21) Lucky AW, Henderson TA, Oison WH, Robisch DM, Lebwohl M,
Swinyer U. Effectiveness of norgestimate and ethinyl estradioi in
treating moderate acne vuigaris. J Am AcaU Dermatol. 1997;37:746-
Q 54.
1241
(22) Cunhiffe WJ, Baron SE, Coulson 1H. A clïnical and therapeutic study
of 29 patients with infantile acne. Br J Dermatol. 2001 ; 145:463-66.
(23) Morello AM, Downing DT, Strauss JS. Octadecadienoic acids in the
skin surface Iipids of acne patients and normal subjects. J Invest
Dermatol. 1976;66:319-23.
(24) Eady EA. Bacterial resistance in acne. Dermatology. 1998;196:59-
66.
(25) Baur DA, Butler RC. Current concepts in the pathogenesis and
treatment cf acne. J Oral Maxillofac Surg. 1 998;56:651 -55.
(26) Bershad SV. The modem age of acne therapy: a review of current
treatment options. Mt 5mai J Med. 2001 ;68:279-86.
(27) Cunliffe W. Acne. lst eU. London: Taylor & Francis; 1989.
(28) Federman DG, Kirsner RS. Acne vulgaris: pathogenesis and
therapeutic approach. Am J Manag Care. 2000;6:78-87.
(29) Feldman S, Careccia RE, Barham KL, Hancox J. Diagnosis and
treatment of acne. Am Fam Physician. 2004;69:2123-30.
o
1242
Ç’ (30) Keilett SC, Gawkrodger DJ. The psychological and emotional impact
of acne and the effect of treatment with isotretinoin. Br J Dermatol.
1999; 140:273-82.
(31) Krowchuk DP, Stancin T, Keskinen R, Waiker R, Bass J, Anglin TM.
The psychosocial effects of acne on adolescents. Pediatr Dermatol.
1991 ;8:332-38.
(32) Cunliffe WJ. Acne and unemployment. Br J Dermatol.
1986;1 15:386.
(33) Yazici K, Baz K, Yazici AE, Kokturk A, Tot S, Demirseren D et al.
Disease-specific quality of life is associated with anxiety and
depression in patients with acne. J Eur Acad Dermatol Venereol.
2004; 18:435-39.
(34) Gupta MA, Gupta AK. Depression and suicidai ideation in
dermatology patients with acne, alopecia areata, atopic dermatitis
and psoriasis. BrJ Dermatol. 1998;139:846-50.
(35) Kiassen AF, Newton JN, Mallon E. Measuring quality of life in
people referred for specialist care of acne: comparing generic and
disease-specific measures. J Am Acad Dermatol. 2000;43:229-33.
o
1243
C (36) MalIon E, Newton JN, Kiassen A, Stewart-Brown SL, Ryan TJ,
Finlay AY. The quality of life in acne: a comparison with general
medical conditions using generic questionnaires. Br J Dermatol.
1 999;140:672-76.
(37) Lasek RJ, Chren MM. Acne vulgaris and the quality of life of aduit
dermatology patients. Arch Dermatol. 1998;134:454-58.
(38) Cotterill JA, Cunhiffe WJ. Suicide in dermatohogical patients. Br J
Dermatol. 1997;137:246-50.
(39) Leyden JJ. The acne challenge. Medical Crossfire. 2002;3:1-15.
(40) Liao DC. Management of acne. J Fam Pract. 2003;52:43-51.
(41) Leyden JJ. Current issues in antimicrobial therapy for the treatment
of acne. J Eur Acad Dermatol Venereol. 2001 ;1 5 Suppl 3:51-55.
(42) Wyatt El, Suifer SH, Drake LA. The Pharmacological Basis of
Therapeutics. 1 Oth eU. New York: McGraw-Hill; 2001.
(43) Berson DS, Shalita AR. The treatment of acne: the role of
combination therapies. J Am Acad Dermatol. 1995;32:S31-S41.
o
244
C’ (44) Gollnick HP, Krautheim A. Topical treatment in acne: current status
and future aspects. Dermatology. 2003;206:29-36.
(45) Thomas DR, Raimer S, Smith EB. Comparison of topical
erythromycin 1 .5 percent solution versus topical clindamycin
phosphate 1 .0 percent solution in the treatment cf acne vulgaris.
Cutis. 1 982;29:624-32.
(46) Becker LE, Bergstresser PR, Whiting DA, Clendenning WE, Dobson
RL, Jordan WP et al. Topical clindamycin therapy for acne vulgaris.
A cooperative clinical study. Arch Dermatol. 1981 ;117:482-85.
(47) Ellis CN, Gammon WR, Stone DZ, Heezen-Wehner JL. A
comparison of Cleocin T Solution, Cleocin T Gel, and placebo in the
treatment of acne vulgaris. Cutis. 1988;42:245-47.
(48) Pochi PE, Bagatell FK, Ellis CN, Stoughton RB, Whitmore CG,
Saatjian GD et al. Erythromycin 2 percent gel in the treatment of
acne vulgaris. Cutis. 1988;41:132-36.
(49) Lookingbill DP, Chalker DK, Lindhoim JS, Katz HI, Kempers SE,
Huer-ter CJ et al. Treatment cf acne with a combination
clindamycin/benzoyl peroxide gel compared with clindamycin gel,
o
e I 245
O benzoyl peroxide gel and vehicle gel: combined resuits of two
double-blind investigations. J Am Acad Dermatol. 1997;37:590-595.
(50) Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of
the efficacy and toierability of adapalene 0.1% gel versus tretinoin
0.025% gel in patients with acne vulgaris: a meta-analysis 0f five
randomized trials. Br J Dermatol. 1998;139 Suppl 52:48-56.
(51) Brogden RN, Goa KE. Adapalene. A review of its pharmacologicai
properties and clinical potential in the management of mild to
moderate acne. Drugs. 1 997;53:51 1-19.
(52) Shalita A, Weiss JS, Chalker DK, Ellis CN, Greenspan A, Katz HI et
al. A comparison of the efficacy and satety of adapalene gel 0.1%
and tretinoin gel 0.025% in the treatment of acne vulgaris: a
muiticenter trial. J Am Acad Dermatol. 1 996;34:482-85.
(53) Caron D, Sorba V, Clucas A, Verschoore M. Skin tolerance 0f
adapalene 0.1% gel in combination with other topical antiacne
treatments. J Am Acad Dermatol. 1997;36:S113-S115.
(54) Verschoore M, Poncet M, Czernielewski J, Sorba V, Clucas A.
Adapaiene 0.1% gel has 10w skin-irritation potential. J Am Acad
Dermatol. 1997;36:S104-5109.
I 246
(55) Clucas A, Verschoore M, Sorba V, Poncet M, Baker M,
Czernielewski J. Adapalene 0.1% gel is better tolerated than
tretinoin 0.025% gel in acne patients. J Am Acad Dermatol.
1 997;36:S1 16-Si 18.
(56) Haider A, Shaw JC. Treatment of acne vulgaris. JAMA.
2004;292:726-35.
(57) MiIls OH, Jr., Kiigman AM, Pochi P, Comite H. Comparing 2.5%,
5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J
Dermatol. 1 986;25:664-67.
(58) Webster G. Combination azelaic acid therapy for acne vulgaris. J
Am Acad De rm atol. 2000 ;43 :S47-S50.
(59) Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic
acid cream in the treatment 0f acne vulgaris. Comparison with
vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh).
1989; 143:35-39.
(60) Graupe K, Cunhiffe WJ, Gollnick HP, Zaumseil RP. Efficacy and
safety of topical azelaic acid (20 percent cream): an overview of
resuits from European clinical trials and experimental reports. Cutis.
1996;57:20-35.
1247
(61) Sykes NL, Jr., Webster GF. Acne. A review of optimum treatment.
Drugs. 1 994;48:59-70.
(62) Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunhiffe WJ.
lnflammatory events are involved in acne lesion initiation. J Invest
Dermatol. 2003;121 :20-27.
(63) Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin
Dermatol. 2004;22:412-18.
(64) Leyden JJ, McGinley KJ, Kligman AM. Tetracycline and minocycline
treatment. Arch Dermatol. 1982; 118:19-22.
(65) Czeizel AE, Rockenbauer M. A population-based case-control
teratologic study cf oral oxytetracycline treatment during pregnancy.
Eur J Obstet Gynecol Reprod Biol. 2000;88:27-33.
(66) Shapiro LE, Knowles SR, Shear NH. Comparative safety cf
tetracycline, minocycline, and doxycycline. Arch Dermatol.
1997;133:1224-30.
(67) Gammon WR, Meyer C, Lantis S, Shenefelt P, Reizner G, Cripps
DJ. Comparative efficacy cf oral erythromycin versus oral
G
1248
tetracycline in the treatment cf acne vulgaris. A double-blind study. J
Am Acad Dermatol. 1986;14:183-86.
(68) Eady EA, Jones CE, Tipper JL, Cove JH, Cunhiffe WJ, Layton AM.
Antibiotic resistant propionibacteria in acne: need for policies to
modify antibiotic usage. BMJ. 1993;306:555-56.
(69) Poulos ET, Tedesco FJ. Acne vulgaris: double-bhind trial comparing
tetracychine and chindamycin. Arch Dermatol. 1976;112:974-76.
(70) Steer HW. The pseudomembranous colitis associated with
clindamycin therapy--a viral colitis. Gut. 1975;16:695-706.
(71) Lucky AW. Hormonal correlates ot acne and hirsutism. Am J Med.
1 995;98:89S-94S.
(72) Rosenfield RL. Pilosebaceous physiology in relation to hirsutism and
acne. Clin Endocrinol Metab. 1986;15:341-62.
(73) Lever L, Marks R. Current views on the aetiology, pathogenesis and
treatment of acne vulgaris. Drugs. 1990;39:681-92.
(74) Tan JK, Degreef H. Oral contraceptives in the treatment cf acne.
Skin Therapy Lett. 2001 ;6:1-3.
249
Ç (75) Redmond GP, Oison WH, Lippman JS, Kafrissen ME, Jones TM,
Jorizzo JL. Norgestimate and ethinyi estradiol in the treatment of
acne vuigaris: a randomized, piacebo-controlled trial. Obstet
Gynecoi. 1997;89:615-22.
(76) Erkkoia R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S.
Ovulation inhibitors containing cyproterone acetate or desogestrel in
the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol
Scand. 1990;69:61-65.
(77) Aydinhik S, Kaufman J, Lachnit-Fixson U, Lehnert J. Long-term
therapy of signs of androgenisation with a iow-dosed antiandrogen
oestrogen combination. Clin Triais J. 1 990;27:392-402.
(78) Goiinick H, Aibring M, Brui K. [The effectiveness of oral cyproterone
acetate in combination with ethinyiestradiol in acne tarda of the
facial type]. Ann Endocrinoi (Paris). 1999;60:157-66.
(79) Rudiger T, Beckmann J, Queisser W. Hepatocellular carcinoma
after treatment with cyproterone acetate combined with
ethinyioestradioi. Lancet. 1 995;345:452-53.
(80) Brambiila G, Marteili A. Are some progestins genotoxic iiver
C’ carcinogens? Mutat Res. 2002;512:155-63.
o1250
(81) Health Canada. Health Canada advises consumers 0f new warning
for Diane-35. http://www, hc-sc.gc.ca/ahc-asc/media!advisories
avis/2005/2005 39 e.html . 2005. 28-3-2007.
(82) Monheit GD. The Jessners-trichloroacetic acid peel. An enhanced
medium-depth chemical peel. Dermatol Clin. 1995;13:277-83.
(83) Cunliffe WJ, Goulden V. Phototherapy and acne vulgaris. Br J
Dermatol. 2000;1 42:855-56.
(84) Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415
nm) and red (660 nm) light in the treatment of acne vulgaris. Br J
Dermatol. 2000;142:973-78.
(85) Ho V, Schachter D, MiNer R. Acne management for the 90s: Current
treatment guidelines. Can J Diagnosis. 1995;12(suppl):1-25.
(86) Madden WS, Landelis ID, Poulin Y, Searles GE, Smith KC, Tan JK
et al. Treatment of acne vulgaris and prevention of acne scarring:
Canadian consensus guidelines. J Cutan Med Surg. 2000;4 Suppl
1:S2-13.
P a e 251
(87) Cheng AL, Chuang SE, Su IJ. Factors associated with the
therapeutic efficacy cf retinoic acids on malignant lymphomas. J
Formos Med Assoc. 1 997;96:525-34.
(88) Grunwald F, Menzel C, Bender H, Palmedo H, Otto R, Fim mers R et
al. Redifferentiation therapy-induced radioiodine uptake in thyroid
cancer. J Nucl Med. 1998;39:1903-6.
(89) Huang C, Ma WY, Dawson Ml, Rincon M, Flaveil RA, Dong Z.
Blocking activator protein-1 activity, but not activating retinoic acid
response element, is required for the antitumor promotion effect ot
retinoic acid. Proc Nati Acad Sci U S A. 1997;94:5826-30.
(90) Eckhoff C, Nau H. Vitamin A supplementation increases levels of
retinoic acid compounds in human plasma: possible implications for
teratogenesis. Arch Toxicol. 1 990;64:502-3.
(91) Sehgal VN, Srivastava G, Sardana K. lsotretinoin--unapproved
indications/uses and dosage: a physician’s reference. Int J
Dermatol. 2006;45:772-77.
(92) Wert S. Identification and management of oral isotretinoin use
inconsistent with product labeling. Manag Care Interface.
2003;16:41-3, 55.
I 252
C (93) Kunynetz RA. A review of systemic retinoid therapy for acne and
related conditions. Skin Therapy LeU. 2004;9:1-4.
(94) Fleischer AB, Jr., Simpson JK, McMichael A, Feidman SR. Are there
racial and sex differences in the use of oral isotretinoin for acne
management in the United States? J Am Acad Dermatol.
2003;49:662-66.
(95) White RM. Unraveling the Tuskegee Study of Untreated Syphilis.
Arch lntern Med. 2000;160:585-98.
(96) Wysowski DK, Swann J, Vega A. Use of isotretinoin (Accutane) in
the United States: rapid increase from 1992 through 2000. J Am
Acad Dermatol. 2002;46:505-9.
(97) Koren G, Avner M, Shear N. Generic isotretinoin: a new risk for
unborn chiidren. CMAJ. 2004;1 70:1567-68.
(98) Chen K, White TJ, Juzba M, Chang E. Oral isotretinoin: an analysis
of its utilization in a managed care organization. J Manag Care
Pharm. 2002;8:272-77.
o
GPae 253
(99) Harms M, Masouye I, Radetf B. The relapses of cystic acne after
isotretinoin treatment are age-related: a Iong-term follow-up study.
Dermatologica. 1986;172:148-53.
(100) Chivot M, Midoun H. Isotretinoin and acne--a study of relapses.
Dermatologica. 1990; 180:240-243.
(101) Stainforth JM, Layton AM, Taylor JP, Cunhiffe WJ. Isotretinoin for the
treatment of acne vulgaris: which factors may predict the need for
more than one course? BrJ Dermatol. 1993;129:297-301.
(102) Lehucher-Ceyrac D, Weber-Buisset MJ. Isotretinoin and acne in
practice: a prospective analysis of 188 cases over 9 years.
Dermatology. 1 993;1 86:123-28.
(103) Layton AM, Knaggs H, Taylor J, Cunhiffe WJ. Isotretinoin for acne
vulgaris--lO years later: a safe and successful treatment. Br J
Dermatol. 1993;129:292-96.
(104) Lehucher-Ceyrac D, de La SP, Chastang C, Morel P. Predictive
factors for failure of isotretinoin treatment in acne patients: resuits
from a cohort of 237 patients. Dermatology. 1999;198:278-83.
P g e 254
(105) Quereux G, Volteau C, N’Guyen JM, Dreno B. Prospective study of
risk factors of relapse after treatment of acne with oral isotretinoin.
Dermatology. 2006;21 2:168-76.
(106) ShahiduNah M, Tham SN, Goh CL. Isotretinoin therapy in acne
vulgaris: a 10-year retrospective study in Singapore. Int J Dermatol.
1 994;33:60-63.
(107) Haryati I, Jacinto SS. Profile of acne patients in the Philippines
requiring a second course of oral isotretinoin. Int J Dermatol.
2005;44:999-1 001.
(108) Ng PP, Goh CL. Treatment outcome ot acne vulgaris with oral
isotretinoin in 89 patients. lntJ Dermatol. 1999;38:213-16.
(109) Al-Mutairi N, Manchanda Y, Nour-Eldin O, Sultan A. Isotretinoin in
acne vulgaris: a prospective analysis of 160 cases from Kuwait. J
Drugs Dermatol. 2005;4:369-73.
(110) White GM, Chen W, Yao J, Wolde-Tsadik G. Recurrence rates after
the first course of isotretinoin. Arch Dermatol. 1998;134:376-78.
(111) Kamm JJ. Toxicology, carcinogenicity, and teratogenicity of some
orally administered retinoids. J Am Acad Dermatol. 1982;6:652-59.
I 255
Ç (112) Benke PJ. The isotretinoin teratogen syndrome. JAMA.
1 984;251 :3267-69.
(113) Rosa FW. Teratogenicity of isotretinoin. Lancet. 1983;2:513.
(114) FDA. Drug Bulletin. 13, 21-22. 1983.
(115) Zarowny DP. Accutane Roche: risk of teratogenic effects. Can Med
Assoc J. 1984;131:273.
(116) de la CE, Sun S, Vangvanichyakorn K, Desposito F. Multiple
congenital malformations associated with maternai isotretinoin
therapy. Pediatrics. 1 984;74:428-30.
(117) Daniel KL, Goldman KD, Lachenmayr S, Erickson JD, Moore C.
interpretations of a teratogen warning symbol. Teratology.
2001 ;64:148-53.
(118) Wiilhite CC, Hill RM, irving DW. lsotretinoin-induced craniofacial
malformations in humans and hamsters. J Craniofac Genet Dey Bioi
Suppl. 1 986;2: 193-209.
I 256
Ç (119) Atanackovic G, Koren G. Young women taking isotretinoin stili
conceive. Role of physicians in preventing disaster. Can Fam
Physician. 1 999;45:289-92.
(120) Dai WS, LaBraico JM, Stem RS. Epidemiology of isotretinoin
exposure during pregnancy. J Am Acad Dermatol. 1992;26:599-606.
(121) Honein MA, Paulozzi U, Erickson JD. Continued occurrence of
Accutane-exposed pregnancies. Teratology. 2001; 64:142-47.
(122) Moerike S, Pantzar JT, De Sa D. Temporal bone pathology in
fetuses exposed to isotretinoin. Pediatr Dey Pathol. 2002;5:405-9.
(123) Jahn AF, Ganti K. Major auricular malformations due to Accutane
(isotretinoin). Laryngoscope. 1 987;97:832-35.
(124) Stem RS, Rosa F, Baum C. Isotretinoin and pregnancy. J Am Acad
Dermatol. 1984;10:851-54.
(125) Ceviz N, Ozkan B, Eren S, Ors R, Olgunturk R. A case of
isotretinoin embryopathy with bilateral anotia and Taussig-Bing
malformation. Turk J Pediatr. 2000;42:239-41.
o
I 257
0 (126) Dos Santos AM, Vaillant C, Pedespan JM, Fontan D, Guillard JM.
[Teratogenicity of isotretinoinJ. Arch Pediatr. 1998;5:1046-47.
(127) Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med.
1 998;338: 1128-37.
(128) Atanackovic G, Koren G. Fetal exposure to oral isotretinoin: failure
to comply with the Pregnancy Prevention Program. CMAJ.
1999;160:1719-20.
(129) Bérard A, Azoulay L, Koren G, Biais L, Perreault S, Oraichi D.
Isotretinoin, pregnancies, abortions and birth defects: a population
based perspective. Br J Clin Pharmacol. 2007;63: 196-205.
(130) Brinker A, Kornegay C, Nourjah P. Trends in adherence to a revised
risk management program designed to decrease or eliminate
isotretinoin-exposed pregnancies: evaluation of the accutane
SMART program. Arch Dermatol. 2005;141:563-69.
(131) Abroms L, Maibach E, Lyon-Daniel K, Feldman SR. What is the best
approach to reducing birth defects associated with isotretinoin?
PL0S Med. 2006;3:e483.
Q
P a p 258
(132) Almond-Roesler B, Blume-Peytavi U, Bisson S, Krahn M, Rohloff E,
Orfanos CE. Monitoring of isotretinoin therapy by measuring the
plasma levels of isotretinoin and 4-oxo-isotretinoin. A useful tool for
management 0f severe acne. Dermatology. 1 998;1 96:176-81.
(133) Silverman AK, Ellis ON, Voorhees JJ. Hypervitaminosis A
syndrome: a paradigm of retinoid side effects. J Am Acad Dermatol.
1 987;1 6:1027-39.
(134) Goulden V, Layton AM, Cunliffe WJ. Long-term safety 0f isotretinoin
as a treatment for acne vulgaris. Br J Dermatol. 1 994;1 31:360-363.
(135) Bigby M, Stem RS. Adverse reactions to isotretinoin. A report from
the Adverse Drug Reaction Reporting System. J Am Acad Dermatol.
1988; 18:543-52.
(136) McElwee NE, Schumacher MC, Johnson SC, Weir TW, Greene SL,
Scotvold MJ et al. An observational study of isotretinoin recipients
treated for acne in a health maintenance organization. Arch
Dermatol. 1991 ;127:341-46.
(137) Leyden JJ. The role of isotretinoin in the treatment of acne: personal
observations. J Am Acad Dermatol. 1998;39:S45-S49.
P a p 259
(138) Fraunfelder ET, Fraunfelder FW, Edwards R. Ocular side effects
possibly associated with isotretinoin usage. Am J Ophthalmol.
2001 ;1 32:299-305.
(139) Egger SE, Huber-Spitzy V, Bohier K, Raif M, Scholda C, Barisani T
et al. Ocular side effects associated with 1 3-cis-retinoic acid therapy
for acne vulgaris: clinical features, alterations of tearfiim and
conjunctival flora. Acta Ophthalmol Scand. 1995;73:355-57.
(140) Alcalay J. Myths of isotretinoin therapy in patients with acne: a
personal opinion. J Drugs Dermatol. 2004;3:179-82.
(141) Zech LA, Gross EG, Peck GL, Brewer HB. Changes in plasma
cholesterol and triglyceride levels after treatment with oral
isotretinoin. A prospective study. Arch Dermatol. 1983;119:987-93.
(142) Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B et
al. Changes in plasma lipids and lipoproteins during isotretinoin
therapy for acne. N EngI J Med. 1 985;31 3:981-85.
(143) Lyons F, Laker ME, Marsden JR, Manuel R, Shuster S. Effect of oral
13-cis-retinoic acid on serum lipids. Br J Dermatol. 1982;107:591-
95.
oP a e 260
(144) Marsden JR, Trinick TR, Laker ME, Shuster S. Effects of isotretinoin
on serum lipids and lipoproteins, liver and thyroid function. Clin
Chim Acta. 1984;143:243-51.
(145) Georgala S, Schulpis KH, Potouridou I, Papadogeorgaki H. Effects
cf isotretinoin therapy on lipoprotein (a) serum levels. Int J Dermatol.
1 997;36:863-64.
(146) Barth JH, Macdonald-Hull SP, Mark J, Jones RG, Cunliffe WJ.
Isotretinoin therapy for acne vulgaris: a re-evaluation of the need for
measurements cf plasma lipids and liver function tests. Br J
Dermatol. 1993;129:704-7.
(147) Alcalay J, Landau M, Zucker A. Analysis of laboratory data in acne
patients treated with isotretinoin: is there really a need to perform
routine laboratory tests? J Dermatolog Treat. 2001 ;12:9-12.
(148) Altman RS, Altman U, Altman JS. A proposed set of new guidelines
for routine blood tests during isotretinoin therapy for acne vulgaris.
Dermatology. 2002;204:232-35.
(149) Lindemayr H. Isotretinoin intoxication in attempted suicide. Acta
Derm Venereol. 1986;66:452-53.
e 261
(150) Burket JM, Storrs FJ. Nodulocystic infantile acne occurring in a
kindred cf steatocystoma. Arch Dermatol. 1987;123:432-33.
(151) Villalobos D, Ellis M, Snodgrass WR. Isotretinoin (Accutane)
associated psychosis. Vet Hum Toxicol. 1 989;31 :362.
(152) Hepburn NC. Deliberate self-poisoning with isotretinoin. Br J
Dermatol. 1990;122:840-841.
(153) Gatti S, Serri F. Acute depression from isotretinoin. J Am Acad
Dermatol. 1991 ;25:132.
(154) Aubin S, Lorette G, Muller C, Vaillant L. Massive isotretinoin
intoxication. Clin Exp Dermatol. 1995;20:348-50.
(155) Cott AD, Wisner KL. Isotretinoin treatment of a woman with bipolar
disorder. J Clin Psychiatry. 1999;60:407-8.
(156) Middelkoop T. Roaccutane (Isotretinoin) and the risk 0f suicide:
case report and a review of the literature and pharmacovigilance
reports. J Pharm Practice. 1999;12:374-78.
(157) Ng OH, Tam MM, Hook SJ. Acne, isotretinoin treatment and acute
depression. World J Biol Psychiatry. 2001 ;2:159-61.
g e I 262
(158) La PM. Acute depression from isotretinoin. Another case. J Eur
Acad Dermatol Venereol. 2005;19:387.
(159) Burket JM, Storrs FJ. Nodulocystic infantile acne occurring in a
kindred of steatocystoma. Arch Dermatol. 1 987;1 23:432-33.
(160) Hepburn NC. Deliberate seif-poisoning with isotretinoin. Br J
Dermatol. 1 990;122:840-841.
(161) Cott AD, Wisner KL. Isotretinoin treatment of a woman with bipolar
disorder. J Clin Psychiatry. 1999;60:407-8.
(162) Aubin S, Lorette G, Muller C, Vaillant L. Massive isotretinoin
intoxication. Clin Exp Dermatol. 1 995;20:348-50.
(163) Bruno NP, Beacham BE, Burneif JW. Adverse effects of isotretinoin
therapy. Cutis. 1 984;33:484-6, 489.
(164) Scheinman PL, Peck GL, Rubinow DR, DiGiovanna JJ, Abangan
DL, Ravin PD. Acute depression from isotretinoin. J Am Acad
Dermatol. 1990;22:1 112-14.
(165) Duke EE, Guenther L. Psychiatric reaction to the retinoids. Can J
Dermatology. 1993;5:467.
Pa 1263
(166) Byrne A, Costello M, Grcene E, Zibin T. Isotretinoin therapy and
depression: evidence for an association. Ir J Psych Med.
1998; 15:58-60.
(167) Burket JM, Storrs FJ. Nodulocystic infantile acne occurring in a
kindred of steatocystoma. Arch Dermatol. 1 987;1 23:432-33.
(168) Hepburn NC. Deliberate seif-poisoning with isotretinoin. Br J
Dermatol. 1990;122:840-841.
(169) Aubin S, Lorette G, Muller C, Vaillant L. Massive isotretinoin
intoxication. Clin Exp Dermatol. 1 995;20:348-50.
(170) Cott AD, Wisner KL. Isotretinoin treatment of a woman with bipolar
disorder. J Clin Psychiatry. 1999;60:407-8.
(171) La PM. Acute depression from isotretinoin. Another case. J Eur
Acad Dermatol Venereol. 2005; 19:387.
(172) Bruno NP, Beacham BE, Burnett JW. Adverse effects of isotretinoin
therapy. Cutis. 1984;33:484-6, 489.
E 264
Q (173) Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression
and suicide in patients treated with isotretinoin. J Am Acad
Dermatol. 2001 ;45:51 5-19.
(174) Wooltorton E. Accutane (isotretinoin) and psychiatric adverse
effects. CMAJ. 2003;168:66.
(175) ODonneil J. Overview of existing research and information Iinking
isotretinoin (accutane), depression, psychosis, and suicide. Am J
Ther. 2003;10:148-59.
(176) Wysowski DK, Pifls M, Beitz J. Depression and suicide in patients
treated with isotretinoin. N Engi J Med. 2001 ;344:460.
(177) Important safety information on Accutane [Dear Healthcare
Professional LetterJ. Health Canada . 2001. Mississauga (ON),
Hoffman-La Roche Limited. 12-4-2006.
(178) HulI PR, Demkiw-Bartel C. Isotretinoin use in acne: prospective
evaluation of adverse events. J Cutan Med Surg. 2000;4:66-70.
(179) Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and
risk of depression, psychotic symptoms, suicide, and attempted
suicide. Arch Dermatol. 2000;1 36:1231-36.
1265
(180) HulI PR, D’Arcy C. Isotretinoin use and subsequent depression and
suicide: presenting the evidence. Am J Clin Dermatol. 2003;4:493-
505.
(181) Wysowski DK, Beitz J. Methodological limitations of the study
“lsotretinoin use and risk of depression, psychotic symptoms,
suicide, and attempted suicide”. Arch Dermatol. 2001;137:1102-3.
(182) McLane J. Analysis of common side effects of isotretinoin. J Am
Acad Dermatol. 2001 ;45:S188-S194.
(183) Ng CH, Tam MM, Celi E, Tate B, Schweitzer I. Prospective study of
depressive symptoms and quality of life in acne vulgaris patients
treated with isotretinoin compared to antibiotic and topical therapy.
Australas J Dermatol. 2002;43:262-68.
(184) Hersom K, Neary MP, Levaux HP, Klaskala W, Strauss JS.
Isotretinoin and antidepressant pharmacotherapy: a prescription
sequence symmetry analysis. J Am Acad Dermatol. 2003;49:424-
32.
(185) Maclure M, Mittieman MA. Should we use a case-crossover design?
Annu Rev Public Health. 2000;21:193-221.
o
1266
C (186) Schatzberg AF. New indications for antidepressants. J Clin
Psychiatry. 2000;61 Suppl 1 1:9-17.
(187) Ferahbas A, Turan T, Esel E, Utas S, Kutiugun C, Kilic CG. A piiot
study evaluating anxiety and depressive scores in acne patients
treated with isotretinoin. J Dermatolog Treat. 2004;15:153-57.
(188) Kellett SC, Gawkrodger DJ. A prospective study of the
responsiveness of depression and suicidai ideation in acne patients
to different phases of isotretinoin therapy. Eur J Dermatol.
2005; 15:484-88.
(189) Chia CY, Lane W, Chibnall J, Allen A, Siegfried E. Isotretinoin
therapy and mood changes in adolescents with moderate to severe
acne: a cohort study. Arch Dermatol. 2005;141 :557-60.
(190) Cohen J, Adams S, Patten S. No association found between
patients receiving isotretinoin for acne and the development of
depression in a Canadian prospective cohort. Can J Clin Pharmacol.
2007; 1 4:e227-e233.
(191) Friedman T, Wohl Y, Knobler HY, Lubin G, Brenner S, Levi Y et al.
lncreased use of mental health services related to isotretinoin
C
a : 267
treatment: a 5-year analysis. Eur Neuropsychopharmacol.
2006; 16:413-16.
(192) Bremner JD. Does isotretinoin cause depression and suicide?
Psychopharmacol Buli. 2003;37:64-78.
(193) Restak RM. Pseudotumor cerebri, psychosis, and hypervitaminosis
A. J Nerv Ment Dis. 1972;155:72-75.
(194) O’Donnell J. Polar hysteria: an expression of hypervitaminosis A.
Am J Ther. 2004; 1 1:507-16.
(195) Sakai Y, Crandail JE, Brodsky J, McCaffery P. 13-cis Retinoic acid
(accutane) suppresses hippocampal celi survival in mice. Ann N Y
Acad Sci. 2004;1021:436-40.
(196) Sheline Yl, Sanghavi M, Mintun MA, Gado MH. Depression duration
but not age predicts hippocampal volume loss in medically healthy
women with recurrent major depression. J Neurosci. 1999;19:5034-
43.
(197) O’reilly KC, Shumake J, Gonzalez-Lima F, Lane MA, Bailey SJ.
Chronic Administration of 13-Cis-Retinoic Acid Increases
I 268
C Depression-Related Behavior in Mice. Neuropsychopharmacology.
2006.
(198) Bremner JD, Fani N, Ashraf A, Votaw JR, Brummer ME, Cummins T
et al. Functional brain imaging alterations in acne patients treated
with isotretinoin. Am J Psychiatry. 2005;162:983-91.
(199) Lafarge H, Levy P. Evaluation économique d’une innovation
médicamenteuse: le traitement de l’acné sévère par Roaccutane. J
Econ Méd. 1987;5:117-27.
(200) Lee ML, 000per A. Isotretinoin: cost-benefit study. Australas J
Dermatol. 1991 ;32: 17-20.
(201) Cunliffe W, Gray JA, Macdonald-Hull SP, Hughes BR, Calvert RT,
Burnside CJ. Cost effectiveness of isotretinoin. J Dermatol Treat.
1991; 1:285-88.
(202) Honein MA, Paulozzi U. Cost-effectiveness of oral isotretinoin.
Dermatology. 1 999;1 98:404-6.
(203) Newton J. Reply [cost-effectiveness of oral isotretinoin).
Dermatology. 1999;198:405.
o
1269
(204) World Health Organization. International Classification of Diseases,
Ninth Revision (lCD-9). 1977. Geneva, Switzerland, World Health
Organization.
(205) Régie de l’assurance maladie du Québec. Statistiques annuelles.
1997. Quebec, Government of Quebec.
(206) Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription
daims databases in pharmacoepidemiological research: the
accuracy and comprehensiveness of the prescription daims
database in Quebec. J Clin Epidemiol. 1995;48:999-1009.
(207) Tamblyn R, Reid T, Mayo N, McLeod P, Churchill-Smith M. Using
medical services daims to assess injuries in the elderly: sensitivity
of diagnostic and procedure codes for injury ascertainment. J Clin
Epidemiol. 2000;53:183-94.
(208) Levy AR, Mayo NE, Grimard G. Rates of transcervical and
pertrochanteric hip fractures in the province of Quebec, Canada,
1981-1992. Am J Epidemiol. 1995;142:428-36.
(209) Tan JK. Perspectives on isotretinoin and the Canadian Consensus
Guidelines on treatment of acne. Skin Therapy Lett. 2000;6:1-4.
1270
Q (210) Box GEP, Tiao GO. Intervention analysis with applications to
economic and environmental problems. J Am Stat Assoc.
1 975;70:70-79.
(211) Régie de l’assurance maladie du Québec. Statistiques annuelles.
2003. Quebec, Government of Quebec.
(212) Richardson DB. An incidence density sampling program for nested
case-control analyses. Occup Environ Med. 2004;61 :e59.
(213) Rothman KJ, Greenland S. Modem Epidemiology. 2nd ed.
Philadeiphia, PA: Lippincott-Raven; 1998.
(214) Maclure M. The case-crossover design: a method for studying
transient effects on the risk of acute events. Am J Epidemiol.
1991 ;133:144-53.
(215) Dixon KE. A comparison of case-crossover and case-control
designs in a study of risk factors for hemorrhagic fever with renal
syndrome. Epidemiology. 1 997;8:243-46.
(216) American Psychiatric Association Staff. Diagnostic & Statistical
Manual of Mental Disorders, DSM-IV: Text Revision 2000. 4th ed.
Trade Paper; 2000.
271
(217) Wang PS, Schneeweiss S, Glynn RJ, Mogun H, Avorn J. Use cf the
case-crossover design to study prolonged drug exposures and
insidious outcomes. Ann Epidemiol. 2004;1 4:296-303.
(218) Aubin S, Lorette G, Muller C, Vaillant L. Massive isotretinoin
intoxication. Clin Exp Dermatol. 1 995;20:348-50.
(219) Aubin S, Lorette G, Muller C, Vaillant L. Massive isotretinoin
intoxication. Clin Exp Dermatol. 1 995;20:348-50.
(220) Perkins A], Kroenke K, Unutzer J, Katon W, Williams JW, Hope C et
al. Common comorbidity scales were similar in their ability to predict
health care costs and mortality. J Clin Epidemiol. 2004;57:1040-
1048.
(221) Suissa S. The case-time-control design. Epidemiology. 1 995;6:248-
53.
(222) Valois M, Peterson R, Bouthillier L. Patient-physician-regulator triad.
CMAJ. 2005;172:15.
(223) Canadian Dermatology Association. Position statement on
isotretinoin.
http ://www. de rm atoloQy.ca/med ialrosition statement/position isotre
P e g e 272
tinoin.html . 2007. Canadian Dermatology Association. 11-6-2007.
(224) Judd LL, Paulus MP, Wells KB, Rapaport MH. Socioeconomic
burden of subsyndromal depressive symptoms and major
depression in a sample of the general population. Am J Psychiatry.
1996;153:141 1-17.
(225) Gelenberg AJ, Hopkins HS. Assessing and treating depression in
primary care medicine. Am J Med. 2007;120:105-8.
List of anti-acne medïcations and theïr drug identification numbers
Anti-acne medïcations Drug identification numbers
Systemic antibiotics
2084090, 2084104, 2230735, 2230736, 2173514, 2173506, 2154366,
2153394, 2108143, 2108151, 2239238, 2239239, 1914138, 1914146,
2237313, 2237314, 2242080, 2242081
580929, 2169924, 717606, 156744
740713, 874256, 817120, 860751, 742562, 887064, 725250, 2158574,
2091232, 2093103, 24368, 578452
563854, 563854, 1925938, 726672, 682020, 637416, 545678, 688568,
583782, 893862, 607142, 704393, 704377, 2051850, 769991
2245232, 2245233, 2248525, 2248526, 30570, 2182866, 2241709,
2241710, 2130033, 2192659, 2242409, 2242410
2212021, 2231143, 2223716, 2223724, 2239952
Minocycline
Tetracycline
Doxycycline
Erythromycin
Cli ndamyci n
Azithromycin
Miscellaneous agents
. 406848 370568 187585 1908871 432938 374318, 263699, 403571,Benzoyl peroxide 373036
Oral contraceptives
(Diane-35®) 2233542
Topical retinoids
897329, 897310, 443794, 870021, 870013, 443816, 657204, 578576,
Tretinoin 518182, 587958, 587966, 641863, 578568, 518174, 662348, 1926497,
1926500, 1926519, 1926527, 1926470, 1926489, 1926462
Tazarotene 2243895
Topical antibiotics
Erythromycin 1910086, 1902628
Clindamycin 2230540, 2230535, 260436, 582301
Dermatologic code RAMQ description
9249 Dermatologie cabinet privé : consultation
9220 Dermatologie cabinet privé : supplément de durée
9182 Dermatologie cabinet privé : visite de contrôle
9180 Dermatologie cabinet privé : visite principale
9250 Dermatologie centre hospitalier de soins de courte durée:
externe consultation
9187 Dermatologie centre hospitalier de soins de courte durée:
externe visite de contrôle
9186 Dermatologie centre hospitalier de soins de courte durée:
externe visite principale
9184 Dermatologie centre hospitalier de soins de courte durée:
hospitalisation consultation
99 Dermatologie centre hospitalier de soins de courte durée:
hospitalisation tournée des malades le week-end
9185 Dermatologie centre hospitalier de soins de courte durée:
hospitalisation visite de contrôle
9183 Dermatologie centre hospitalier de soins de courte durée:
hospitalisation visite principale
9181 Dermatologie en CHSLD (et centre d’accueil) : consultation
(incluant la visite principale et le supplément de consultation)
9189 Dermatologie en CHSLD (et centre d’accueil) : visite de
contrôle
425 Dermatologie infiltration intralésionnelle (une (1) ou plusieurs
lésions)
468 Dermatologie injection de substance sclérosante,
intralésionnelle (dermatologie) une (1) ou plusieurs
9190 Dermatologie domicile : visite principale
9188 Dermatologie en CHSLD (et centre d’accueil) : visite
principale
9206 Dermatologie local sous gestion du gouvernement visite de
contrôle
9251 Dermatologie local sous gestion du gouvernement
consultation (incluant la visite principale et le supplément de
consultation)
Dermatologic procedure codes
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Madame Aanick erard
Centre de recherche
Hépital 5ainteJusrine
3175. Cête Sainte Carberme
Menrraal (Québec) H3T 105
03 2070
adumc,
Nous avals bien reçu votre demande doutarnatian dobtenir, pour votre
erude communication de renseiqnements nominatifS detenus par la Pégie de
assurance roalad e ou Q<cbeo tRAMQ) et le miniStère de e Sante et de Services
sociaux (M5551 Ootre proet vise à étudier I rt.lisalion dc iverretinoine auprès
dune cohorte d’hommes et de femmes incidence oc orossesse, incidence de mal
formations conyenrtoles assocé ou medicoment ainsi ouc les coûts pour le systeme
de santé associés o un SUiVi inapproprié
Aprds stude de cette demande et coriformrnent à iartrcle 125 de la toi ur
/ acaè ;ox tocunrcnt Jar ctrarhlne pvhhcs at rrJr <à pro tCJT017 ClOS OOflSC!7flC
‘OcflrSOcronnCiS nous vous autorisons à recevoir’ de o R4MÇ et du M5à5 les ren
scqnements nomriatifs specifies ci-opres et énumerés en annexe
i’ source selection par la RAMQ de la cohorte dhommes et de femmes exposés o
[isntretnone et de eurs bebés
ous es hommes lanviron 18 000) et toutes les feirmos (enrrcn
2% 000) assures par o PAMQ pui anS eu au moins une pi caur p non
pour i isatrctinoinc (code S1N 00582352 AHFS 24 36 00 ATC
5108A01) entre e 1<’ Janvier 1°82 et le 31 decembre 2002 ainsi que
tous les bébés ace de ces femmes pendant o mOrne période Pour le
2 o g e xxiii
2
hommes les femmes et les bébés identfié, les renseiqnements autori
52e Sont énumérés à lannexe 1
source opparernent ce la cohorte avec le fichier MEr ECHO
lu cohorte sélectionnée à la PAMQ sera appariée au ficher de MEO
ECHC du M555 par le numéro O’ assurance malade (NAM), La P
transférera les NAM (bcouihés et non hi’ouihés de sujets inclus oens
conorte (sot ‘es hommes et les femmes exposes l:dt.t et
tous leurs bébés) ainsi que les aatee d début des hens (date dobten
ton oies NAM des bébés) à MEb-ECHO. Le M555 retournera ou cher
chejr un fichier contenant le NAM brouillé pour chacun des sujets ainsi
que l’information relative à toutes les hoepitolisatiuris que les sijets
ont eues entre le 1 onvier 1982 et le 31 décembre 2003 Les rcnsei
anements autorisés sont énumérés à l’annexe 2.
source appar:ement de cette i..oharte avec le Registre des événementS oérno
oraphinues
la cohorte sera ensuite appariée ou Registre des événements démogra
phiques, La RAMQ fournira é I Institut de la statistique du Québec
‘iSQt manaatoire du M555 ç NAM brouillé de o mère et le NAM
braullé des bébés, ainsi que es nom et prènom de o mere, la dace de
naissance de la mère et la date de nassonce des bébés. Pour chotsie
bébé, appariement se fera à mdc des quatre variables suivantes es
nom et prénom de la mére, la date de raissancc de la mère et o dote de
naissance du bebé. L ISQ remettra ou chercheur un fichier contenant
es NAM brouillés des mères, pères et des bébés ainsi nue les ‘ensei
gnements concernant ces personnes, enurnéreS à l’annexe 3 pour la
période du i jonviet’ 1982 au 31 décembre 2003.
2ette autorisation est cependant ossortie des conditons suiances que vous
dc,’cz respecTer
cous devez assurer la confidentialité 0es renseiqnements niominarfe que vous
r’eçevrez’
‘,‘auS UCve: faire signer un engocement à la confdentiulit2 aux membres de
‘équpe de recherche qui n ont pas sique le formulaire de demande à autorsotion
et à toute outre personne QUi s’ajoutera par la suite, à cette équipe:
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vous devez ut;ser les renseignements reçus unquernent pour cette recherche
aarticulière:
dans vas rapports, vous ne devez pus publier un renseionemen’r permettanï
diden b fier un individu;
vous ne dzvez pas communauer un renseivnement resu à d’autres personnes que
celles qu Sont utorisécs à le recevom dans le cadre de cette recherche,
- vous devez détruite tous les r’enseqnementS reçus, énumérés en annexe pour
lesouels iautr Sntion de o Ccmmission vaus cst accordee eu plus tard ‘e 28
tévrèr 2009
énfin, il est opportun de vous rappeler eue la décision ultime de vouS coin
meniquer’ ou non ces renseanemenls nominatifs oppartient toujourS aux organismes
détenteurs, en [accurrence la PAMQ et le M555.
Veuillez agréer. Madame, expression de nos sentiments les meideurs
Le directeur général
DM!LB/lp tenis Morency
cc. M. André-Gadtan Corneau, AMQ
M” Joanne Gaumond, tAMQ
M. Claude Lamarre, M555
M” Louise Légaré, M555
M”’ Louise Harvev, 150
